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New Psychoactive Substances (NPS) are synthesised to produce similar effects to 
controlled drugs of misuse, with an alteration in chemical structure to circumvent drugs 
of misuse legislation. One of the most prevalent NPS groups are synthetic cannabinoid 
receptor agonists (SCRAs). This research was performed to investigate the 
epidemiology and mechanisms of NPS toxicity.    
Analysis of enquiry data from the UK National Poisons Information Service (NPIS) 
demonstrated that SCRAs were the NPS group most commonly reported in episodes 
of toxicity. There were increases in reported episodes of NPS toxicity over the last 
decade, with reductions associated with legal controls for specific NPS, e.g.  
mephedrone (2010). There has been a recent decline in episodes predating the 
introduction of the UK Psychoactive Substances Act (2016), which has since 
continued.  
Reports of toxicity resembling serotonin syndrome in SCRA users could be due to 
structural similarities between indole SCRAs (e.g. JWH-018) and serotonin. This was 
investigated using ex-vivo rat brain slices. The inhibitory effect on serotonin reuptake 
observed with fluoxetine was not demonstrated with JWH-018 or CP 55,940 (non-
indole SCRA). 
Effects of chronic exposure to SCRA were investigated in a human neuronal stem cell 
model, examining effects on cell viability and gene (RNAseq) and protein expression 
(western blotting). The SCRAs studied had different toxicity profiles and were more 
toxic to immature than mature cells, while the cathinone stimulant mephedrone was 
toxic to mature cells. Chronic low dose exposure to the SCRAs MDMB-CHMICA and 
5F-ADB induced changes in gene and protein expression related to protein synthesis, 
perturbation of mitochondrial function and increased cellular stress. 
Toxicity caused by NPS in the UK has recently declined and legislation may have 
contributed to this. Neurotoxicity, gene and protein expression results suggest that 
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PSA Psychoactive Substances Act 
ROS Reactive Oxygen Species 
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SCRA Cannabinoids Receptor Agonist 
SERT Serotonin Transporter 
TCDO Temporary Class Drug Orders 
TPH Tryptophan 5-hydroxylase enzyme 
tRNA Transfer RNA 
UGTs Glucuronosyltransferase 
UNDOC United Nation Office on Drug and Crime 
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The past 10 years have witnessed a substantial increase in the abuse of recreational 
drugs previously referred to as “legal highs” but now more correctly termed New 
Psychoactive substances (NPS). These substances are usually synthetic and similar 
in structure to traditional controlled drugs, but small changes to the molecule are made 
to evade control of drugs legislation based on exact chemical structure and/or 
detection by usual drug analysis methods (Johnson et al., 2013). Various terms have 
been used to refer to NPS, such as ‘research chemicals’, ‘synthetic drugs’, ‘designer 
drugs’, and ‘herbal highs’ (Winstock and Wilkins, 2011). The term ‘New Psychoactive 
Substances’ is more appropriate as a scientific term (Corazza et al., 2013), but more 
recently the term ‘New Psychoactive Substances’ is more often used. (Measham and 
Newcombe, 2016). NPS are defined by the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA), as: 
“As a new narcotic drug or a new psychotropic drug that has not been scheduled under 
the 1961 and 1971 United Nations international drug control conventions, and which 
may pose a threat to public health comparable to the substances listed there in”. 
NPS may be provided as synthetic chemicals, plant material or plant material sprayed 
with synthetic psychoactive drugs (Arunotayanun and Gibbons, 2012). Although 
previously commonly referred to as “legal highs”, it is important to note that some NPS 
products may contain controlled substances and not all produce a euphoriant effect 
(‘high’), with some for example being depressants. The term may have been used by 
suppliers to suggest to the users that the active substances included are not controlled 
under Misuse of Drugs Legislation. Users may also believe that the term legal implies 
that they are safe to use (Vardakou et al., 2011). This may encourage use, especially 
by young people, and this became common in Europe, Australia and the United States.  
In response, the European Monitoring Centre for Drug and Drug Addiction (EMCDDA) 
founded the European Union Early Warning System (EWS) in 1997 and was 
strengthened in 2005 to monitor and response to problems raised by the NPS 
(EMCDDA). 
A particular challenge for managing the public health impact of NPS use is their 
availability for purchase via the internet, which  facilitates the marketing of NPS as well 
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as the unrestricted and easy exchange of unedited thoughts and opinions about them 
(Wax, 2002, Brenda Wasunna 2015). NPS are also commonly sold in specialist shops, 
often termed ‘head shops’ or by street-level drug dealers who may also sell traditional 
illegal drugs of misuse. Marketing of NPS products may be enhanced by attractive 
packaging and their creative and appealing product names which tempt young people 
to use them and they are sold without any age restrictions (Weaver et al., 2015). 
A further public health challenge associated with NPS is that active ingredients of 
specific branded NPS products may change over time, including after changes in drug 
legislation. This potentially puts the user in danger of acute toxicity because there may 
be no information on the safety in humans of exposure to an emerging NPS. In the 
other hand, the user will be unfamiliar with the active substance and the appropriate 
dose to use to obtain the desired effects (Davies et al., 2010).                      
There are two ways that an NPS may be developed. The first classical and generally 
easier way is by creating a structural analogue of a known psychoactive drug with 
sufficient changes to the structure so that it is not captured by control of drugs 
legislation. The second (more challenging) way is by synthesising a drug with similar 
pharmacological effects to a controlled drug, but with a substantially different structure 
to avoid detection (Brandt et al., 2014). 
There are many types of NPS available; examples are synthetic cannabinoid receptor 
agonists (SCRAs), phenethylamines, amphetamines, tryptamines, synthetic 
cathinones, arylcyclohexamines, piperazines, pipradoles, piperidines, aminoindanes, 
opioid analogues, benzodiazepine analogues and tropane alkaloids (see Section 1.3). 
1.1 Risks and effects 
Concerns about the public health impact of NPS use arise from the numbers of people 
using these products and the wide range of chemicals that have been involved. During 
2018 alone the EMCDDA reported the identification of 55 new NPS, and by the end of 
that year more than 730 NPS had been reported to the EMCDDA since their record 
began (EMCDDA, 2019). Almost all of these have not undergone any clinical testing; 
while some were originally developed for medicinal use, they did not progress to clinical 
use, sometimes because of safety issues (Helander et al., 2016). The current efforts 
to limit the emergence and spread of NPS are limited by a lack of scientific information, 
the originality of different psychoactive blends and the continuous development of new 
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substances. The combination of these substances with potentially bioactive material 
from different plants is a further challenge. Although, chemical analysis performed in 
December 2008 revealed that the psychoactive effects of some herbal mixtures tested 
were due to added synthetic cannabinoid receptor agonists rather than the plant 
material present in the herbal products (Dresen et al., 2010).  
Legislative bans on use of one type of emerging drug often results in it being replaced 
very rapidly by a new uncontrolled drug (Gorun et al., 2010, Uchiyama et al., 2014). As 
an example, in Germany in 2009 the authorities banned the synthetic cannabinoid 
JWH-018, which was commonly responsible for the psychotropic effects of ‘spice’ 
products at that time. Four weeks after the ban, JWH-018 was no longer identified in 
spice products, but  had been replaced by the newer synthetic cannabinoid JWH-
073, which had not yet been regulated (Lindigkeit et al., 2009). This cat and mouse 
game potentially increases the hazards for users as even less may be known about 
appropriate dosing and adverse effects of the newer substance, which may have more 
deleterious consequences than the original drug in relation to drug dependency, 
toxicity and long term health effects (Baumeister et al., 2015).  
A further concern, considering their increasing use, is the lack of pharmacological and 
toxicological information about NPS. Most of the available data are obtained from 
retrospective studies and analysis of intoxicated cases reported by the hospitals or 
poisons centres. Interpretation of these data are made especially difficult because 
multiple substances may be involved and these are usually not analytically confirmed 
as part of routine clinical practice. This makes it difficult to link a specific substance to 
an observed clinical effect (Hohmann et al., 2014). In addition, pharmacological and 
toxicological data are not available for the metabolites of these newly emerging drugs 
and these could potentially produce more potent effects than the parent compound 
(Crews and Petrie, 2015). 
The potential serious health consequences of NPS use are also illustrated by the 
increasing frequency of presentation by NPS users to Emergency Departments 
(Baumann and Volkow, 2015). Mortality data are also concerning, for example in 
England and Wales, the number of fatalities ascribed to NPS increased between 2011 
and 2018, although there was a transient reduction in  2017, as shown in Figure 1.1 




Figure 1.1  Number of deaths related to NPS poisoning in England and Wales 
(2008-2018).  
 
Furthermore, rapid, efficient and inexpensive methods of detection of new synthetic 
NPS and their metabolites are not yet feasible. This is due to the complexity of the 
analytical methods required for each new compound, the lack of analytical reference 
standards and time required for establishing a standard procedure for each new 
compound (Favretto et al., 2013, Ibáñez et al., 2014). Synthetic chemists producing 
NPS may move onto a newer compounds while these analyses are being developed. 
In addition, there is a particular lack of information about the longer term consequences 
of NPS use, which may present a severe challenge to public health (Ayres and Bond, 
2012). Risks of social problems such as job loss, financial difficulties, family and 
relationship problems and criminal behaviour are likely, as is the case for established 
or ‘traditional’  drugs of misuse (Hill and Thomas, 2016). Very little information is 
available on the longer term toxic effects of NPS exposure, which is a particular 
concern for repeated users (Cooper, 2016). It is possible that NPS have important 
longer-term effects on the central nervous system; however, the exact mechanisms by 
which these compounds might exert these effects is not known. NPS affect monoamine 
neurotransmitters for example dopamine, serotonin and noradrenaline (Iversen et al., 
2013). Mephedrone, for example induces serotonergic and dopaminergic neurotoxicity 
including serotonin and dopamine transporter loss with decreases in tryptophan 

























Nagai et al. (2007) reported that several types of designer drugs, including synthetic 
amphetamines, tryptamine analogues and piperazines strongly act on the CNS and 
inhibit monoamine uptake and release in rat brain synaptosomes (Nagai et al., 2007). 
Synthetic cannabinoid receptor agonists may induce neurotoxicity through CB1 
mediated cytotoxicity proceeding via apoptosis and this might be responsible for 
impaired attention and memory loss (Tomiyama and Funada, 2014).  
1.2  Prevalence of use of NPS 
It is difficult to determine the prevalence of NPS use because of continuous changes 
in the types, numbers and availability of these compounds. This is further complicated 
by the difficulty in identifying the chemical composition of the many branded products 
that have a wide variety of ‘street names’. Therefore, most estimates of NPS use arise 
from general population surveys which have been conducted in many countries using 
various methods amongst different populations. While population surveys tend to 
evaluate the reported use of traditional drug of abuse, few surveys include NPS, or the 
survey may be restricted to specific categories such as synthetic cannabinoids, leaving 
other NPS not assessed (Palamar and Acosta, 2015). Most of the data on NPS that 
come from general surveys has its limitations as some groups might be 
underrepresented. In addition, some surveys focused on NPS use in certain 
populations at high risk. For instance, psychiatric patients (Stanley et al., 2016), gay 
people (Measham et al., 2011), prisoners (Ralphs et al., 2017) and dance drug users 
(Palamar et al., 2016). Data from poisons centres as well as hospital admission and 
mortality statistics can also help to provide estimation of NPS use and toxicity in the 
population. 
1.2.1 NPS prevalence in the UK 
Several countries have recently started to include NPS in their national drug surveys 
to collect information about the prevalence of NPS use, including in the UK the annual 
crime survey for England and Wales (CSEW). NPS terminology was first introduced 
for the 2014/2015 survey. The CSEW has demonstrated that the prevalence of NPS 
use is low in comparison with some other traditional drugs of abuse, such as cannabis. 
Cannabis was the most frequently used drug in adults aged 16-24 years in 2018/2019 
survey. Prevalence of use over the previous year was 18.6%,16%, 
17.1%,15.7%,13.5%, 15.1%, 16.4%,15.7%,16.4%,16.7% and 17.3 for the years 2008 
to 2019. For NPS, last year prevalence of use  (16-24 years ) was 2.8%, 2.6%, 1.2%, 
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1.2% and 1.4% over the years 2014 to 2019 respectively (Home Office, 2019). In 
Northern Ireland, the life time prevalence of NPS use was 6% in adults aged 15-36 
years and the last year prevalence of use was 6.7% in 2010/11 and 1.6% in 2014/15 
for the same age group (The National Advisory Committee on Drugs and Alcohol, 
2015). In Scotland, the lifetime prevalence of NPS was 1.8% overall of the respondents 
in 2017/2018 with the highest prevalence in those aged 25-44 years. In addition, this 
survey provided the first estimates of the prevalence of SCRA use, which was 2% over 
the previous year (Scottish Government, 2019). 
The Forensic Early Warning System (FEWS) was established in the UK in 2011 to 
identify NPS present or provided for sale in the UK. The 2016/17 FEWS annual report 
reported that 57% of seized drug samples contained at least one NPS and 103 different 
NPS were encountered including 17 NPS new to UK. It was reported that SCRA were 
the most prevalent NPS, and the total number of new substances identified through 
FEWS since 2011 is now 67 (FEWS, 2018). The number of seizures of synthetic 
cannabinoids (spice) in prisons in England and Wales increased dramatically from 15 
in 2010 to 86 in 2011, 133 in 2012, 262 in 2013 and 430 in 2014 (UK Government 
press release, 2015).  
Separate studies have also reported NPS prevalence statistics for the UK, including 
for specific NPS types. An anonymous international survey of 14,966 participants was 
conducted on-line between November 23rd and December 21st in 2011(Winstock and 
Barratt, 2013b). The survey was promoted through social media such as Twitter and 
Facebook and in collaboration with the dance music magazine Mixmag and the 
Guardian newspaper. More than 50% of the participants were from the UK, 23% from 
the USA, 5.5% from Canada, 2.8% from Australia and 2% from Ireland.  Two-thirds of 
them were male and the median age of respondents was 26 years. Of the participants, 
16.8% reported using synthetic cannabinoid receptor agonists (SCRAs) during their 
lifetime with 41% of those reporting use of SCRAs in the last year. Of the recent SCRA 
users, 98% had also used cannabis, while about 50% reported consumption of MDMA 
and about one third reported intake of mushrooms, cocaine, LSD and/or 
benzodiazepines during the last year. About 93% of SCRA users preferred cannabis 
over SCRAs as they perceived the latter to have more undesirable effects. Corazza et 
al. (2014) reported that 31% of the participants in their on line survey among UK 
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students had used ‘legal highs’ including mephedrone (41.4%) and spice (10%) and 
15.7% did not know what compounds they had consumed (Corazza et al., 2014).  
In a study among 533 students aged 15-18 years attending London schools, 20% of 
the participants reported lifetime use of recreational drugs, with cannabis the most 
common (18.7 %) and NPS use was reported by only 1.1% of the participant (Penney 
et al., 2015). In a cross sectional on line survey, of 7700 UK poly drug users’ 
responding, 326 (4.2%) reported the use of the NPS Methoxetamine (Winstock et al., 
2016).  
Most of the data on NPS use arising from general surveys has limitations as some 
groups might be underrepresented. In addition, some surveys focused in NPS use in 
certain higher risk populations. Therefore, there remains incomplete information on the 
prevalence and trends in NPS use in the UK.  
1.2.2 Global NPS prevalence   
The World Drug Report for 2019 has reported that the quantity of NPS seized in 2017 
was more than 400 times greater than that recorded in 2001. Over the period of 2007-
2017 a total of 66 countries reported seizures of NPS, with this number increasing from 
15 countries in 2007 to 45 in 2017 (World Drug Report, 2019). The report also, noted 
that 36% of the NPS identified in 2009-2018 were stimulants and 30% were SCRA. 
However, in recent years the emergence of synthetic opioid NPS has increased and 
has led to serious adverse effects and deaths, particularly in North America.  
The Global Drug Survey (GDS) assesses drugs use in a predominately young 
educated population, across 35 countries with a sample size of 3900 participants. The 
survey showed that 4.3% of the respondents has used an NPS during the last 12 
months and 35.1% of these were younger than 25 years of age (Global Drug Survey, 
2019). A US nationally representative survey, it was reported that 1.2% of subjects 
aged 13-34 years reported use of NPS (Palamar et al., 2015). Tryptamines were the 
most commonly used NPS followed by psychedelic phenethylamines and SCRA. Other 
research, however, has suggested that SCRA are the most commonly used type of 
NPS in the USA. For example, the Monitoring the Future (MTF) survey is designed to 
monitor substance use in the young US population. This reported that SCRAs were 
the second most commonly used illicit drug of abuse after cannabis. The prevalence 
in 12th grade students was 11.4 % in 2011 and 2012, but dropped to 7.9% and 5.8 %in 
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the following years (Miech et al., 2015). In most recent MTF survey, SCRAs use among 
12th grade students had fallen further to 5.5% in 2015, 3.5% in 2016, 3.7% in 2017 and 
3.5% in 2018% (Schulenberg et al., 2019). In another study performed between 
January 2012 and July 2013, 1080 participants in the USA (age range 18-25 years, 
53.4% males, from different ethnic origins) were questioned about their use of alcohol 
and drugs, including SCRAs in the previous 30 days. Of these, 9.3% reported “spice” 
use and 40% marijuana use on a daily basis over the last 30 days (Caviness et al., 
2015).   
A recent study reported that the life time prevalence of NPS use in 6 German states 
ranged from 2.2 to 3.9% making these the most commonly used illegal drugs after 
cannabis (de Matos et al., 2018).  In 2014 the STRIDA project, which monitors the 
presence and health impacts of NPS use in Sweden, assessed the prevalence in NPS 
use among drug poisoning cases presenting to hospital emergency departments and 
intensive care units across the country. Of samples submitted, 83% tested positive for 
at least one drug and 50% of the cases for more than one drug. More than 50 
substances were detected including synthetic cannabinoids, piperazines, substituted 
phenethylamines, synthetic cathinones, hallucinogenic tryptamines, piperidines, opioid 
related substances, ketamine and related substances, GABA analogues and 
phenethylamines. The age range of the cases was 13-63 years (median 20 years) and 
about 80% were adult males. (Helander et al., 2014) Recently, 14 analytically 
confirmed intoxications involving number of synthetic opioids were identified,  9 
involving fentanyl, 3 involving 4-methoxybutyrfentanyl,1 involving furanylfentanyl and 
1 involving 4-methoxybutyrfentanyl and furanylfentanyl together (Helander et al., 
2016). 
In a study by Martinotti et al. (2015) involving 3011 healthy Italian subjects (44.7% 
male; 55.3% female) from different Italian cities, aged between 16 and 24 years, 40.3% 
of the participants reported drug use with cannabis ranked first at 84.1%. NPS use was 
reported by 4.7%, including mephedrone (3.3%), SCRA (1.2%), saliva divinorum 
(0.3%), metamphetamine (0.2%) and desomorphine (0, 1%) (Martinotti et al., 2015). 
In 2012 a Polish epidemiological study conducted on 10,083 school pupils and 4,428 
university students showed that 4.49% of pupils and 1.83% of university students 
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admitted using ‘designer’ drugs. The prevalence in males (4.74%) was higher than in 
females (2.77%)  (Bilinski et al., 2012).  
In Australian cross- sectional surveys among 693 regular ecstasy users, 28% reported 
use of NPS in the past six months, 20% from the stimulant class (17% mephedrone) 
and 13% from the ‘other psychedelic’ class (2C-derivatives, DOI, Mescaline, 5-MeO-
DMTand DMT) (Bruno et al., 2012). 
Collectively, these surveys provide an overview of the prevalence of NPS, but they are 
not directly comparable as each one has a different definition of NPS and targets 
different populations.  
1.3 Types of New Psychoactive Substances 
NPS can be classified according to their chemical structure, pharmacological 
properties, clinical effects, or a combination of these factors (Liechti, 2015, Hill and 
Thomas, 2011, Gibbons, 2012). A useful classification is shown in Table 1.1.  




Synthetic cannabinoid receptor agonists, JWH-
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2-Aminoindane (2-AI), 5-Iodo-2-aminoindane (5-

































Table 1.1  Classification of NPS and related traditional recreational drugs. * 
Overlaps in the structural classification exist such that some chemicals may belong to more 
than one group. 
From all the above categories SCRA has been the NPS group most commonly 
encountered, therefore these are considered in further details below. 
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1.4 Synthetic Cannabinoids Receptor Agonists (SCRAs) 
The term cannabinoids is used in general for “all naturally or synthetic compounds that 
can mimic the actions of plant-derived cannabinoids or that have structures that closely 
resemble those of plant cannabis” (Pertwee, 2005). Cannabinoids act on a cell 
membrane G-protein coupled receptor family, which is subdivided into CB1 and CB2 
receptors. The term SCRAs refers to a “homogenous group of compounds that were 
originally developed as probes of the endogenous cannabinoid system or as potential 
therapeutic agents” (Zaurova et al., 2016).  
Synthetic cannabinoids were first synthesised in the 1960s to mimic the action of 
tetrahydrocannabinol (∆9-THC), the active ingredient of Cannabis sativa (marijuana, 
hashish), to increase the therapeutic, anti-inflammatory and analgesic effects of this 
compound for medicinal benefits. However, it was very difficult to isolate the desired 
therapeutic properties from the undesirable psychoactive effects of these drugs 
(Musselman and Hampton, 2014).   
The term “spice” became popular in Europe in 2005, as a term describing products 
containing synthetic cannabinoids as a legal alternative to cannabis (Auwarter et al., 
2009). A variety of other names have also been used for cannabinoid containing 
products such as Joker, Black Mamba, Kush, Kronic etc. These products are 
commonly advertised as incense blends to be burned to scent rooms, meditation 
potpourris, bath additives or air fresheners and they are usually labelled “not for human 
consumption”. It has been suggested that the psychotropic effects were derived from 
the plant material included in the products to allow smoking. The real action, however, 
results from the addition of a synthetic substance into the botanical mix with agonist 
action on the CB1 receptor. The ingredients listed on the packaging are often incorrect 
or inadequate. One gram of “spice” contains 77.5-202 mg of synthetic compound   
(Auwarter et al., 2009, Simolka et al., 2012).  
Spice is usually smoked, using a pipe or by rolling in a cigarette paper. This is popular 
with users because of the relatively rapid absorption and onset of pharmacological 
effects. Synthetic cannabinoids are non-polar lipid soluble compounds and are 
volatilized readily without decomposition under smoking conditions (B. Zawilska, 
2011). They can also be ingested as a tea or infusion, or pure powder may be inhaled. 
Products are also available for inhalation (‘vaping’) using e-cigarettes (Debruyne and 
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Le Boisselier, 2015). Synthetic cannabinoids vary considerably in chemical structure 
and, while they all act as agonist at CB1 receptors, some may be not structurally 
related to classical cannabinoids (Fattore and Fratta, 2011). For this reason, the term 
‘Synthetic Cannabinoid Receptor Agonist’ or SCRA is more precise than ‘Synthetic 
Cannabinoid’. 
 In 2008, JWH-018 was the first SCRA reported to the EMCDDA. The numbers 
reported continued to grow and had reached 179 SCRAs by the end of 2017, making 
this the largest group of NPS monitored (EMCDDA, 2018). The large number of 
SCRAs, their different chemical structure and the continuous emergence of new 
compounds every year have made it challenging in terms of identification and 
monitoring. This problem is further worsened by the lack of available knowledge about 
their pharmacological and toxicological effects. However, SCRA users may suffer 
severe poisoning and even death. The numbers of cases of toxicity associated with 
SCRA use reported to drug monitoring systems and poisons centres has been 
increasing in Europe, the UK , US and Australia (Tait et al., 2016). Increases have 
occurred in the UK in spite of legislation introduced in 2009, 2012 and 2016 (see 
Chapter 2 for further details on legislation). Each new drug may have different 
pharmacological and toxicological effects and this necessitate the evaluation of the 
interaction of SCRA with many receptors and systems in the body. The clandestine 
industry keeps changing the structure of the substances they sell and these 
synthesized substances had not been evaluated or tested in animals or in humans. 
The pharmacology of SCRAs must be considered individually for each substance 
because any modification in the structure may produce in certain instances, important 
differences in pharmacological action. Recent findings revealed the complex 
cannabinoid signaling pathways (Demuth and Molleman, 2006) and that SCRAs may 
target systems other than CB receptors. Therefore, it is important to characterize the 
pharmacological and biochemical effects of SCRAs not just on CB receptors but also 
on other pharmacological systems, for example, the monoamine transport system. 
1.4.1 Pharmacology of Cannabinoids 
Cannabinoid pharmacology has been researched for over 40 years. Cannabinoid 
agonists are compounds that act on CB receptors. Three main CB ligands have been 




The endocannabinoids are the endogenous agonists for CB receptors. So far, five 
types of endocannabinoids have been characterised. The endocannabinoids are found 
in all organs and body fluids (Di Marzo, 2006b).  
The recognised psychotropic actions of marijuana is mainly due to ∆9-THC, which is 
predominantly responsible for the CNS effects in humans including euphoria, alteration 
in sense of time and hallucinations after high doses (Isbell et al., 1967). Approximately, 
60 cannabinoids have been identified in the cannabis plant but, ∆9-THC is the only one 
with psychotropic effects while the other natural occurring cannabinoids such as 
cannabinol and cannabidiol lack psychotropic effects but have anticonvulsant (Cunha 
et al., 1980), antianxiety (Guimaraes et al., 1990), antiemetic, anti-inflammatory and 
antitumour properties (Mechoulam et al., 2002). Cannabidiol actions may be due to 
inhibition of anandamide breakdown, antioxidant properties or an interaction with an 
up till now unidentified cannabinoid receptor, rather than a direct interaction with CB1 
or CB2 receptors (Pacher et al., 2006).  
SCRAs are potent full CB1 receptor agonists; for example JWH018 is five times more 
potent than ∆9-THC and this probably explains the stronger psychotropic effects of 
SCRAs compared with cannabis. Besides SCRA effects on the endocannabinoid 
system, they might also be able to interact with other targets. For example, JWH-018 
binds to 5-HT2B and the GABAA receptor (Wiley et al., 2016). However, data on SCRA 
actions at non-CB receptors are limited. 
SCRA are highly lipid soluble substances and follow the characteristics of lipid soluble 
drugs. They are rapidly distributed into fat tissue where they can accumulate resulting 
in a rapid reduction in blood concentrations after administration (Kneisel et al., 2014). 
They can pass through the blood-brain barrier and accumulate in brain tissue, leading 
to a higher concentrations than in the blood (Poklis et al., 2012). SCRA undergo phase 
I and phase II metabolism. They are first oxidised by cytochrome P450 enzymes, then 
conjugated with glucuronic acid in the presence of glucuronosyltransferase (UGTs) 
enzymes to be excreted in the urine (Fantegrossi et al., 2014). These enzymes are 
found at high concentrations in the liver, but they also present in the human brain. 
Therefore, the activity of these enzymes may regulate the levels of SCRA in the brain 
and their activation of CB receptors.  
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1.4.2 The endocannabinoid system 
The endocannabinoid system consists of cannabinoid receptors (CB1 and CB2), 
endogenous cannabinoids (endocannabinoids), and the enzymes responsible for the 
synthesis and degradation of the endocannabinoids. It is considered to be a 
neuromodulator system which has a significant role in CNS development, synaptic 
plasticity and response to external and internal insults (Lu and Mackie, 2016). It plays 
a role in many body function such as memory, behaviour, appetite control, etc. (Le 
Boisselier et al., 2017). 
1. Cannabinoid receptors 
Up to the present time, two cannabinoid receptors have been recognised, CB1 and 
CB2 that are encoded by CNR1 and CNR2 genes respectively. However, due to 
complex pharmacology of the endocannabinoid system there was growing evidence to 
postulate the presence of further cannabinoid receptors in addition to CB1and CB2 
(Begg et al., 2005). Recently, G-protein-coupled receptors (GPCRs) such as GPR18 
and GPR55 has been suggested as a potential member of cannabinoid receptors. In 
addition, transient receptor potential vanilloid type 1 receptor (TRPV1) has been shown 
to be activated by different cannabinoids (Brown, 2007). In addition, there are many 
GPCRs that have been suggested as a potential CB receptor such as GPR3, GPR6, 
and GPR12. However, the absence of selective ligands for these receptors along with 
their complex signalling pathways is impeding the identification their relationship with 
the endocannabinoid system (Morales and Reggio, 2017).    
CB1 and CB2 receptors belong to the G-protein coupled receptor family that bind to 
the inhibitory guanine nucleotide binding protein (Galal et al., 2009). Stimulation of 
cannabinoid receptors leads to inhibition of adenylate cyclase, therefore, inhibiting the 
formation of cyclic adenosine monophosphate (cAMP) from adenosine triphosphate 
(ATP) and activates inwardly rectifying potassium channels and mitogen-activated 
protein (MAP) kinase (Figure 1.2) (Grotenhermen, 2004). CB1 receptors acts as a 
neuromodulator through modulation of neurotransmitter release from CB1 expressed 
in the presynaptic terminals, by inhibition of presynaptic Ca++ channels. This may take 
place by direct interaction with the G protein subunit or indirectly by K+ channel opening 
leading to reduction in neurotransmitter release, including acetylcholine, dopamine, γ-
aminobutyric acid (GABA), histamine, serotonin, glutamate, norepinephrine, 
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prostaglandins and opioid peptides (Grotenhermen, 2004). These findings might 
explain some of pharmacological effects of cannabinoids.  
 
 
Figure 1.2  Cannabinoids receptors activation. CB receptors activation inhibits Ca++ 
channels and activate K+ channels. In addition, CB receptors control gene expression by 
activation of MAPK and inhibition of adenylate cyclase and cAMP- protein kinase signalling. 
Figure taken from (Hondebrink et al., 2018). 
 
The CB1 receptor is expressed mainly in the CNS, particularly in the basal ganglia, 
cerebellum, hippocampus and cortex. CB1 receptors are located in presynaptic 
neurons, and to a lesser extend in oligodendrocytes and astrocytes. It is also 
expressed in peripheral neurons and non-neuronal cells, including those in the heart, 
endocrine glands and gastrointestinal tract (Pertwee, 1997, Di Marzo, 2006a). CB1 
receptors are responsible for the psychotropic effects of cannabinoids. (Pertwee, 
2005). CB1 receptors are involved in food intake regulation, accumulation of fat and 
glucose and lipid metabolism (Svíženská et al., 2008). In addition, CB1 is expressed 
in 78-83% of nociceptive neurons of the dorsal root ganglia indicating a role in pain 
modulation (Mitrirattanakul et al., 2006). 
The CB2 receptor is located mainly in immune tissues and blood cells, but has also 
been located in the retina and the CNS (Ashton et al., 2006). These receptors are 
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responsible for the immunomodulatory effects of cannabinoids (Di Marzo et al., 2004) 
through the induction of apoptosis, inhibition of cell proliferation, inhibition of cytokine 
and chemokine production, and induction of regulatory T cells (Rieder et al., 2010).  
2. Endocannabinoids 
This term is used to describe the endogenous ligands for CB1 and CB2 receptors 
which are capable of binding and activating cannabinoid receptors (Di Marzo et al., 
2004). Endocannabinoids are produced within the body and serve as intercellular “lipid 
messengers” and are considered either neurotransmitters or neuromodulators (Figure 
1.3). They have different synthesis pathways and are released from cells upon 
depolarization and calcium entry and their action is rapidly terminated by enzymatic 
degradation and reuptake. It is believed that they are synthesized “on-demand” rather 
than made and stored for later use (Raymon and Walls, 2007, Vardakou et al., 2010). 
Anandamide (N-arachidonoylethyethanolamine) was the first endocannabinoid 
isolated from porcine brain in 1992, followed by the discovery of 2-arachidonoylglycerol 
(2-AG) in 1995. Other endogenous compounds have also been reported, but 
anandamide and 2-AG (Pacher et al., 2006) remain the best studied. 
 
 
Figure 1.3  The endocannabinoid system as neuromodulator. After neuronal 
depolarization and calcium entry, the endocannabinoids bind to presynaptic CB1 receptor. CB1 receptor 
activation result in the inhibition of neurotransmitter release. By doing this, the endocannabinoid system 




1.4.3 Clinical toxicity   
There is lack of information about the potential adverse effects of recreational use of 
cannabinoids such as ‘spice’. The limited available information is from the medical 
literature reporting cases of cannabinoid intoxication or from self-reported surveys. 
Many of the effects of synthetic cannabinoids are similar to those of Δ9-THC especially 
at high doses of the latter and the duration of action of both ranges from 4-14 hours 
(Hermanns-Clausen et al., 2013). But some reports demonstrated that the toxic effects 
of SCRA tend to be more severe and complex than cannabis-related ones (Darke et 
al., 2020). Anxiety was a prominent feature after smoking spice confirmed to contain 
JWH-018 and JWH-073 (Schneir et al., 2011). Psychosis and other psychological 
problems such as panic attacks have also been reported (Müller et al., 2010, Fattore, 
2016). Seely et al. (2012) summarised the most common adverse effects of synthetic 
cannabinoid abuse as affecting the central nervous system, including psychosis, 
seizures, anxiety, agitation, irritability, memory changes, sedation and confusion. 
Cardiovascular (e.g. tachycardia, tachyarrhythmia, cardiotoxicity and chest pain) and 
gastrointestinal (e.g. nausea, vomiting and appetite changes) effects may also occur 
(Seely et al., 2012b). In a study of patients with analytical confirmation of the presence 
of MDMB-CHMICA and AB-CHMINACA, depression was the most common CNS 
clinical symptom (61%); disorientation (45.5%), restlessness/agitation (34.1%), 
hallucinations (34.1%), generalized seizures (27.3%) and anxiety (18.2%) were also 
common. Other reported effects included trembling, mydriasis, sluggish pupillary 
responses, tachycardia, hypertension, and vomiting (Hermanns-Clausen et al., 2018). 
In addition,  most common adverse effects of SCRA reported by undergraduate 
university students were anxiety, depression, rapid heart rate,  paranoia, headache, 
time distortion, confusion, nausea, vomiting, visual and auditory hallucinations, panic 
attacks, intensified sensation and racing thoughts (Mathews et al., 2019). Other 
reported effects associated with the synthetic cannabinoid MDMB-CHMICA  use were 
acidosis, reduced level of consciousness, mydriasis, tachycardia, agitation and tonic-
clonic convulsions (Hill et al., 2016). In a review by Kohen and Weinstein (2018), the 
authors reported that SCRA mimic the effects of Δ9-THC. However, they cause more 
severe adverse effects including sever psychosis symptoms, agitation, hallucinations 
hypertension, tachycardia, respiratory difficulties, chest pain, muscle twitches, acute 
renal failure, anxiety, suicidal ideation, and cognitive impairment (Cohen and 
Weinstein, 2018). It can be noted that SCRA have been associated with several  
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neurologic and psychiatric effects and they might cause recurrence of psychosis in 
vulnerable subjects and trigger psychotic symptoms in in subjects with no previous 
history (Alipour et al., 2019). Some of these adverse effects are congruent with those 
associated with serotonin syndrome (e.g., hypertension, agitation, confusion, anxiety 
and seizures). This can be rather than a direct result of SCRA agonism but could be 
direct or indirect effect of SCRA on serotonergic system.  
SCRAs users may also develop dependence and withdrawal syndromes as also 
encountered in some cannabis users (Zimmermann et al., 2009). However, clinical 
effects not generally associated with Δ9-THC have also been reported after SCRA use. 
These include seizures, hypertension, hypokalemia, agitation and renal failure. These 
may result from the higher affinity to CB1 receptors of SCRAs compared to Δ9-THC or 
their full as opposed to partial agonism at these receptors (Pertwee et al., 2010). The 
possibility also remains that actions may occur via other receptor systems as research 
on their pharmacology is very limited. Also, unexpected toxicity could arise from 
unreported co-use with other drugs of misuse. 
SCRA-containing products can sometimes cause severe toxicity requiring hospital 
admission, but most cases are rapidly discharged from the hospital after supportive 
therapy (Harris and Brown, 2013). To establish patterns of toxicity from SCRAs use, 
enquiries to the National Poison Information Services in the UK were screened for 
potential exposure to SCRA-containing products over the period 2007 to 2014. 
Enquiries were identified involving 510 individuals with probable SCRAs use, with 
annual incidence rising year on year. Of the patients identified,  80.8% were male and 
the median age was 21 years;  90% reported using SCRAs alone prior to their acute 
presentation, while in the remainder SCRAs were used in combination with other 
substances, mostly ethanol, opioids or benzodiazepines (Waugh et al., 2016). In 433 
patients reporting SCRAs use alone, features commonly reported were tachycardia 
(17%), reduced level of consciousness (16%), agitation or aggression (10%), vomiting 
(7%), dizziness (6%), confusion (5%), mydriasis (5%) and hallucinations (5%). Chest 
pain (4%), acidosis (3%), seizures (2%) and elevations in plasma creatinine (2%) were 
recorded less frequently. A systemic review by Tait et al. (2016), reported that 
cardiovascular adverse effects, acute kidney injury, generalised tonic- clonic seizures 
and hyperemesis were the main presentations of SCRA poisoning (Tait et al., 2016).  
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The potential toxic effects that result from long term use of these compounds or their 
metabolites are still unknown (Seely et al., 2012a). Previous studies revealed an 
association between chronic exposure to cannabis and cognitive impairment 
particularly affecting memory, verbal learning and attention (Broyd et al., 2016). In 
addition, repeated cannabis exposure is considered as a risk factor (Andreasson et al., 
1987) for many psychiatric disorders such as schizophrenia, psychosis (Di Forti et al., 
2014) and bipolar disorder (Weinstock et al., 2016). SCRA are often suggested to be 
more potent than cannabis, it may be anticipated that the long-term effects could be 
more severe. There is a growing body of literature that reports chronic SCRA exposure 
inducing similar adverse effects to those of cannabis but more potent and longer lasting 
(Weinstein et al., 2017, Cohen et al., 2017). 
SCRA containing products usually have other additives and adulterants and these may 
contribute to their effects. In addition, SCRA users might also have used alcohol or 
other drugs and this further complicates assessment and clinical management. It is 
important to understand the mechanism of SCRA induced adverse effects with the 
spectrum of toxicities reported in the literature in order to recognise effective protocols 
for the management of acute and chronic toxicity.   
1.4.4 Classification of SCRAs 
SCRAs are classified according to their chemical structure, as follow: 
1. Classical cannabinoids 
These include substances with a similar chemical structure to ∆9-THC (Figure 1.4); 
examples are nabilone (a licensed anti-emetic) and HU-210. ∆9-THC acts as a partial 
agonist at CB1 and CB2 receptors, while HU-210 acts as a full agonist and this may 
explain differences in potency and effects. 
 
Figure 1.4 Chemical structure of some classical cannabinoids.                                                                   
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2. Non classical Cannabinoids 
These compounds were first developed by Pfizer for possible beneficial therapeutic 
effects. They have a simplified chemical structure consisting of two of the three ring 
structures of ∆9-THC (Figure 1.5); examples are CP-50,556-1, CP-47,497, and the C8 
akyl homolog of CP-47,497, CP-50,556-1, which is also known as levonantradol. Some 
of these compounds are 30-fold more potent than ∆9-THC on CB1 receptor.  
                                        
 
Figure 1.5  Chemical structure of some non-classical cannabinoid. 
3. Aminoalkylindoles (AAIs) 
This group of SCRAs are subdivided into four groups, the naphthylmethylindoles (e.g. 
JWH-017), benzoylindoles (e.g. paverlone), phenylacetylindoles (e. g.JWH‐250), and 
naphthoylindoles (e. g. JWH‐073). AAIs showed higher relative potency than ∆9-THC 
on CB1 receptors. In addition, JWH compounds demonstrate various selectivity toward 




                       
Figure 1.6 Chemical structure of some aminoalkylindoles. 
4. Eicosanoids 
The eicosanoids are cannabinoids include some endocannabinoids (e.g. anandamide 
and 2-Arachidonoylglycerol (2-AG), their synthetic derivatives and noladin ether 
(Figure 1.7). The endocannabinoid anandamide has binding affinity to CB1 Receptor 
comparable to ∆9-THC and produce pharmacological effect similar to cannabinoid 
agonists (Lin et al., 1998, Seely et al., 2011, Hohmann et al., 2014). 
 




1.5 The Role of Serotonin (5-HT) in Cannabinoid Toxicity  
Reports of acute and chronic adverse effects of SCRA are accumulating in the 
literature (Section 1.4.3) such as tachycardia, agitation, hallucinations, hypertension, 
vomiting, chest pain, seizures, myoclonia and acute psychosis. These adverse effects  
could be consistent with possible serotonergic involvement (Louh and Freeman, 2014, 
Yip and Dart, 2014).  
Although, the recognition of possible serotonergic features may suggest serotonergic 
involvement in SCRA intoxication, a systematic understanding of how the cannabinoid 
system interacts with serotonergic transmission is still lacking. The involvement of 
cannabinoids in serotonergic transmission could either be through direct interaction 
with the serotonergic receptor, increased 5-HT release or uptake inhibition, or indirectly 
through modulations of these activities via CB1 receptor activation.  
Early studies revealed that ∆9-THC and several of its derivatives were able to inhibit 
the uptake of 3H-labelled noradrenaline (NE), dopamine (DA), GABA and 5-HT in rat 
brain (Sofia et al., 1971, Hershkowitz et al., 1977, Banerjee et al., 1975). Acute or 
perinatal ∆9-THC exposure produces different effects on 5-HT levels in different brain 
regions with no change in the densities of 5-HT uptake sites (Molina-Holgado et al., 
1993). Subsequent studies that investigated the crosstalk between the 2 systems were 
mainly motivated by the potential to use the endocannabinoid system as a potential 
therapeutic target.  5-HT neurons play a role in mediating cannabinoid anti-emetic 
actions and some types of analgesia by direct inhibition of the 5-HT3 receptor by 
cannabinoids (Barann et al., 2002). In addition, 5-HT has been involved in 
cannabinoid-induced hypothermia (Malone and Taylor, 1998), sleep (Mendelson and 
Basile, 2001) and appetite stimulation (Rowland et al., 2001). 
 It has been suggested that CB1 receptors are located presynaptically on serotonergic 
neurons (Nakazi et al., 2000), alongside proteins responsible for re-uptake and 
monoamine release (Lau and Schloss, 2008). The co-expression of CB1 receptors with 
different subtypes of 5-HT receptors might further indicate interactions between the 
two systems at the level of binding sites (Hermann et al., 2002).  
Studies examining the effects of chronic cannabinoid exposure demonstrate that this 
leads to an increase in the 5HT content of the rat frontal cortex (Sagredo et al., 2006), 
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upregulated 5-HT2A activity and concomitant down-regulated 5-HT1A activity (Hill et al., 
2006). 
In the central nervous system, an important action of cannabinoids is inhibition of 
neurotransmitter release (Schlicker and Kathmann, 2001). In addition, cannabinoids 
modulate the firing of monoaminergic neurons and the release of DA, NE and 5-HT 
(Fišar, 2012). Moreover, cannabinoid receptors could play an indirect role in the 
regulation of serotonin transporter (SERT) activity (Kenney et al., 1999) by affecting 
intracellular levels of cAMP and Ca++ which in turn regulate SERT protein (Yammamoto 
et al., 2013, Ciccone et al., 2008). However, Steffens et al. (2004) showed that the 
inhibitory effect of the synthetic cannabinoid WIN55212-2 and the endocannabinoid 
anandamide on DA and 5-HT uptake was mediated by a decrease in Na+ / K+-ATPase 
activity rather than via the CB receptor (Steffens and Feuerstein, 2004). In one study, 
both in vivo and in vitro effects of ∆9-THC, anandamide and the CB receptor agonist 
WIN 55,212-2 were investigated on platelet 5-HT uptake. It was concluded that SERT 
was inhibited acutely by cannabinoids at high concentrations, and the increase in 
maximal velocity of 5-HT uptake could be due to adaptive changes in the serotonergic 
system induced by chronic cannabis use (Velenovská and Fišar, 2007). In addition, 
∆9-THC affects the organization of the developing diencephalic serotonergic system 
without affecting the 5-HT uptake site density (Molina-Holgado et al., 1996, Molina-
Holgado et al., 1993).Interestingly, it has been reported that repeated exposure to CB2 
receptor agonists can upregulate 5-HT2A receptors in rat neuronal cells that express 
both 5-HT2A and CB2 receptors (Franklin and Carrasco, 2013, Franklin et al., 2013b). 
Modulation of 5-HT2A play an important role in many physiological function such as 
anxiety (Weisstaub et al., 2006) and the psychoactive effects of the 
phenylisopropylamine hallucinogens and LSD (Titeler et al., 1988). 
Collectively, these studies show complex serotonergic responses to cannabinoids. It 
is possible that SCRA increase serotonergic activity through different mechanisms, but 
the structure similarity of indole containing SCRAs with serotonin might allow them to 
act as competitive inhibitors of 5-HT uptake or activate 5-HT receptors. Further 
characterisation of SCRA actions on 5-HT systems is needed to advance the 
understanding of how these drugs affect different brain area.   
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1.6 Serotonin, 5-HT  
5-Hydroxytryptamine (Serotonin, 5-HT) was originally detected as the substance that 
gives the serum its vasoconstrictive properties (Page, 1954) and was identified 
chemically as 5 hydroxytryptamine (Rapport, 1949).  
The synthesis of serotonin (Hamlin and Fischer, 1951) opened the door for researchers 
in neuroscience to understand and investigate many of the physiological activities and 
behavioural disorders in the human body. Interest in 5-HT as a possible CNS 
transmitter started when Gaddum found that lysergic acid (LSD) acted as a 5-HT 
antagonist in peripheral tissue and suggested that its central effect might related to 5-
HT action (Gaddum and Hameed, 1954). Since then, 5-HT has been shown to act as 
neurotransmitter in the CNS and as a hormone in the peripheral vascular system. 
Although over 90% of the total body 5-HT is found outside the CNS, 5-HT plays a vital 
role in modulation of many behavioural and neuropsychological processes. In the 
periphery, 5-HT regulates vascular tone, gut motility, primary homeostasis and cell-
mediated immune responses (Veenstra-VanderWeele et al., 2000).   
 
1.6.1 5-HT pathways in the CNS 
The distribution of 5-HT containing neurons (Figure 1.8) is similar to that of adrenergic 
neurons, but the serotonergic system is more expansive (Jacobs and Azmitia, 1992). 
The cell bodies of the neurons are concentrated in the pons and upper medulla, close 
to the midline and referred as the raphe nuclei. They are clustered in two general 
groups: a superior group (rostral nuclei) comprised of four groups of serotonergic 
nuclei, the dorsal raphe, median raphe, caudal linear, as well as the supralemniscal 
nucleus. The second group is the inferior group (caudal nuclei), that consists of the 
nucleus raphe obscurus, nucleus raphe pallidus, nucleus raphe magnus, ventral lateral 
medulla, and the area postrema. The rostral nuclei project into many parts of the cortex 
and to the hippocampus, basal ganglia, limbic system and hypothalamus, while the 






Figure 1.8  The 5-HT pathways in the brain illustrating the serotonergic neurons 
and the distribution of their axon projections in the brain. Figure taken from 
Serotonin and motivation: How does serotonin affect motivation? 
https://en.wikiversity.org/wiki/Motivation_and_emotion/Book/2017/Serotonin_and_motivation. 
 
5-HT is synthesized in the brain from the amino acid L-tryptophan in a two-step 
enzymatic process (Figure 1.9). The first step is hydroxylation of L-tryptophan by the 
tryptophan 5-hydroxylase enzyme (TPH) to form 5-hydroxytryptophan; this is the rate 
limiting step of the synthesis (Fitzpatrick, 1999). Two isoforms have been identified, 
TPH1, which is mainly localised in the periphery, and TPH2, which is mainly found in 
neuronal cells and the CNS (Walther et al., 2003). The second step is decarboxylation 
of 5-hydroxytryptophan by the enzyme hydroxytryptophan decarboxylase to form 5-HT 
(Fernstrom, 1983). The synthesized 5-HT is then transported from the cytoplasm into 
storage vesicles via two forms of vesicle monoamine transporter, VMAT1 and VMTA2 
(Erickson and Eiden, 1993). VMAT1 occurs in non-neural cells of the periphery, 
whereas VMAT2 occurs in neurons.  
 
Figure 1.9  Biosynthesis of 5-HT. 
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The vesicles release 5-HT into the synaptic cleft by exocytosis after activation of 
calcium channels by an action potential (Elhwuegi, 2004).  The intensity and the 
duration of 5-HT release are controlled by the reuptake of 5-HT into the presynaptic 
terminal or the glial cells (Figure 1.10). Reuptake into the presynaptic terminal is 
facilitated by the high affinity serotonin transporter (SERT), which represents the major 
pathway for presynaptic 5-HT clearance (Torres et al., 2003). In addition, recent 
studies revealed a second transport system of 5-HT, which consists of the organic 
cation transporter (OCT) and plasma membrane monoamine transporter (PMAT). 
According to these findings SERT is termed the uptake 1 transporter and OCT and 
PMAT the uptake 2 transporter and these play important roles in serotonin uptake 
(Zhou et al., 2007).  
 
Figure 1.10  Diagram of serotonergic nerve terminal illustrating the synthesis, 
release, reuptake and metabolism of 5-HT. TpH: tryptophan hydroxylase; 5-HTP: 5-
hydroxy-L-tryptophan; 5-HT: serotonin; SERT: serotonin transporter; MAO: monoamine 
oxidase; 5-HIAA: 5-hydroxyindoleacetic acid; 5-HTR: serotonergic receptor (Buller et al., 
2012). 
 
Degradation of 5-HT in serotonergic neurons occurs through oxidative deamination, 
catalysed by monoamine oxidase enzymes (MAO) (Shih et al., 1999). MAO occurs in 
two forms in the brain, MAO-A, which has higher affinity for 5-HT and other 
monoamines, and MAO-B, which has higher affinity for phenylethylamines. Both are 
located in the outer membrane of mitochondria (Green and Youdim, 1975). 5-HT is 
catabolised by MAO-A into 5-hydroxyindole acid aldehyde which is further oxidised by 
aldehyde hydrogenase enzyme into 5-hydroxyindole acetic acid (5-HIAA) which is 
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excreted in the urine and can be used as indicator  of 5-HT production in the body 
(Virkkunen et al., 1995).   
 
1.6.2 Pharmacology of 5-HT 
The actions of 5-HT are numerous and complex and influence a broad range of 
physiological systems. The diversity in 5-HT action is due to differences in 5-HT 
receptors and sub receptors. Currently there are 14 known receptors subtypes, divided 
in 7 classes (5-HT 1-7). These receptors are different in protein structure and the 
affinity for various agonist or antagonist ligands (Hoyer et al., 1994). All the 5-HT 
receptors are G-protein-coupled receptors with the exception of 5-HT3 receptors, which 
are ligand gated ion channel receptors (Green, 2006). Consequently, efforts are 
concentrating on the identification of selective ligands more specific for receptor type 
to enhance drug treatment with fewer adverse effects (Hoyer et al., 2002). The 
following sections outline briefly the main sites of 5-HT action. 
1.6.2.1 Central nervous system  
All brain regions express multiple serotonin receptors in a receptor subtype-specific 
fashion (Lucki, 1998). 5-HT is involved in many vital physiological processes in  the 
brain including sleep (Jouvet, 1999), appetite (Blundell, 1976) and behavioural 
functions such as aggression, sexual behaviour, pain sensitivity, sensorimotor 
reactivity and learning (Lucki, 1998), as well as in psychiatric disorders such as 
schizophrenia, clinical depression and anxiety. Moreover, deficiency in serotonergic 
neurons in aging may contribute to late-age depression and Alzheimer disease 
(Meltzer et al., 1998). 
1.6.2.2 Gastrointestinal tract (GIT) 
5-HT has long been assumed to play a major role in GIT function since its isolation and 
characterisation as ‘enteramine’ in 1952 (Erspamer and Asero, 1952). More than 90% 
of body serotonin exists in the gut wall with only 10% located in neurons. 5-HT that is 
located in the enterchromaffin cells plays essential role in several aspects of gut 
function including secretion, motility and sensation (Gershon, 1999). The action of 5-
HT in the gut is complex. Different subtypes of 5-HT receptor are present throughout 
the enteric nervous system and the gut muscles. Alterations in 5-HT synthesis or 
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uptake have been implicated in bowel disorders, including irritable bowel syndrome 
and ulcerative colitis (Coates et al., 2004). 
1.6.2.3 Platelets and blood vessels  
Platelets uptake 5-HT synthesised in the gut via SERT and store it in storage granules. 
When platelet aggregation starts the serotonin is released in to the circulation and 
causes further enhancement of platelet aggregation (Vanhoutte, 1991). In addition 5-
HT promotes vasoconstriction of the surrounding blood vessels and facilitates 
haemostasis if the endothelium is intact, but if the endothelial is damaged, 5-HT can 
exert a harmful vasoconstrictive effect (Kaumann and Levy, 2006). Interestingly 5-HT 
can either cause vasoconstriction or vasodilation, depending on the type of receptors 
expressed in each vessel and in the surrounding smooth muscle (Ullmer et al., 1995).  
1.7 Neurotoxicity of Synthetic Cannabinoids Receptor Agonists 
The data on the harms associated with acute and chronic use of SCRAs is limited and 
still emerging. To date, there are few studies that have investigated the toxicology or 
metabolism of SCRA. While considerable research has been carried out on cannabis, 
it cannot be assumed that the risks connected with cannabis use is similar with those 
associated with SCRA. Since the main targets of cannabinoids; whether they are 
natural or synthetic, is the CNS, the focus of this thesis is on the toxic effect on the 
brain.  
Recent studies on regular cannabis users have demonstrated that chronic cannabis 
exposure induces functional and structural changes in the human brain. Weinstein et 
al. (2016) reviewed the brain-imaging, pharmacological and neurobiological studies of 
cannabis users. They revealed that regular use of cannabis results in volumetric and 
structural changes in the grey and white matter in the brain, in particular in the 
hippocampus and the amygdala. Regular cannabis use resulted in reduced dopamine 
transporter occupancy and reduced dopamine synthesis but not in reduced striatal 
D2/D3 receptor occupancy compared with healthy control participants (Weinstein et 
al., 2016). In a study of SCRA users Nurmedov et al. (2015) reported that grey-matter 
volume in the left cerebellum and thalamus was reduced in SCRA users in comparison 
to healthy volunteers (Nurmedov et al., 2015). Furthermore, Zorlu et al. (2016) reported 
that SCRAs users had a significant reduction in white matter in numerous brain areas 
including the left temporal lobe, subcortical structures and brainstem (Zorlu et al., 
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2016). These studies suggest potential neurotoxic effects of SCRA use and the need 
for further research. Therefore, the next section highlights some of the in vivo and in-
vitro studies of SCRA cytotoxicity. 
1.7.1 In vivo cytotoxicity studies of SCRAs 
In vivo animal studies revealed that JWH-018 and JWH-210 reduce locomotor 
activities and cause neuronal damage through distortion of nucleus membranes in the 
core shell of the nucleus accumbens (Cha et al., 2015). Moreover, both cannabis and 
SCRA decreased both short- and long-memory retention in mice (Barbieri et al., 2016, 
Fehr et al., 1976, Heyser et al., 1993, Basavarajappa and Subbanna, 2014). In 
addition, JWH-018 and its derivatives cause locomotor suppression, antinociception 
and hypothermia, as does Δ 9 –THC and other types of SCRA (Compton et al., 1992, 
Wiley et al., 2012, Vigolo et al., 2015, Ossato et al., 2016). JWH-018 impairs 
sensorimotor function in mice (Ossato et al., 2015), increases indices of anxiety (Macrì 
et al., 2013), and increases dopamine release in the nucleus accumbens shell of mice 
(De Luca et al., 2015). Finally, AM2201-induced seizures which might be related to 
rapid increases in glutamate release in the hippocampus (Funada and Takebayashi-
Ohsawa, 2018).  However, withdrawal signs have been reported after withdrawal of 
repeated exposure with higher potency SCRAs including CP-55,940, WIN-55,212-2, 
and JWH-073 (Oliva et al., 2003, Aceto et al., 2001, Nacca et al., 2013). 
1.7.2 In vitro cytotoxicity studies of SCRAs 
There have been few studies investigating the cytotoxicity of SCRAs. Koller et al. 
(2013) reported JWH-018, JWH-073, JWH-122, JWH-210 and AM-694 induced cell 
membrane damage at buccal (TR146) and breast (MCF-7) derived cells at 
concentrations higher than 75µM, but they did not affect mitochondria, protein 
synthesis, or lysosomal functions at the same concentration (Koller et al., 2013). 
Couceiro et al. (2016) reported that JWH-018 metabolites were more toxic than the 
parent compound on neuroblastoma SH-SY5Y and human kidney cell lines and these 
toxicities were not mediated via the CB1 receptor (Couceiro et al., 2016).  
Bologov et al. (2011) evaluated the effects of the cannabinoids CP 55,940, HU-210, 
WIN 55,212-2 and ∆9-THC on the neuroblastoma cell line N18TG2. They suggested 
that the tested cannabinoids induced cytotoxicity when the cells were under stress, but 
failed to induce toxicity under optimal cell conditions. They concluded that the various 
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physiological responses to cannabinoids, which have different intracellular 
mechanisms, depend on the state of the cells (Bologov et al., 2011). Almada et al. 
(2017) reported that the synthetic cannabinoid WIN-55,212 induced cell cycle arrest 
and reduced cell viability in a human choriocarcinoma cell line through disruption of 
mitochondrial membrane potential and activation of caspases -9 and -3/-7. This action 
was mediated through the CB1 receptor (Almada et al., 2017). Likewise, WIN 55,212–
2 was reported to induce cell death and induce cytotoxic effects in a renal carcinoma 
cell line (Khan et al., 2018). Another study reported the concentration dependant 
cytotoxicity of the synthetic cannabinoids CP-47,497, CP-55,940 and CP-47,497-C8 in 
a NG 108-15 cell line. The study suggested that cell death was through caspase 
cascade activation leading to apoptosis and this effect was mediated via the CB1 
receptor (Tomiyama and Funada, 2014). Similarly, Koller et al (2014) reported the 
cytotoxic properties of the synthetic cannabinoid CP-47,497-C8 was through interfering 
with protein synthesis and causing cell membrane and DNA damage at a concentration 
of more than 10 µM in buccal derived (TR146) and liver derived (HepG2) cell lines 
(Koller et al., 2014).The cytotoxic properties of cannabinoids, however, remain 
contentious. Pereira (2014) reported the cytotoxicity of JWH-250 at 50 µM, whereas 
JWH-073 was not toxic in a SH-SY5Y cell line (Pereira, 2014). Some studies have 
reported that SCRAs (Bileck et al., 2016) can cause genotoxic damage to DNA that 
may have adverse health effects (Koller et al., 2015, Koller et al., 2013, Ferk et al., 
2016).  
Currently, no definitive mechanism by which SCRAs induce cytotoxicity and cell 
damage has been established. Tomiyama and Funada (2011) suggested the role of 
apoptosis through the activation of the caspase-cascades signalling pathway, whereas 
Couceiro et al. (2016) proposed that cell death was induced through necrosis and this 
was not mediated by CB1 receptors. Almada et al. (2017) reported that reduction in 
cell viability in WIN-55,212 exposed cells resulted from the disruption of the 
mitochondrial membrane potential and activation of caspases -9 and -3/-7. Recently, 
Oztas et al. (2019) reported that the cytotoxicity of the synthetic cannabinoid AKB48 in 
SH-SY5Y cells was due to an increase in reactive oxygen species (ROS) production 
and significant increase in gene expression level of NF-κB and MAPK8. They 
concluded that lower doses induce apoptotic effects, while both apoptotic and necrotic 
effects were induced at higher doses (Oztas et al., 2019). 
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Overall, the information available on the safety and toxicity of SCRA is limited and 
differs considerably in methodology and SCRA analysed. Most of the research on 
SCRA-induced cytotoxicity tested individual SCRA on different cell lines that varied in 
the type of receptors expressed. Furthermore, most of the above studies tested high 
concentrations of SCRA, far above those observed after human use. In addition, most 
of the tests were for acute short-term exposure to establish the mechanisms of cell 
death. Data on the long-term exposure effects of SCRA are scarce and the changes 
they induce on long term use are still not known. 
1.8 Mitochondrial role in cellular stress responses  
Stress signalling pathways play an important role in maintaining cellular homeostasis. 
Cells can react to stress in different ways, from activating survival pathways to initiating 
cell death, which ultimately eliminates damaged cells. The early response of the cells 
to a stressful stimulus may provide protection against the insult and allow recovery 
from it. Nevertheless, if the harmful stimulus is unresolved, then death signalling 
pathways will be activated (Hotamisligil and Davis, 2016). The cellular response to 
stress depends on the kind and severity of the insult which in turn can activate different 
defence mechanisms. Stressors can be physical or chemical in nature and can be 
intrinsic such as DNA mutation and deletion or calcium overload, or extrinsic such as 
environmental toxins and chemicals (Eisner et al., 2018).  
Mitochondria are responsible for oxidative phosphorylation and energy production in 
form of ATP. In addition, they are responsible for controlling intracellular Ca++ signalling 
and metabolism, thermogenesis and ROS production and they act as initiators of 
programmed cell death (apoptosis) (Scheffler, 2001). In view of their vital role in cellular 
functioning, mitochondria are one of the first responders to different stressors that 
perturb cellular homeostasis (Manoli et al., 2007). Many stressors target non-
mitochondrial cell components, but often pathways converge on the mitochondrion, 
because of its main function in producing energy and signalling survival and adaptation 
to stressors (Picard et al., 2018). Other stressors interfere with mitochondrial functions 
directly, involving energy production, calcium signalling cell death and cell dynamics 
(Meyer et al., 2018). The mitochondrial response to cellular stress and signalling 







Figure 1.11 Mitochondrial response to different cell stressors. Outlines how mitochondria response to intrinsic and extrinsic stimulus. 
Different responses may arise and consequently lead to physiological and pathological changes. UPRmt, mitochondrial unfolded protein response; 
MDVs, mitochondria-derived vesicles; PTP, permeability transition pore; CMG, circulating mitochondrial genome (also ccf-MT-DNA); SASP, 
senescence-associated secretory profile. Figure taken from (Eisner et al., 2018).  
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One of the directly affected targets is mitochondrial DNA (MT-DNA, Figure 1.12). This 
encodes 13 protein subunits, two rRNA and 22 tRNA that are vital for the function of 
oxidative phosphorylation system, which consists of four respiratory-chain complexes 
and adenosine triphosphate (ATP) synthase (Gustafsson et al., 2016 1282). Mutations 
in MT-DNA lead to interference with respiratory chain complexes and ATP synthase, 
which interferes with oxidative metabolism and disturbs electron transport chain (ETC) 
function and this impacts on ATP production (Suomalainen and Battersby, 2018).  
Mitochondria are sensitive to oxidative damage caused by reactive oxygen species 
(ROS) (Turrens, 1997). ROS are reactive oxygen intermediates, they usually result 
from excitation of O2 to from a superoxide radical, hydroxyl radical or hydrogen 
peroxide. They are produced as by-products of cellular metabolism, mainly in the 
mitochondria or in cellular responses to xenobiotic (Ray et al., 2012). Normally, ROS 
are neutralised by the cellular antioxidant defence system, but when there is an 
increase in their production they can oxidize and induce destruction of cell components 
such as lipids, protein and DNA including MT-DNA (Holmstrom and Finkel, 2014). 
Oxidative damage to protein can lead to modification in cellular protein structure and 
consequent loss of function and accumulation of the unfolded proteins, which can 
impair cell function, leading to endoplasmic reticulum (ER) stress and activation 










Figure 1.12  Mitochondrial DNA (MT-DNA). The protein-coding genes encode for the 
complexes required for oxidative phosphorylation (Complex I: orange, complex III: purple, 
complex IV: pink, complex V: yellow). Figure taken from (van der Wijst et al., 2017). 
1.9 Unfolded protein response (UPR)  
The UPR is a series of signalling pathways, activated in response to accumulation of 
unfolded or misfolded proteins (Walter and Ron, 2011). Proteins are synthesised in the 
endoplasmic reticulum (ER) lumen. The UPR activation aims initially to rectify the 
errors in protein synthesis. This done by reduction in protein synthesis and 
translocation into the ER and increasing ER capacity to handle unfolded protein by 
activation the machinery that is involved in protein folding. If the disruption is prolonged 
and fails to restore homeostasis, UPR triggers apoptosis and cell death (Ron and 





1.10 Thesis objectives  
The research presented in this study aims to evaluate the prevalence of NPS in the 
UK for the last 10 years and explore some of the pharmacological and toxicological 
properties of NPS and in particular SCRA. Specific aims were as follows: 
1. To identify the numbers of NPS poisoning in the UK by analysing data collected 
by poisons centre. 
2. To evaluate the effect of SCRA on 5-HT uptake in a rat brain slice model. 
3. To evaluate the neurotoxicity of some NPS and in particular SCRA using human 
stem cells and to explore the mechanisms of the toxicity observed. 
  The following research was therefore conducted: 
1. An investigation of the prevalence, trends and demographic characteristics of 
people experiencing toxicity after use of NPS, as reported in telephone 
enquiries to the UK National Poison Information Service (NPIS) (Chapter 2). 
2. Research testing the hypothesis that SCRA containing an indole structure can 
affect serotonin uptake without the involvement of CB1 receptors (Chapter 3).   
3. Studies of the cytotoxic properties and changes induced by repeated exposure 





    




 Epidemiology of NPS toxicity 
 
2.1 Introduction 
Over the last decade the numbers of NPS involved in misuse and the numbers of 
people presenting with NPS-associated toxicity have increased at an unprecedented 
rate; this proliferation poses a substantial challenge to drug policy and carries a 
significant hazard to public health (World Drug Report, 2017). The UK has one of the 
highest rates of NPS use in Europe after the Netherlands (Global Drug Survey, 2017). 
In 2016 58% of NPS were purchased online in the UK and there is evidence of adverse 
health effects, with NPS users three times more likely to end up seeking emergency 
medical treatment (Global Drug Survey, 2016). 
In spite of the widespread interest in the social and health impacts of NPS use, there 
is insufficient epidemiological data in the scientific literature and popular media about 
NPS in comparison to traditional drugs of abuse (Bersani et al., 2014). This is in part 
because, while routine data collection is in place in many countries for traditional drugs, 
it is challenging to adapt this to the rapidly evolving use of NPS.  
In the UK information is available about diagnosis in patients admitted to hospital or 
presenting at emergency departments, but this not specifically available for 
presentations after use of NPS as coding does not involve this level of detail and also 
commonly coding are not very accurate (Wood et al., 2011). In any case, the NPS 
involved may not be characterised accurately because the laboratory analysis required 
is not done as part of routine patient care. Data on causes of death is published and 
this may include information on deaths related to NPS, but information about specific 
NPS is not included (Office for National Statistics, 2016) and detailed analytical 
toxicology is not performed on in all drug related deaths. Other data sources regarding 
NPS are also available such wastewater or urinal analysis, festival screening, data 
from seizures of drugs and case reports or case series. In addition, the information on 
the prevalence of use of NPS could come from small-scale studies among specific 
population sub-groups, for instance club attenders, military forces or representative 
population-based surveys among the general population.  
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Table 2.1 shows the potential data sources regarding NPS that might help to 
understand the pattern of NPS toxicity with their strengths and limitations (Wood and 
Dargan, 2012, Hill and Dargan, 2018). 
Data Source Strengths Limitations 
Analysis of drug product 
Drug seizures by law 
enforcement (Police, 
Border Force etc) 
Provide quantitative data about: 
 
 Types and amounts of drug 
seized 
 Purity of the marketed drugs 
 Identifies new drugs appearing 
in the market 
Do not reflect the number of users 
involved or the frequency of toxicity 
Analysis of voluntarily 
submitted samples, e.g. 
WEDINOS, FUSE 
Routinely collected health information 
Emergency department 
attendances or hospital 
admissions 
High-volume national-level data 
Coding may not be available for some 
individual substances, especially NPS 
 
Coding may be inaccurate 
 
Data may be reported by drug group 
rather than specific substance 
 
No analytical confirmation available to 
identify individual NPS 
 
Poisons centre data (e.g. 
NPIS) 
 
Data are collected continuously 
using consistent methodology. 
 
High-volume national-level data 
about individual substances 
 
Time trends in episodes of drug 
toxicity can be measured indirectly. 
 
Characteristics of toxicity can be 
described 
 




Lack of analytical confirmation. 
 
Data depend upon voluntary reporting by 
health professionals or members of the 
public (not UK) 
 
Rates of reporting may decrease with 
increasing familiarity about the 
substances involved 
Referrals to drug 
treatment / addiction 
services 
 
Data are collected continuously 
using consistent methodology. 
 
High-volume national-level data 
about individual substances 
 
 
Lack of analytical confirmation 
 
No information available on acute toxicity 
 
Coding often not available for NPS 
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Mortality statistics (e.g. 
ONS, NRS, NISRA) 
 
 
National-level data available 
 
Analytically confirmed drug 
prevalence 
 
Reflect most extreme forms of 
toxicity 
Inconsistent drug analysis ordered by 
coroners – may not include emerging 
drugs of misuse 
 
Drugs identified may not be the cause of 
death 
 
Delay to statistics being available 
 
Collected in different formats in the 
various devolved administrations 
Population surveys/information 
Population surveys such 
as CSEW 
Reflect the prevalence of reported 
drug misuse in the population (e.g. 
aged 16- 59 in the CSEW) 
Relies on user reports 
 
No analytical confirmation available 
 
No information about toxicity provided 
 
Information on some NPS not collected 
Internet discussion and 
blogs such as Drugs 
forum and Erowid 
Detailed information dose, routes 
of administration and desired and 
unwanted effects. 
 
No analytical confirmation of the NPS 
used. 
 
Unrestricted and unedited thoughts and 




among specific population 
sub-groups such as 
festival goers 
Provide a picture of prevalence of 
use of NPS in that setting 
May not reflect other drug user groups 
 
No analytical confirmation 
 
Used predetermined questions that 
may limit any additional information 
 
Analytical surveys 
Clinical studies of drug 
users (e.g. IONA, 
STRIDA) 
Comprehensive analysis of clinical 
features and outcomes 
Analytical conformation of 
substances involved 
May require patient consent 
 
Not all drug misuse may qualify for entry 
 
May not cover whole country 
Wastewater and urine 
analysis 
Identifies analytically substances 
of specific interest 
Prevalence of use or toxicity cannot be 
determined 
Others 
Case reports or case 
series 
Detailed clinical data provided 
Limited case numbers 
 
Some do not include analytical 
confirmation of the drug(s) involved 
 
Table 2.1 Sources of Data about NPS in UK.  
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All these approaches have their limitations and therefore the overall assessment of 
NPS use, trends and effect remains challenging and incomplete. 
While use of specific NPS can be suppressed by legal controls based on chemical 
structure, including the UK Misuse of Drugs Act (1971), this can prompt the emergence 
of further NPS with chemical structures modified to avoid capture by pre-existing 
legislation. The aim of prohibition of the use of drugs of abuse is to reduce their use 
and the associated health and societal impacts. Such legislation often targets specific 
drugs or drug groups on the basis of their chemical structures and associated health 
and societal impacts using an evidence-based process which usually takes some time. 
Modifications of a chemical structure may produce a drug that is no longer legally 
controlled but retains activity as a potential drug of misuse. Trying to cope with the 
increased number of NPS, the UK government introduced temporary class drug orders 
(TCDO) to bring new emerging NPS under control more rapidly. A TCDO bans a drug 
or chemical for 12 months to allow time for further assessment; after that the drug is 
either controlled permanently using the Misuse of Drugs Act, if sufficient evidence of 
harms is available, or extend the TCOD to gather more evidence or it reverts to 
becoming legal again (Home Office, 2011). However, even using this regulatory 
approach to classifying drugs, it is often not possible to match the speed of their 
appearance on the market.     
The UK government therefore enacted generic legislation to restrict the production, 
distribution and sale of any psychoactive substance if the substance is likely to be used 
for its psychoactive effects. This Psychoactive Substances Act (PSA) was enacted into 
law in the UK on 26th May 2016. Some substances are exempted, including alcohol, 
nicotine, caffeine and licensed medicines (Home Office, 2015b). 
Research presented in this chapter investigated the prevalence, trends and 
demographic characteristics of people experiencing toxicity after use of NPS, as 
reported in telephone enquiries to the UK National Poison Information Service (NPIS) 
over the last decade. The NPIS provides poisons information and clinical advice via 
telephone to health care professional across the UK about diagnosis, treatment and 
management of patients who may have been poisoned, including those exposed to 
drugs of misuse. Telephone enquiries are more likely when the substances involved 
are unfamiliar, such as NPS. Data are available on temporal trends and demographics 
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for specific substances and it is possible to extract data for individual NPS as reported 
by enquirers.  
The NPIS is provided by four individual Units, based in Birmingham, Cardiff, Edinburgh 
and Newcastle, supported by consultants from two further NHS provider Trusts. These 
are staffed by Consultant Clinical Toxicologists and Specialists in Poisons Information 
who work together to provide information and advice by telephone to health 
professional enquirers on a 24/7 basis (National Poisons Information Service, 2018).  
In addition, the NPIS provides an on-line poisons information database called 
TOXBASE®, which contains information about diagnosis and management of 
approximately 17,000 medicines, chemicals and toxins.  
Heath professionals managing people presenting with poisoning of any type, including 
toxicity relating to drug misuse, are encouraged to use TOXBASE® as their first line 
information source. Most accesses to TOXBASE® are made in this context, but some 
are made out of interest or for educational reasons and there may be several accesses 
about the same patient by different health professionals. Access numbers are therefore 
an indirect measure of clinical activity and interest relating to specific substances. 
Telephone enquiries are made to the service by health professionals when the 
information on TOXBASE® is inadequate or when there is no specific entry, as may 
happen for a recently emerging NPS. Enquiries are also more likely to occur for 
unfamiliar substances or for more severe toxicity. Telephone enquiries made for 
reasons other than obtaining specific management advice about individual affected 
cases are uncommon. Most seek advice on the management of episodes of acute 
toxicity and staff of hospital emergency departments and acute medical wards are high 
volume users.  
NPIS data are collected continuously using consistent methodology and time trends in 
episodes of drug toxicity can be measured indirectly as numbers of NPIS telephone 
enquiries and as accesses to TOXBASE®. Unlike emergency department 
attendances, hospital admissions, or routinely available mortality data, NPIS telephone 
enquiry and TOXBASE® access data are available by specific substances reported. 
Although the information available has some limitations, it enables the monitoring of 
emerging new drugs causing toxicity in UK drug users (Wood et al., 2014, Waugh et 
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al., 2016). Poisons centre data has also been used to monitor drug misuse trends in 
other countries (Hondebrink et al., 2015, Wood et al., 2014, Maxwell, 2018).  
The patterns of enquiries made to the UK National Poisons Information Service about 
drugs of misuse since 2009 were extracted and the impact of various legislative 
changes analysed by comparing data before and after these changes. A more detailed 
analysis, including time series analysis, was performed to assess specifically the 
impact of the enactment of the PSA in May 2016. Data was also extracted for five 
common conventional drugs of misuse to allow study of any secondary effects on 
enquiries relating to these established drugs of misuse.  
2.2 Aims 
The aims of this study were to describe demographic characteristics and geographic 
distribution of NPS users experiencing toxicity and to evaluate time-trends and patterns 
of NPS exposures reported to the NPIS in UK over a 10-year period. The research also 
aimed to evaluate the public health impacts of legislative prohibitions of NPS use, and 
other major policy initiatives. 
2.3 Methods 
Telephone enquiries received by the NPIS are recorded onto a computer database 
(the UK Poisons Information Database, UKPID) using a pre-set on-line form, in real 
time as enquiries are answered. The details documented include a unique call ID, the 
date and time of enquiry, enquirer postcode, patient's age, sex, substances reported 
to have been taken including co-ingestants or other co-used substances, route of 
exposure, mode and symptoms of poisoning, treatment already provided, severity of 
poisoning and the place where the incident occurred. Clinical outcome is logged when 
this is known, but these data are incomplete. While follow up is attempted for severe 
or unusual cases, often the only information available is derived from a single 
telephone call made around the time the patient presents to health services. 
2.3.1  NPIS Telephone enquires 
Telephone enquiries to the NPIS were extracted for the period January 2009 to 
December 2018 and reviewed retrospectively. Enquiries related to recreational abuse 
and intentional intake of recreational drugs were included in the data set, but those 
concerning therapeutic errors, body packers or stuffers, accidental poisoning or spiked 
food or drinks were excluded. The drugs of misuse involved were classified manually 
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into 8 categories according to their principle clinical effects or chemical structures as 
follows: benzodiazepines, cannabis, stimulants, opioids, hallucinogens, SCRAs, 
dissociative drugs and ‘products’. Products consisted of branded drug products (e.g. 
products sometimes previously termed ‘legal highs’) such as “Black Mamba”, “Exodus”  
“Annihilation”, etc. While the ‘products’ group is likely to contain drugs from other 
categories, it is not possible to classify these more accurately as the content of 
products is not usually known and may vary with time and location (Shanks et al., 
2012a).  
After classification, NPS were extracted from all the various categories according to 
the 2018 United Nation Office on Drug and Crime (UNODC) definition: ‘NPS are 
defined as substances, whether in a pure form or a preparation, which are not 
controlled by the international drug control conventions but which may pose a public 
health threat’ (UNDOC, 2018). For this study, all drugs that were not already controlled 
in January 2009 were considered as NPS. New drug legislation has been introduced 
over the period of study (Table 2.2) and many drugs considered as NPS for this study 
have been placed under legal control since 2009. In addition, all branded drug products 
were considered as containing NPS, although the specific composition of products 
used in individual cases is often not known, and some may include conventional drugs 
of misuse or no drugs at all. Unknown substances were classified as “not known”, 
including unidentified white powders or herbal preparations, which might be NPS or 
other drug of misuse. They were not classified as NPS. Figure 2.1 shows how the data 
was sorted and classified. Patient age, sex and severity of exposure were also 









Date Type Substances affected 
December 2009 MDA 
Gamma butyryl lactone, 1,4-butanediol (Class C) 
Benzylpiperazine and related piperazine compounds (Class 
C) 
Further group of anabolic steroids (Class C) 
2 non-steroidal agents (Class C) 
First generation SCRA (Class B ) 
Oripavine (Class C) 
April 2010 MDA Mephedrone and other cathinone derivatives (Class B) 
July 2010 MDA 
Naphyrone and other naphthylpyrovalerone analogues 
(Class B) 
April 2012 TCDO Methoxetamine, and its simple derivatives. 
June 2012 MDA 
2-DPMP and other pipradrol-related compounds; (Class B) 
Phenazepam and esters or ethers of pipradrol (Class C) 
February 2013 MDA 
2nd Generation SCRA (Class B) 
Methoxetamine and other related compounds (Class B) 
O-desmethyltramadol and tramadol? (Class B) 
June 2013 TCDO 
25I-NBOMe and related compounds 
5- or 6- APB and related substance substances, including 
5-IT and 6-IT.  
June 2014 MDA 
NBOMe compounds (by generic definition, Class A)  
Benzofuran compounds (by generic definition, Class B) 
Lisdexamphetamine (Class B) 
January 2015 MDA 
AH-7921 (Class A) 
LSD-related compounds (Class A) 
Tryptamines including AMT and 5-MeO-DALT (Class A) 
February 2015 MDA 
4,4 DMAR (Class A) 
MT-45 (Class A) 
November 2015 TCDO Methiopropamine 
December 2016 MDA 3rd Generation SCRA 
June 2017 MDA 
U47,700 (ClassA) 
12 methylphenidate-related substances (Class B) 
16 benzodiazepines (including etizolam, Class C) 
November 2017 MDA Methiopropamine 
 
Table 2.2 Legislation affecting NPS, 2009-2018. SCRA - synthetic cannabinoid receptor 






Figure 2.1 The classification of NPIS phone calls and NPS extraction. Each 
substance reported in the phone calls is recorded into the relevant category. Some enquires 
reported more than one substance therefore, the number of substances reported are more 
than the number of phone calls received.  
 
2.3.2 TOXBASE® accesses 
TOXBASE® is considered the first line information source for UK healthcare 
professionals. Its content is updated on at least a 4-year cycle. New substances 
reported during this time are listed as soon as possible, with priority given to unlisted 
substances reported in multiple telephone enquiries. Across the whole database, 4,599 
product entries were created or updated in the reporting year 2016/2017 (National 
Poisons Information Service). 
TOXBASE® accesses were quantified as user sessions; these are defined as a user 
logging onto TOXBASE® and viewing the relevant page, including multiple views of 
the same page, screen refreshes or screen time-outs in the same user session. User 
sessions from educational establishments (e.g. universities) or NPIS units were 
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excluded. Because of the very large numbers of products of all types for which 
TOXBASE® provides information, analysis regarding NPS was restricted to all those 
drug products likely to contain NPS that had appeared in the top 10 drug products 
accessed during any of the ten study years, 24 separate products as shown in Table 
2.3; as well as all accesses to synthetic cannabinoid receptor agonists and 
mephedrone. TOXBASE® data cannot be linked back to specific patients and 
demographic information about users is not available.  Finally, 5 conventional drugs of 
abuse (amphetamine, cocaine, MDMA, heroin and cannabis) were also studied, 
including telephone enquiry and TOXBASE® access data.  
 
Angel Dust Herbal highs 
Annihilation Ivory Wave 
Bath salts Jamaican Bubbles 
Black Mamba Liquid Gold 
Bonzai Monkey Dust 
Cherry Bomb Plant Food 
Clockwork Orange Red Raspberry 
Diablo XXX Strong as Hell Sky high 
Doves Spice 
Eric 3 Spice Arctic 
Exodus Strawberry 
Exodus Damnation Sweet Leaf Herbal Blend 
 
Table 2.3 Products appearing in the top 10 for TOXBASE® accesses in any single 
year, 2009-2018. 
 
2.3.3 Statistics  
Medians, interquartile ranges (IQR) and mean were used as descriptive statistics and 
ages of NPS users were compared by the Mann-Whitney U test. To investigate trends 
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in calls and TOXBASE® sessions for NPS and other drugs of misuse, generalised 
least squares analysis was used in R, using the nlme package of Pinheiro and Bates 
(Pinheiro et al., 2018). Monthly NPIS telephone enquiries and TOXBASE® accesses 
for each NPS and conventional drug of misuse were used as dependent variables in 
interrupted time series analyses, with the number of months since January 2009 and 
time since enactment of the PSA used as indices of time.  The date the PSA came into 
law (26th May 2016) was coded as a dummy variable (0= before the point of 
intervention and 1=after the intervention). Time since PSA enactment was included as 
a continuous predictor variable. Total calls were log-transformed to normalise the 
residuals. There was evidence that NPIS telephone enquiries were serially correlated, 
so models with an autoregressive moving average correlation were used to adjust for 
the serial dependence. Analyses were first undertaken to investigate trends in calls for 
NPS and then for the five other drugs of misuse.  
2.4 Results 
The recreational and intentional intake telephone enquiry numbers to the NPIS 
involving conventional drugs of misuse and NPS for the period January 2009 to 
December 2018, classified according to their clinical effects or chemical structures are 
shown in Table 2.4. 
 
Table 2.4 Numbers of drugs of abuse reported to NPIS according to their 
principle chemical and clinical effect. 
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During the ten years 2009-2018 there were 3866 telephone enquiries received by the 
NPIS involving exposure to a NPS, with annual enquiry numbers shown in Figure 2.2. 
 
Figure 2.2 Number of Telephone Enquires related to NPS during 2009-2018. For 
definition of NPS, see section 2.3.1. 
 
Some calls reported more than one NPS and the total number of NPS reported in these 
3866 telephone enquiries was 4158. Of all the NPS-related calls received, 2195 
(52.8%) involved products (which usually contain one of more SCRA), 1297 (30.2%) 
stimulants, 315 (7.6%) SCRA, 146 (3.5%) benzodiazepines, 103 (2.5%) hallucinogens, 
99 (2.4%) dissociative drugs and 3 (0.1%) novel opioids. The NPS categories reported 
varied widely between years (Figure 2.3). 
 












































































2.4.1 Age and gender distribution 
The age and sex distribution of users is shown in Figure 2.4. There was a clear 
predominance of male NPS users (75%) and their median age was 24 years (IQR 19-
32). Female users made up 23% of the cohort and had a median age of 20 years (IQR 
17-28), which was significantly younger than the male users (p<0.0001); in 2% of 
enquires sex was not recorded. The highest numbers of reported users were in the 16-
20 year age group for both males and females. The age distribution was compared 
across different classes of NPS users. The analysis showed a significant difference 
between; NPS hallucinogens and NPS benzodiazepines users (p= 0.017), and NPS 
hallucinogen users with NPS dissociative users (p= 0.017). There were no significant 
differences in age among users of other NPS classes (p> 0.05). The average age of 





Benzodiazepines Dissociative Hallucinogens Products SCRA Stimulants 
n= 111 n=81 n=92 n=1913 n=278 n=1172 
Median 
(IQR) 
25 (21-30) 24 (20-32) 20 (18- 26) 23 (17-32) 24 (18- 34) 22 (19-29) 
Mean ± 
SD 
26.24 ± 7.5 27.3 ± 8.9 23.0 ± 7.9 26.2 ± 10.9 26.7 ± 10.5 25.0 ± 8.7 
 
Table 2.5 Age distribution of different classes of NPS users.Includes only those 
exposures where the age was known. (Opioids were not included because of very low 
number). 
 
In addition, the age distribution of cannabis users was compared with that of SCRA 
users, since SCRA may be used as an alternative to cannabis. The result showed that 





Figure 2.4 Age and gender distribution among NPS users reported to NPIS 
during 2009-2018. 
 
The age distribution for NPS users was compared with that of the 5 conventional drugs 
user groups by dividing each group into in 3 age bands (younger than 30 years, 31-55 
years and older than 55 years) and median, IQR, mean and the corresponding 
percentages are in demonstrated in Table 2.6. The use of NPS, MDMA and cannabis 
was predominantly by younger users; by contrast, 52.8% heroin users were aged 
between 31 and 55 years. The proportion of users over the age of 55 years was low 
for all drug groups. Users of NPS were significantly older than users of MDMA 
(p<0.0001) and cannabis (p<0.0001), but significantly younger than users of 











































NPS Heroin Amphetamine MDMA Cocaine Cannabis 
n=3649 n=668 n=662 n=1187 n=1465 n=1010 
Median 
(IQR) 
23 (18-31) 32 (26-39) 26 (20-34) 21 (17-29) 27 (22-34) 21 (18-25) 
Mean ± SD 25.77 ± 10 32.63 ± 9.3 28.2 ± 10.2 22.36 ± 7.3 28.79 ± 8.9 23.85 ± 10.6 
<30 years 82% 46.10% 66.60% 88.50% 62.70% 79.50% 
31-55 years 17.50% 52.80% 31.90% 11.10% 36.70% 18.90% 
<55 years 0.60% 1% 1.50% 0.30% 0.50% 1.60% 
 
 
Table 2.6 Age distribution of NPS and conventional drug of users. Includes only 
those exposures where the age was known. The extent to which different age groups took 
different drugs was assessed using the Chi-squared test. The Pearson Chi-square was = 










2.4.2 Geographic distribution of NPS-related NPIS enquiries 
 To investigate the distribution of NPS across the UK, the postcodes of enquirers were 
used. The reported cases were mapped geographically for each year after being 
corrected for population density (per 100,000 using 2011census data, Figure 2.6). 
There was very wide variation between areas in rates of NPS telephone enquiries, but 
without identifiable geographic trends. While increases in NPS use overall are 
documented, especially between 2012 and 2015, the results did not identify any 





















Figure 2.6  Geographical variation of NPS reported to the NPIS in UK during 2009-2018.Showing rates for each area cases with 
population density per 100,000 population. The darkest shading represents the highest density
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2.4.3 Changes in NPS- related NPIS enquiries between 2009-2018  
Monthly NPS enquires to the NPIS over a 10-year period are shown in Figure 2.7 A. 
The largest peak was in 2010 and was largely accounted for by mephedrone enquiries, 
which made up 44% of the enquiries about NPS reported in 2010 (Figure 2.8 A) and 
of which 31% occurred in March 2010. After mephedrone was controlled as a class B 
drug in April 2010 (Home Office circular 10/ 2010), the number of enquiries fell 
substantially. Another, spike in NPS enquiries was in August 2010 and related to a 
product called ‘Ivory Wave’, thought to contain desoxypipradrol (24% of the total 
enquires in August 2010 ) (Figure 2.8 B) and ‘benzo fury’ containing 6-(2-Aminopropyl) 
Benzofuran (6-APB) (Figure 2.8 C) constituting 25% of the total NPS enquires in 
August 2010. Calls related to NPS fell in 2011 compared to 2010, but subsequently 
increased until late 2015, with the continuous emergence of new NPS (Figure 2.8 D, 
E). Subsequently there has been a decline in NPS enquiries. The increase in incidence 
of NPS enquiries during 2013-2015 was largely related to branded products (Figure 
2.8 F).  
Time trends in TOXBASE® accesses for NPS including mephedrone, products and 
SCRA followed a similar pattern to NPIS telephone enquiries, with a peak in 2010, 
followed by a rapid reduction and then an increase between 2011 and 2015 and then 




























Figure 2.7 Trends in monthly of NPS during 2009-2018. (A) Trends in monthly of NPS 
enquires to NPIS during 2009-2018. (B)Time trends in TOXBASE® accesses for top 10 































































Figure 2.8  Time trend of selected NPS. The arrows refer to the date of the drug 
regulations. MDA, Misuse of drugs Act 1971, TCDO Temporary Class Drug Order. 
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2.4.4 Severity of exposure 
Poisoning severity is recorded by the scientist receiving the call using the Poisoning 
Severity Score (PSS) (Persson et al., 1998) which classifies severity as none, minor, 
moderate or severe. Of the 3866 telephone enquiries involving NPS received during 
the study period, 598 (15.5%) were graded as PSS none, 2046 (53%) as minor, 869 
(22.5%) as moderate and 210 (5.4%) as severe. In 143 (3.7%) the PSS was unknown 
or there was inadequate data available for accurate classification. The total number of 
calls reduced over time for all scores, but the proportion of cases with severe poisoning 
increased over the last 5 years of the study (Table 2.7).  
Year Enquiries None Minor Moderate Severe 
2009 176 24 (14%) 115 (65%) 26 (15%) 4 (2%) 
2010 681 77 (11%) 388 (57%) 172 (25%) 23 (3%) 
2011 352 42 (12%) 183 (52%) 98 (28%) 16 (5%) 
2012 471 66 (14%) 244 (52%) 123 (26%) 19 (4%) 
2013 568 107 (19%) 273 (48%) 132 (23%) 31 (5%) 
2014 617 104 (17%) 339 (55%) 122 (20%) 24 (4%) 
2015 624 102 (16) 335 (54%) 122 (20%) 47 (8%) 
2016 195 41 (21%) 81 (42%) 39 (20%) 25 (13%) 
2017 107 19 (18%) 54 (50%) 21 (20%) 12 (11%) 
2018 75 16 (22%) 34 (47%) 14 (12%) 9 (12%) 
 
Table 2.7 Poison Severity Scores assigned to patients with suspected NPS 





2.4.5 Legislative impact on NPS 
To illustrate the impact of individual legislation on specific NPS, NPIS enquires and 
TOXBASE® entries were used to examine changes relating to Mephedrone 
(Stimulant), Spice (SCRA), Black Mamba (branded product sold as SCRA) and the 
product termed ‘Ivory Wave’ (which is most likely Desoxypipradrol (2-DPMP). 
Figure 2.9 shows that for mephedrone, there were a significant reduction in number of 
both telephone enquiries and TOXBASE® accesses after specific legislation was 
introduced. There was also a reduction for 2-DPMP, but that reduction occurred before 
legislation came into effect. Three legislative changes occurring during the period of 
study might have affected enquiries about ‘Spice’ and ‘Black Mamba.’ which are likely 
to contain SCRAs. These were control of the so-called 2nd (February, 2013) and 3rd 
(December, 2016) generation SCRAs and the PSA (May, 2016). There was no 
convincing relationship between any of these legislative actions and numbers of 
enquiries for Spice or Black Mamba.  
 
Figure 2.9 Impact of specific legislations on selected NPS in number of enquires 
reported to NPIS. This includes number of phone enquires and TOXBASE® accesses. The 
blue lines represent when specific legislations were enacted into law.  
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To examine the impact PSA on acute health harms related to NPS, NPIS enquires and 
TOXBASE® entries was analysed using time series analysis. Over the 10 years of the 
study there were 79,271 TOXBASE® accesses related to the top 10 drug products 
accessed in any year (24 in total, Table 2.3) and mephedrone. While there were 3,866 
telephone enquiries related to NPS received by the NPIS.  
 NPIS Telephone enquiries TOXBASE®   accesses 
Variable Estimate St. Error T value P Estimate St. Error t value P 
NPS         
Intercept 3.151 0.114 27.538 <0.001 4.900    0.205 23.843 <0.0001 
Months 0.01 0.002 4.743 <0.001 0.029 0.003 7.408 <0.0001 
Act -1.61 0.231 -6.974 <0.001 -1.379 0.414 -3.327 <0.001 
Post-Act -0.04 0.012 -3.418 0.001 -0.035 0.020 -1.712 0.089 
Cocaine         
Intercept 2.589 0.071 36.515 <0.001 6.062 0.026 225.91 <0.001 
Months -0.003 0.001 -2.552 0.012 0.008 0.000 15.827 <0.000 
Act 0.153 0.143 1.072 0.286 0.050 0.054 0.925 0.357 
Post-Act 0.024 0.007 3.372 0.001 -0.001 0.002 -0.679 0.499 
Heroin                 
Intercept 




Months -0.002 0.002 -1.011 0.314 0.007 0.001 9.604 <0.001 
Act -0.321 0.24 -1.341 0.183 -0.142 0.073 -1.95 0.054 
Post-Act 0.016 0.012 1.373 0.172 -0.006 0.004 -1.535 0.128 
Cannabis                 
Intercept 




Months 0.001 0.001 0.956 0.341 0.007 0.001 13.275 <0.001 
Act -0.237 0.154 -1.543 0.126 -0.197 0.057 -3.442 0.001 
Post-Act 0.015 0.008 1.96 0.052 0.004 0.003 1.547 0.125 
Amphetamine                 
Intercept 




Months -0.01 0.002 -4.967 <0.001 0.002 0.001 2.738 0.007 
Act -0.047 0.204 -0.232 0.817 -0.155 0.081 -1.929 0.056 
Post-Act 0.009 0.01 0.871 0.385 -0.005 0.004 -1.168 0.245 
MDMA                 
Intercept 




Months 0 0.002 0.086 0.932 0.01 0.001 13.031 <0.001 
Act 0.114 0.208 0.546 0.586 -0.055 0.083 -0.661 0.51 
Post-Act 0.005 0.01 0.445 0.657 -0.016 0.004 -3.944 <0.001 
 
Table 2.8 Regression diagnostics relating log transformed number of telephone 
enquiries. (Left) and TOXBASE® accesses (right) for the time since 2009 (‘Months’), the 





For NPS, there were statistically significant increases in monthly TOXBASE® 
accesses (t = 7.408, P<0.0001) and NPIS telephone enquiries (t = 4.74, P<0.001) 
between January 2009 and May 2015 for the NPS studied (Table 2.8). There were 
short term spikes in telephone and TOXBASE® activity in 2010; the first relating to 
mephedrone and the second to 6-(2-aminopropyl) benzofuran and ‘Ivory Wave’ 
(usually desoxypipradrol). There were significant reductions in the number of 
TOXBASE® accesses (t = -3.327, P<0.001) and telephone enquiries (t = -6.974, 
P<0.001) after the enactment of the PSA in May 2016 compared to the period before, 
although these reductions began several months prior to that date (Figure 2.10). There 
have been further significant reductions in telephone enquiries with time after May 
2018 (t = -3.418, P < 0.001) but reductions in TOXBASE®  accesses over the same 
period were not statistically significant (t= -1.712, P= 0.089).  
Regarding other drugs of misuse, Up to the enactment of the PSA, we observed 
significant increases in monthly TOXBASE® accesses for heroin, cannabis, 
amphetamines and MDMA, and reductions in telephone enquiries relating to cocaine 
and (in contrast to the TOXBASE®  data) amphetamines (Table 2.8). Comparing the 
period before and after May 2016, the only significant change observed was an 
increase in TOXBASE® accesses for cannabis (t = 13.275, p < 0.001). Since May 2016 
there has been an increase in telephone enquiries about cocaine (t = 3.372, p < 0.001) 
without significant changes in TOXBASE® accesses. There has also been a reduction 
in TOXBASE® accesses relating to MDMA (t = -3.944, p < 0.001) without a significant 




Figure 2.10 Monthly numbers of NPIS telephone enquiries and TOXBASE® 
accesses relating to NPS and other drugs of misuse. The blue line represents when 
PSA was enacted as a law.   
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2.5 Discussion  
Over the past decade, the worldwide emergence of NPS has created a new drug 
phenomenon and represented a new challenge to public health and policy makers. 
NPS are usually developed to mimic the psychoactive effects of conventional drugs of 
misuse while circumventing drug control legislation based on chemical structure. 
These drugs vary widely in their chemical, pharmacological and psychoactive 
properties. Little is known about their toxicological effects and social impacts, which 
necessitate risk awareness and careful monitoring.  
Studying the epidemiology of drug misuse, especially that involving NPS, is 
challenging. Although various data sources are available in the UK, all of these have 
limitations. Some quantitative data are available from drug seizures made by Customs 
or law enforcement agencies. This provides the types and amounts of drugs seized 
annually and the purity of drug product being marketed but does not reflect the number 
of users of the drugs involved. Data are also available on emergency department and 
hospital admissions which provides useful information about drug morbidity, but these 
data are unhelpful for NPS because routine coding does not provide the required level 
of detail for individual drugs. As with poisons centre data, the specific substances 
involved may not be known because analysis is not done as part of usual clinical 
practice. Population surveys such as the CSEW reflect the prevalence of drug of 
misuse in the population aged between16 and 59 in England and Wales (CSEW, 
2015), but it does not include the whole population. In addition, the survey only 
requests answers to questions about specific drugs, which leads to missing information 
or under reporting of new emerging drugs. Recently, wastewater and urine analysis 
was adapted as a method to study the pattern of NPS use in term of location and actual 
substances used (Ort et al., 2018). However, this method cannot provide information 
on user numbers or any demographic information, (other than a broad geographical 
indication), and therefore should be regarded as a supplementary technique rather 
than a substitute (Stephenson and Richardson, 2014). The Welsh Emerging Drugs and 
Identification of Novel Substances Project (WEDINOS) offers a method for providing 
analysis and identifying the types of chemical compounds in NPS products at a national 
level (Drugs, 2016). This can be used as a complementary method in monitoring 
trends. In addition, The Identification of New Psychoactive Substances (IONA) study 
was established in 2015 for collecting biological samples from patients presented to 
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the UK hospital with severe toxicity arisen potentially from NPS poisoning. The study 
aimed to confirm the analytical findings of NPS and links it with the clinical features in 
users presented to the hospital (Thomas et al., 2018).   
The NPIS data on the harms associated with drug of abuse and can provide a valuable 
method for monitoring NPS use. This method also has important limitations that are 
described in detail below.   
For this study we used TOXBASE® accesses and NPIS telephone enquiry data as a 
proxy for clinical activity relating to these new and conventional drugs of misuse. The 
advantage is that that detailed information is available on the substances reported to 
be involved, unlike national data sets for emergency department presentations or 
hospital admissions, which do not provide this level of detail and where coding of the 
substances involved can be inaccurate (Shah et al., 2011). The disadvantages of NPIS 
data are that enquiries are not made for all presentations, only those where the health 
professional believes they need further advice, often after consulting TOXBASE®. 
Telephone enquiries are therefore more likely for unfamiliar substances or cases with 
severe toxicity. Also, there may be more than one TOXBASE® access or telephone 
enquiry for the same case; alternatively, health professionals may look at TOXBASE® 
when they are not managing a specific patient. In addition, many users are using 
branded products or drugs purchased online and are not aware of the exact drug they 
are taking. Therefore, without analytical confirmation there is limited ability to be sure 
that the drugs reported were in fact the drugs used. Analytical confirmation for NPS is 
rarely available in normal clinical practice, meaning that exposure data may be 
inaccurate or incomplete. Finally, NPIS data does not include information about other 
factors that may be important such as ethnic group or level of education and 
information on clinical outcome is incomplete. 
Branded Products include herbal mixtures sprayed with a synthetic chemical 
substance (usually a SCRA) or may be branded tablets or powders often containing 
stimulants. They have made up the largest category in term of number of NPS being 
reported to the NPIS over the last decade. Although, the exact chemical compositions 
of these branded products is not known and may change with time, most, especially 
those that are herbal mixtures designed for smoking (for example ‘Black Mamba’, 
‘Cherry Bomb’, etc.), contain synthetic cannabinoids, (Lindigkeit et al., 2009, Uchiyama 
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et al., 2010, Uchiyama et al., 2009, Langer et al., 2016). Therefore, branded products 
and SCRA together represent the great majority of SCRA reported to NPIS in 
telephone enquiries in recent years. These findings are in line with the UK Identification 
Of New Psychoactive Substances (IONA) study results, which showed that synthetic 
cannabinoids have been the most common type of NPS identified in patients 
presenting to Emergency Departments with severe toxicity from NPS exposure since 
2015 (Thomas et al., 2018). They are also consistent with the UNDOC statement that 
“Globally, synthetic cannabinoids constitute the largest category in terms of the number 
of NPS reported” (UNDOC, 2018).  
The second largest group reported to the NPIS was the novel stimulants, which 
showed the highest activity in 2010 with the emergence of mephedrone, 2-DPMP and 
benzofuran compounds. Subsequently enquiry numbers relating to these have 
declined (see below). Other categories of NPS were less commonly reported to the 
NPIS. 
2.5.1 Age and gender distribution  
It is well documented in terms of the pattern of substance misuse in the general 
population, that males are more likely to use illegal drugs than females (EMCDDA, 
2005) and the data presented here shows the same pattern for NPS. Most NPS users 
were young and this finding is consistent with other previously published reports on 
NPS use, where half of the users were younger than 26 years (Barnard et al., 2017). 
The findings are broadly similar to those reported from other developed countries 
(Champion et al., 2016, Johnston et al., 2017, Werse and Morgenstern, 2012). The 
descriptive statistics for age grouping across different classes of NPS showed that 
NPS hallucinogens users were the youngest among the group. There was a significant 
difference between hallucinogens and dissociative users, and hallucinogens and 
benzodiazepine users. This might be due to different motivations for NPS use which 
varies between substances. Soussan and Kjellgren (2016) reported that common 
motivation for all NPS classes use was “pleasure and enjoyment”. However, for novel 
hallucinogens and dissociative the main motivations for use were spiritual attainment 
and exploration (Soussan and Kjellgren, 2016). This might be the reason for the 
misuses by the younger population as they tend to be more inquisitive. Thus, 
understanding the reasons younger population prefer different classes of NPS allowing 
more efficient prevention and subsequently harm reduction.   
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Cannabis users were younger than SCRA users, this finding was consistence with 
(Forrester et al., 2012), but other studies reported that there were no significant age 
differences between SCRA and cannabis users (Mensen et al., 2019, Sznitman et al., 
2020). The reason for age differences might be that cannabis is a well-established 
substance of misuse making it easier to obtain to adolescence and they might perceive 
cannabis as "harmless”. In addition, adults could also be more likely to pursue a 
'different' agent compared to young people (Forrester et al., 2012). 
In comparison with other traditional drugs of abuse, the age distribution pattern for NPS 
users was similar to that of cannabis users. This might be because cannabis users 
might wish to compare the effects of SCRA to cannabis. Younger people may also be 
influenced by previous legality of NPS which they may interpret as implying safety, in 
addition to escaping problems associated with illicit cannabis (Winstock and Barratt, 
2013a, Champion et al., 2016). Low cost and easy availability may also be relevant. 
Heroin and cocaine users were significantly older than NPS users and this consistent 
with the other research; for example the mean age of heroin and cocaine users seeking 
treatment in Europe is 35 years (EMCDDA, 2019). In general, NPS, amphetamines, 
MDMA, cocaine and cannabis have shown to be used by younger people. Use of these 
drugs in younger age groups could interfere their developmental processes and could 
be associated with many physical, psychological and social harms(Macleod et al., 
2004).  
2.5.2  Geographic distribution of NPS-related NPIS enquiries 
The geographical distribution did not show an identifiable pattern of NPS use in the 
UK. A limitation was that the post codes analysed were the enquirer rather than the 
users, as user address is not logged by the NPIS. Enquirer location, however, is still 
likely to reflect the broad location of drug use as patients are unlikely to travel many 
miles between drug use and seeking treatment. For the NPIS data, there is a problem 
with low patient numbers, so the analysis may lack sensitivity in detecting regional 
differences. As the geographical trends are not easy to monitor, it might be useful to 
explore the utility of waste water analysis to study the prevalence, patterns and 
geographical differences in NPS use (van Nuijs et al., 2011, Banta-Green et al., 2016). 
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2.5.3 Severity of exposure 
The PSS measures the severity of poisoning and is a useful tool for comparing 
poisoning severity between different substances (Persson et al., 1998). It is useful to 
study severe as well as total enquiry numbers as differences in the way drugs are used 
might influence these in opposite directions. For example, legal control of a relatively 
safe drug might result in reduced drug use overall but some diversion to a less safe 
alternative and a consequent increase in severe cases. 
NPS enquiries were usually associated with minor to moderate severity. The annual 
numbers of reported severe cases decreased each year after 2015, however the 
proportion of enquires that were severe increased. This could reflect use of more toxic 
NPS by smaller numbers of people, but an alternative and probably more likely 
explanation is that clinicians were increasingly confident about managing NPS 
poisoning and were less likely to make a telephone enquiry unless the patient was 
severely affected. It is important to point out that in most exposure cases there is poly-
drug use often in combination with alcohol and that co-used substances may not be 
declared by the patient. Therefore, it is may not be known which drug or combination 
of substances has led to the increased severity.  
2.5.4 Changes in NPS-related NPIS enquiries between 2009-2018 
The number of NPS enquiries reported to NPIS increased steeply between 2009 and 
2010, with a spike in activity in April of that month which was largely accounted for by 
mephedrone enquiries. This had become popular as a party drug and was perceived 
by users to be a better “legal” alternative to illicit stimulant drugs such as cocaine and 
amphetamines (Winstock et al., 2011). Lack of legal control resulted in it being 
available for sale widely, including in convenience stores and petrol stations as well as 
via the internet. The Crime Survey for England and Wales 2010/11 reported that 
mephedrone was the most commonly used NPS at the time in the 16-24 year age 
group (Home Office Statistical Bulletin, 2011).  In March 2010, more than 77 websites 
were found to sell and deliver mephedrone to users in the EU (EMCDDA). The control 
of mephedrone as a Class B drug under the Misuse of Drugs Act in April 2010 came 
after increasing concerns of significant acute intoxication and fatalities (Wood et al., 
2010, Wood et al., 2011, Durham, 2011, James et al., 2011, Kamour et al., 2014). This 
legal control did not eliminate mephedrone use but there was a substantial subsequent 
reduction in telephone enquiries and TOXBASE® accesses related to the drug. 
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Separate research also demonstrated a reduction in the number of acute intoxications 
presenting to one emergency department after legal control (Wood et al., 2013). A 
gradual recent decline in use has been reported by the Crime Survey for England and 
Wales (CSEW) with last year use of mephedrone among adults aged 16–59 years 
being 1.3% in 2010/11, 1% in 2011/12, 0.5% in 2012/13, 2013/14 and 2014/15 then 
0.3% in 2015/16, 0.1% in 2016/17 and 2017/18 to 0 in 2018/2019 (Home Office, 2019)  
Mephedrone, was soon replaced by other uncontrolled stimulants especially ‘Ivory 
Wave’ (mainly 2-DPMP) and ‘benzo fury’ (6-APB) (Durham, 2011, Kim et al., 2010) 
and both were responsible for a second spike in NPS enquiries and TOXBASE® 
accesses  in August 2010. Enquiries related to each of these compounds fell even 
before legal control, which occurred in June 2012 for 2-DPMP (Class B via MDA) and 
in June 2013 for 6-APB (by Temporary Class Drug Order). This reduction in use before 
legal control may have been resulted from the prohibition of importation of ‘Ivory Wave’ 
in November, 2010 (UK Government press release, 2010) because of perceptions of 
its serious effects on physical and mental health. 
By early 2011, NPS-related enquiries were at a lower level than in 2010, largely 
because of the reduction in enquiries relating to stimulants including those described 
above (Figure 2.3). Subsequently there was a gradual increase in NPS enquiries 
reported to the NPIS, with the greatest contribution from branded products which are 
most likely to contain one or more SCRAs (Dresen et al., 2010). The main factors 
influencing the pattern of use of NPS were novel marketing and easy availability and 
accessibility (Weaver et al., 2015). This increase also occurred in the USA (Wood, 
2013, Palamar et al., 2015) and in Europe (EMCDDA 2015).The changes after 2015 
are discussed in more detail below.  
2.5.5 Impact of legislation on NPS toxicity 
This research has demonstrated significant changes with time in the monthly numbers 
of health professional enquiries to the NPIS via TOXBASE® and by telephone 
concerning NPS. Compared with the earlier increasing trend, significant reductions in 
NPS-related TOXBASE® and telephone enquiry numbers occurred after enactment of 
the PSA in May 2016, although reductions were already evident during late 2015. They 
have not been offset by increases in enquiries relating to cannabis, MDMA (ecstasy), 
heroin, or amphetamines. There has been an increase in monthly telephone enquiries 
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relating to cocaine, but this was not accompanied by significant changes in 
TOXBASE® accesses.   
This is an observational study so changes that occur at the same time as a specific 
action can not necessarily be interpreted as being caused by that action. Reductions 
in NPIS activity relating to NPS occurred before the PSA became law. It is possible 
that publicity associated with the introduction of the PSA to Parliament in May 2015 
made potential users more aware of the potential harms of NPS and therefore 
discouraged use. However, other actions were also taking place at that time, including 
the use of existing legislation to supress the sales of NPS (Home Office, 2015a).  It 
was estimated that there were at least 250 retail outlets (‘head shops’) openly selling 
NPS across the UK in 2013. Many of these had already closed down before the PSA 
was enacted (Home Office, 2018), in some cases following actions across the UK by 
police and local trading standards officials (Shapiro and Daly, 2017). In Scotland  
activity to close down head shops in October 2015 (‘Operation Alexander’)  resulted in 
this retail trade being severely curtailed before the PSA was introduced (Scottish 
Government, 2016); this was followed by statistically significant reductions in NPS-
related presentations and admissions for drug toxicity in Edinburgh (Pettie et al., 2018). 
Similar actions were taken in Northern Ireland under the Consumer Protection 
Regulation; following these all shops in Northern Ireland were reported to have stopped 
selling NPS before the Act came into operation (Home Office, 2018). Reductions have 
also been observed in the numbers of English language websites selling NPS and 
shipping to UK addresses since October 2015, especially those with registered domain 
locations in the UK. Overall, almost half had closed before enactment of the PSA and 
by that date there were no remaining active UK-based sites (Wadsworth et al., 2018).  
Other potential explanations for the reduction in NPIS activity after 2015 should also 
be considered. Health professionals may become increasingly familiar with specific 
NPS and the management of toxicity, and therefore less likely to seek further 
information. While this may reduce enquiry workload for specific substances over time, 
it is unlikely to explain the rapid and substantial reductions in NPS-related enquiries 
during 2015. The possibility that reduced TOXBASE® activity from 2015 resulted from 
the loss of interest of health professionals in NPS seems very unlikely at time when 
the passage of the Act through parliament was associated with considerable media 
attention. This would also not explain the similar reduction in telephone enquiries, as 
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these are rarely made for educational reasons but rather to seek advice on 
management of cases of acute toxicity.  We cannot exclude the possibility that dealers 
selling NPS after May 2016 may have mislead users (and the health professionals 
managing them) into believing they were buying substances other than NPS, thus 
explaining an apparent reduction in NPS related enquiries, although this seems 
unlikely.   
Other evidence also suggests reductions in NPS use and toxicity since the enactment 
of the PSA. The Crime Survey for England and Wales (CSEW) has demonstrated a 
reduction in prevalence of NPS use overall and in males in 2016/17 and 2017/18 
compared with 2015/16 (Home Office, 2019). It also demonstrated a reduction in the 
proportion of NPS bought from shops, with an increasing proportion purchased via the 
internet or from street dealers (Home Office, 2019). There have also been successive 
reductions in the numbers of people presenting to drug treatment services with 
problematic NPS use in 2016/17 and 2017/18 compared with 2015/16 (Public Health 
England, 2017). 
Concerns have been raised that legislation that prevents open sale of NPS will result 
in users seeking these substances from street dealers or via the internet, where sellers 
may have less regard for user safety. After introduction of the Criminal Justice 
(Psychoactive Substances) Act 2010 in Ireland, NPS-related deaths continued to 
increase, although the largest increase was sometime later, between 2012 and 2013 
(Health Research Board, 2014). So far, however, most UK data suggests reductions 
rather than increases in NPS toxicity. Hospital Episode Statistics show reductions in 
hospital admissions in England for the category ‘mental and behavioural disorders due 
to multiple drug use and use of other psychoactive substances’,(NHS Digital) although 
in one London hospital the numbers of presentations involving an NPS was higher in 
the year after compared with the year before enactment of the PSA.(Webb et al., 2018)  
Fewer deaths related to NPS were recorded in England in 2017 compared with 
2016,(Office for National Statistics, 2018) although reductions in NPS related deaths 
were not seen in Scotland (National Records of Scotland, 2017).  
Another potential impact is that former NPS users might switch to conventional 
controlled drugs. The data presented here does not suggest that this has happened 
for cannabis, MDMA, heroin, or amphetamines, with no significant changes comparing 
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the periods before and after enactment of the PSA. There were significant reductions 
in MDMA-related TOXBASE® accesses in the period since the PSA. These reductions 
were modest, with annual MDMA TOXBASE® accesses 16% lower in 2018 than in 
2015. Over the same time MDMA-related telephone enquiries increased by 17%, 
although this was not statistically significant. The reduction in TOXBASE® accesses is 
not in line with the increase in prevalence of MDMA use in England and Wales reported 
between 2016/17 (1.3%) and 2017/18 (1.7%), prevalence having fallen in the previous 
2 years (Home Office, 2019) or the increases in MDMA-related mortality reported over 
the last decade (Office for National Statistics, 2018 )This suggests that in isolation, 
small changes in TOXBASE® accesses, even if statistically significant, do not reliably 
predict changes in use or toxicity for drugs of misuse. 
Increases in cocaine-related telephone enquiries following the PSA might suggest 
some NPS users switching to cocaine, although this is speculative and there has been 
no corresponding increase in TOXBASE® accesses. The CSEW detected a recent 
increase in the prevalence of reported cocaine use, although this occurred a year after 
the PSA came into force (Home Office, 2019). There has also been a recent increase 
in the number of young adults seeking treatment for crack cocaine use (Public Health 
England, 2017). These increases in cocaine-related activity may not have any relation 
to the PSA and could reflect the increasing availability of higher purity cocaine in the 
UK and the associated higher risk of adverse health effects (Crawford et al., 2017).  
In summary, this research used NPIS data to provide a snapshot of NPS in UK for the 
last decade. It is possible to use the NPIS data to describe demographic characteristics 
of users and to examine time trends and the effects of legislation. NPS started to 
appear in 2009 with most of the reported cases being male and 34% were between16 
and 25 years old. There were dramatic but short-lived peaks in 2010 related to some 
specific novel stimulants. There was a subsequent gradual increase in NPS-related 
enquiries until 2015, with most of the reported NPS being SCRAs. There have been 
reductions in NPIS TOXBASE® access and telephone enquiry activity relating to NPS 
since the introduction of the PSA to Parliament and its enactment. These changes are 
consistent with other data demonstrating reductions in prevalence of use, hospital 
admissions, drug treatment presentations and NPS-related deaths. The observed 
changes, however, started to occur some months before the PSA came into effect and 
are to some extent offset but a recent increase in telephone enquiries related to 
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cocaine. It remains important to track adverse health and social consequences of NPS 
use, alongside those of traditional drugs of misuse and to study the impact of legislative 
and other measures intended to reduce these. 
It would be useful if more details added to NPIS data such as the ethnicity, level of 
education, etc. Further research is required to elucidate the mechanism of action and 
toxicological consequences of acute and chronic use of NPS, with those most 





















 Effects of indole containing and non-indole containing 
SCRAs on 5-HT uptake  
 
3.1 Introduction  
Products marketed as herbal mixtures, sometimes referred to as “K2” or “Spice” have 
been found to contain SCRAs such as CP-47,479, CP-47,479-C8, JWH-018, JWH-
073, MAM-2201, AKB-48-5F, HU-210 and many others (Lindigkeit et al., 2009, 
Uchiyama et al., 2010, Assemat et al., 2017). Knowledge of the pharmacological and 
toxicological profiles of these drugs is very limited and there may be differences 
between individual SCRAs. The pharmacology of SCRAs is thought to relate to the 
interaction with cannabinoid receptors (CB), but they may also interact with non-CB 
receptors or neurotransmitter systems. However, much of the research to date has 
focused mainly on binding affinities to CB receptors and structure- activity relationships 
of different SCRAs or their cannabimimetic activity rather than interaction with other 
receptor systems. Although SCRAs can produce psychotropic effects similar to those 
of cannabis, there is a higher incidence and severity of adverse effects with SCRAs 
(Chase et al., 2016, Tait et al., 2016, Wiley et al., 2016). Effects such as tachycardia, 
agitation, hallucination, hypertension, minor elevation of blood glucose, vomiting, chest 
pain, seizures, myoclonus and acute psychosis have been documented (Hermanns‐
Clausen et al., 2013, Brewer and Collins, 2014, Sweeney et al., 2016). Some of these 
features are similar to those observed in the serotonin syndrome, which is caused by 
excessive serotoninergic transmission and may be due to an increase in 5-HT release 
or reductions in its reuptake and /or metabolism (Boyer and Shannon, 2005). Serotonin 
syndrome is clinically characterised by symptoms such as tachycardia, hypertension, 
hyperthermia, myoclonus and agitation.   
Many SCRAs contain an indole ring within their structure, similar to a moiety found in 
5-HT as shown in Figure 3.1. SCRAs containing this indole moiety could potentially 
bind with 5-HT receptors or act as a 5-HT reuptake inhibitors, as there is evidence that 
chemicals containing the indole moiety can be potent 5-HT reuptake inhibitors (El‐
Subbagh et al., 2002, Mignani et al., 1993). SERT regulates the serotonergic activity 
in the brain by clearing 5-HT following its release into the synaptic cleft. Inhibition of 
SERT activity therefore results in increased 5-HT concentrations in the synaptic cleft 
and subsequently increases in duration and intensity of 5-HT action (Blakely et al., 
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1994). The increase in 5-HT concertation in the CNS will lead to a spectrum of toxic 
manifestations ranging from mild to severe effects, depending on the extent that  5-HT 
is increased (Buckley et al., 2014). This structural similarity has led to speculation that, 
in addition to cannabinoid receptor agonism, SCRAs might bind to 5-HT receptors or 
SERT and affect 5-HT neurotransmission (Pascolo-Fabrici and Bonavigo, 2015, 
Papanti et al., 2014). 
    
Figure 3.1 Chemical structure of 5-HT and JWH-018 showing common indole      
moiety found in 5-HT and many SCRAs. 
Research presented in this chapter investigated the effects of JWH-018, an indole-
containing SCRA on 5-HT transporter (SERT) function. CP 55,940 ,was used as a  
comparator of a non-indole SCRA (Figure 3.2) to test its effect on 5-HT uptake.  
 
Figure 3.2 Chemical structure of synthetic cannabinoid CP55, 940.                                                                                                                             
74 
 
The tested substance, JWH-018 (1-pentyl-3-(1-naphthoyl) indole) is a synthetic 
cannabinoid receptor agonist belonging to the aminoalkylindole group (Huffman et al., 
1994). JWH-018 was one of the earliest SCRAs reported through the European Early 
Warning System following identification in Germany and Austria in 2008 (EMCDDA 
2009). JWH-018 is a potent agonist at CB1 and CB2 receptors with high binding 
affinities to the CB1 receptor (Ki= 9 nM) and CB2 receptor (Ki= 3 nM) (Aung et al., 
2000). CP 55,940 (2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-
methyloctan-2-yl)phenol) is a synthetic cannabinoid developed by Pfizer and 
subsequently used as a ligand to study cannabinoid receptors (Palmer et al., 2002). It 
also has high binding affinity for both CB1 and CB2 receptors with binding affinity Ki = 
0.5-5 nM and Ki = 0.69-2.8nM respectively (Devane et al., 1988).  
3.2 Aims 
To investigate the potential effect of a SCRA containing an indole core moiety (JWH-
018) on SERT function, utilising ex-vivo rat brain slices and radiolabelled 5-HT. To 
achieve these two objectives were set. 
1. To develop the ex-vivo rat brain slice model to measure 5-HT uptake and 
validate it using the selective serotonin reuptake inhibitor fluoxetine and the 
stimulant D-amphetamine. 
2. To compare the effect of the SCRAs JWH-018 (indole core) and CP55, 940 
(non-indole-containing) on SERT function, by measuring 5-HT uptake in ex-vivo 
rat brain slices.  
3.3 Materials and Method 
The 5-HT uptake was measured using radio-labelled 5-HT in rat brain slices 
(hippocampus) in the presence and absence of SCRAs, JWH-018 and CP 55,940. 
3.3.1 Chemicals 
Radiolabelled [3H]5-HT (specific radioactivity 91.7 and 82.6 Ci/mmol) was purchased 
from PerkinElmer (USA). D-amphetamine sulphate, JWH-018 and CP55, 490 were 
purchased from Tocris (UK). Fluoxetine was purchased from Sequala Research 
Products Ltd (UK). Pargyline and Rimonabant were purchased Sigma (UK). Perchloric 
acid was purchased from VWR international (UK). NaCl, Dimethyl sulfoxide (DMSO) 
and HEPES were purchased from Sigma-Aldrich, (UK). KCl was purchased from Santa 
Cruz Biotechnology Inc. (Germany), KH2PO4 was purchased from ACROS Organics 
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(UK). MgSO4 was purchased from Scientific Laboratory Supplies Ltd (UK). Isoflurane 
was purchased from Abbot Ltd. (UK). Liquid scintillation cocktail (Scintisafe III/code 
sc/9205/21) was purchased from Fisher Chemicals. 
Artificial cerebral spinal fluid (aCSF) composition (mM) was as follows: MgSO4 
2.4;NaCl 124; KH2PO4 1.25; KCl 3.25; NaHCO3 26; CaCl2 2 ; glucose 10, pH 7.4) was 
made on the day of the experiment from stock solutions. Sucrose buffer composition 
(mM) was: sucrose: 200; HEPES 10; MgSO4 7; NaH2PO4 1.2; KCl 2.5; NaHCO3 25; 
CaCl2 0.5; d-glucose 10; pH 7.4. This was made in batches and frozen at -20  ̊C for 
storage. To allow the frozen sucrose to thaw but remain slushy for the experiment, a 
500 ml bottle was transferred to 4  ̊C the day before the experiment. 
Stock solutions of the selective 5-HT reuptake inhibitors fluoxetine (10 mM in water), 
D-amphetamine sulphate (20 mM in DMSO), JWH-018 (20mM in DMSO), CP 55,940 
(20nM in DMSO), the CB1 antagonist rimonabant (10 mM in DMSO) and the MAO 
inhibitor pargyline (10mM in water) were stored at -4  ̊C for up to 10 days. Secondary 
stocks were freshly prepared for each experiment with aCSF. A secondary stock 
solution of radio-labelled 5-HT was prepared from 91.7 and 82.6 Ci/mmol primary 
stocks. The final concentration in each test tube was either 7.72 or 8.57 nmol/ml. 
3.3.2 Rat brain slices preparation 
All experiments were carried out in adherence with the UK Animals (Scientific 
procedures) Act of 1986. Experiments were conducted on Hooded-Lister male rats 
(Charles River, Kent, UK). Animals were housed in groups of 3-4 per cage in a 
temperature-controlled room (21-24 °C) with a 12:12 h light/ dark cycle with ad libitum 
access to food and water. These rats (n= 47) weighing 200-300g were killed by an 
overdose of isoflurane, immediately decapitated by small animal guillotine and the 
brain rapidly removed. The brain was chilled in ice cold sucrose buffer which was 
oxygenated with 95% O2 and 5% CO2. The brain was cut coronally and the cut side of 
the front half of the brain glued onto a vibratome chuck which was then secured in the 
vibratome. Coronal brain slices (0.4 mm thick) containing the dorsal hippocampus (n 
= 34 experiments) or slices containing the frontal cortex (n=19 experiments) were cut 
using a Vibratome® 1000 (St. Louis, USA) in ice cold sucrose buffer bubbled with 95% 
O2 and 5% CO2. Slices containing hippocampus (4-5 slices per brain) were taken from 
bregma 3.3-3.7, and those containing cortex (4-5 slices per brain)  were taken from 
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bregma 2.7-1.2, according to the atlas of Paxinos and Watson (1998) (Figure 3.3). 
Slices were immediately placed in pre-oxygenated ice-cold sucrose buffer, transported 







Figure 3.3 Figure depicting brain slices collected for this experiment.  
Region of interest are outlined in red. Figures adapted from “the rat brain stereotaxic 
coordinates” (Paxinos and Watson, 1998). 
 
3.3.3 Uptake assay 
After 30-215 min, brain slices were dissected in sucrose buffer and the cortex and the 
hippocampus were removed. Left and right dorsal hippocampi (n = 8 - 10) or cortical 
(n = 8 - 10) sections were transferred to oxygenated aCSF (800 µl) in individual test 
tubes and incubated in a water bath at 34 ̊ C for 30 min (Figure 3.4).  




Figure 3.4  Schematic illustration for 5-HT uptake experiment and how to deliver 




Secondary stock solutions of 100 µL of the test compounds were added and then 100 
µL [3H]5-HT was added to give a final concentration of 7.72 or 8.57 nmol in a total 
incubation volume of 1 ml.  
Table 3.1 shows the final tested compounds concentrations.in each experiment a 
range of concentrations were tested (2 sections per concentration). This was incubated 
at 34 ̊C for another 30 min with 95% O2 and 5% CO2. The reaction was stopped by 
transferring the test tubes into ice and the sections were washed three times using 2 
ml chilled aCSF. The sections were weighed and transferred into scintillation vials, and 
250 µl of 0.1 N perchloric acid was added to solubilize the tissue (overnight). 
Subsequently 4-10 ml of scintillation liquid was added to each vial and the radioactivity 
in the incubation media and in the tissue was recorded using a multi-purpose 
scintillation counter (Beckman coulter, USA) as disintegrations per minute (DPM). 
These values were taken as a measure of the amount of 5-HT taken up by the tissue. 
Non-specific binding of [3H]5-HT to the brain section tissue may occur by adherence 
of 3H-5HT to the surface of the section, or by passive diffusion. To assess this, 
additional sections were incubated with aCSF (900 µl) and [3H]5-HT (100 µL) was 
carried out at 0° C as a measure for passive diffusion, and at zero time as a measure 
for the radioactivity adhered to the slices. 
Chemical tested Final concentrations (µM) 
Fluoxetine (hippocampus)  0.1, 1, 10 and 100 
Fluoxetine (cortex)  0.3, 1, 3,10 and 100 
D-amphetamine (hippocampus)  0.01, 0.1, 1, 10, 30 and 100 
D-amphetamine (cortex)  0.5, 1, 3, 5, 10 and 100  
JWH-018 (hippocampus) 0.001, 0.01,0.1, 1 and 10 
CP55-940 (hippocampus)  10  
Rimonabant (hippocampus)  1 
 




3.3.4 Calculations and Statistics  
To determine the uptake of [3H]5-HT into sections the presence/absence of SCRA the 
following calculations were utilised: 
Tissue/medium (T/M) ratios were calculated as DPM of tritium in one gram of tissue 
per DPM of tritium in one millilitre of incubation medium (Shaskan and Snyder, 1970).  
The average weight of the hippocampal sections was 5.39 ± 1.7 mg (n=199) and of 
cortical sections was 5.34 ± 1.6 mg (n=118). The average weight of the sections was 
used in calculating DPM per gram. 
In each experiment, 2 hippocampal or cortical sections were incubated in aCSF with 
[3H]5-HT at 34 C̊ for 30 minutes in the absence of a test compound. The tissue/medium 
(T/M) ratio for each of these sections was calculated and the T/M ratios averaged for 
each experiment. This averaged control value was used as (T/M) for each experiment. 
To calculate the passive diffusion, (T/M) ratios for ice control slices were calculated. In 
addition to the amount of radioactivity adhered to the slices, the (T/M) ratio for slices 
at 0 time was calculated. 
Then the non-specific (T/M) ratios were calculated according the following equation 
where T/M represents DPM/mg tissue /DPM/ml incubation medium, (T/M) 0 represents 
T/M value for ice control slices or at 0 time and (T/M) c represents T/M for 34 C̊ controls 




× 100    
Then total non-specific uptake for both 0 time and ice controls was subtracted from  
(T/M) ratio from each experimental slice before further analysis ((T/M) in slice – ((T/M) 
in slice*non-specific (T/M) ratio) and this represent the specific[3H]5-HT uptake in each 
slice. 
The specific [3H]5-HT uptake was expressed as a percentage of control where T/M= 
DPM/mg tissue /DPM/ml incubation medium, (T/M)t represents T/M value for brain 
section with tested concentration and (T/M)c represents T/M for 34 C̊ controls 
(absence of test compound) :     
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% of [3H]5-HT uptake =
  ( / )
 ( / )
× 100  
Statistical analysis was carried out using SPSS (V24; IBM SPSS Statistics USA).  
Normality of the data distribution was assessed by the Shapiro-Wilko test. Differences 
between means were tested for significance by one-way analysis of variance (ANOVA) 
(when data followed normal distribution), or by the Kruskal-Wallis test for data that was 
not normally distributed. All values were expressed as mean ± standard error.   
 
3.4 Results 
3.4.1 Initial assessment of 5-HT uptake assay in hippocampal and cortical 
sections 
Initially, several experiments were conducted to confirm the suitability of rat brain 
section assay to assess 5-HT uptake. 
The competitive effect of increasing concentrations of non-labelled 5-HT (0, 1, 10 and 
100 nM) on uptake of labelled [3H]5-HT was tested (10 µM pargyline, a monoamine 
oxidase inhibitor, was used in the aCSF to maximize uptake). In the absence of non-
labelled 5-HT (0 nM; n=6). The average T/M ratio for cortical sections was 9.09 ± 1.5 
(n=6) following subtraction of nonspecific uptake (0.048). Specific [3H]5-HT uptake was 
calculated for 1 (n=6), 10 (n=6), 100 (n=6) nM non-labelled 5-HT. Specific [3H]5-HT 
uptake was calculated non-labelled 5-HT concentration of 1(n=6), 10 (n=6) and 100 
(n=6) nM. 
As might be expected, [3H]5-HT uptake was inhibited by increasing concentrations of 
non-labelled 5-HT; t-tests revealed a significance differences in [3H]5-HT uptake at 10 




Figure 3.5 Effect of non-labelled 5-HT on [3H]5-HT uptake in rat cortical 
sections.The uptake is expressed as percentage of [3H]5-HT uptake in control sections. The 
cortical sections were incubated with 5-HT (0-100 nM) [3H]5-HT for 30 min at 34 ̊C under 
O2/CO2 atmosphere. Each point represent mean ± SEM of 3 experiments. 
 
To confirm the suitability of using the ex-vivo rat brain sections to assess 5-HT uptake, 
the accumulation of 5-HT in rat brain slices was assessed in the absence and presence 
of the selective serotonin reuptake inhibitor fluoxetine. 
In the absence of fluoxetine, the average T/M ratio for hippocampal sections incubated 
for 30 min in aCSF at 34 ̊C was 8.11 ±1.52 (n=12), the T/M ratio at 0 time was 0.2± 
0.03 (n=8) and for the ice control 0.39±0.07 (n=8). Therefore, the T/M ratio at 0 time 
was 2.48% of the total [3H]5-HT T/M ratio and in 0 C̊ was 4.9 % of the total [3H]5-HT 
T/M ratio. The non-specific T/M ratio was subtracted from the total [3H] 5-HT T/M ratio 
in each experimental slice before further analysis. 
Specific [3H]5-HT uptake was calculated for each fluoxetine concentration of 0.1 (n=5). 
Fluoxetine inhibited specific [3H]5-HT uptake in hippocampal sections in a 
concentration dependant manner (Kruskal-Wallis H test, X 2,3 =15.921, p< 0.001; 
Figure 3.6). 
The same experiments were repeated with cortical sections. In the absence of 
fluoxetine, the average T/M ratio for cortical sections incubated for 30 min in aCSF at 
34 C̊ was 22.6 ± 3.01 (n=6); the T/M ratio at 0 time was 0.16± 0.02 (n=7) and for the 









































HT T/M ratio and at 0 ̊C was 3.6 % of the total [3H]5-HT T/M ratio. The total non-specific 
T/M ratio was subtracted from the total [3H] 5-HT T/M ratio in each experimental section 
before further analysis. 
Specific [3H]5-HT uptake was calculated for each fluoxetine concentration of 0.3 (n=3), 
1 (n=3), 10 (n=6) and 100 (n=3) µM. 
Fluoxetine inhibited specific [3H]5-HT uptake in cortical sections (Kruskal-Wallis H test 
X2, 18= 11.42, P <0.002, Figure 3.6). 
 
 
Figure 3.6 Effect of fluoxetine on specific [3H]5-HT uptake in rat brain sections 
(hippocampus and cortex).The uptake is expressed as the percentage of [3H]5-HT 
uptake in control slices. The sections were incubated with fluoxetine (0 – 100 µM) and [3H]5-
HT for 30 min at 34°C under O2/CO2 atmosphere. Each point represents mean ± SEM of (3-
5) experiments. 
 
The effect of D-amphetamine on [3H]5-HT uptake was assessed. In the absence of D-
amphetamine, the average T/M ratio for hippocampal sections incubated for 30 min in 
aCSF at 34 ̊C was 9.04± 1.5 (n=9), the T/M ratio at 0 time was 0.2± 0.03 (n=8) and for 
the ice control 0.39±0.07 (n=8). Therefore, the T/M ratio at 0 time was 0.4 % of the 
total [3H] 5-HT (T/M) ratio and at 0 ̊C was 4.4 % of the total [3H]5-HT T/M ratio. The 
non-specific T/M ratio was subtracted from the total [3H]5-HT T/M ratio in each 








































Specific [3H]5-HT uptake was calculated for each D-amphetamine concentration of 
0.01 (n=4), 0.1 (n=4), 1 (n= 5), 10 (n= 4), 30 (n= 6) and 100 (n=4) µM. D-amphetamine 
had a variable effect on [3H]5-HT uptake inhibition in hippocampal sections at different 
concentrations.  However, overall [3H]5-HT uptake was significantly inhibited (X2, 6= 
13.805, P <0.03, Figure 3.7). 
The average T/M ratio of amphetamine on  cortical sections incubated for 30 min in 
aCSF at 34 ̊C was 16 ± 2.5 (n=12), the T/M ratio at 0 time was 0.14± 0.02 (n=6) and 
for the ice control 1 ±0.1 (n=6). Therefore, the T/M ratio at 0 time was 0.85% of the 
total [3H]5-HT T/M ratio and at 0 ̊C was 6.08 % of the total [3H]5-HT T/M ratio. Total 
non-specific T/M ratio was subtracted from the total [3H]5-HT T/M ratio in each 
experimental section before further analysis. 
Specific [3H]5-HT uptake was calculated for each D-amphetamine concentration 
0.5(n=6), 1(n=8), 3(n=4), 5(n=4), 10 (n=4) and 100 (n=4) µM. 
There was no statistically significant effect of amphetamine at the concentrations 
tested on [3H]5-HT uptake inhibition in cortical sections (Kruskal-Wallis H test X2, 5 
=2.14, p > 0.05; Figure 3.7). 
 
Figure 3.7 Effect of D-amphetamine on specific [3H]5-HT uptake in rat brain 
sections (hippocampus and cortex). Sections were incubated with D-amphetamine (0 – 
100 µM) and [3H]5-HT for 30 min at 4°C under O2/CO2 atmosphere. The uptake is expressed 
as the percentage of [3H]5-HT uptake in control sections. Each point represents mean ± SEM 





































3.4.2 Ex-vivo brain slice experiment optimization 
In the previous experiments, it was evident there was variability between experiments 
of different days. To reduce the variability between different experiments, the 
oxygenation of the slices continued during dissection, and they were dissected in aCSF 
instead of sucrose buffer. In addition, the time between the dissection of slices to the 
start of incubation reduced from (30-215 min) to (15-30 min). Therefore, the 
experiments with D-amphetamine were repeated and the results show improvements 
in uptake and reduced variability.  
In the absence of D-amphetamine, the average T/M ratio for cortical sections incubated 
for 30 min in aCSF at 34 ̊C was 10 ± 1.03 (n=6), the T/M ratio at 0 time was 0.39± 0.09 
(n=3) and for the ice control 1.1 ± 0.05 (n=3). Therefore, the T/M ratio at 0 time was 
3.64% of the total [3H]5-HT T/M ratio and at 0 ̊C was 10.3% of the total [3H]5-HT T/M 
ratio. Total non-specific T/M ratio was subtracted from the total [3H]5-HT T/M ratio in 
each experimental section before further analysis. [3H]5-HT 
Specific [3H]5-HT uptake was calculated for each of D-amphetamine concentrations 
1(n=6), 10 (n=6) and 100 (n=6) µM. 
There was a statistically significant effect of amphetamine concentration on [3H]5-HT 
uptake inhibition in cortical sections (one way ANOVA, F (3, 18) = 3.8 p < 0.05; Figure 
3.8). The optimisation improved 5-HT uptake and reduced 5-HT uptake variability 




Figure 3.8 The effect of optimisation on percentage of inhibition of [3H]5-HT 
uptake by amphetamine in rat cortical brain sections. Sections were incubated with 
D-amphetamine (0 – 100 µM) and [3H]5-HT for 30 min at 4°C under O2/CO2 atmosphere. The 
uptake is expressed as the percentage of [3H]5-HT uptake in control sections. Amph.cx pre 
represents the experiments prior to optimisation. Amph.cx post represents the experiments 
after optimisation. Each point represents mean ± SEM of experiments of 3 experiments. 
 
 
The uptake inhibition of D-amphetamine in cortical sections was assessed again after 
the addition of 10 µM of the monoamine oxidase inhibitor pargyline to the incubation 
aCSF to reduce the metabolism of 5-HT. 
In the absence of D-amphetamine, the average T/M ratio for cortical sections incubated 
for 30 min in aCSF at 34 C̊ was 19 ± 3.1 (n=6), the T/M ratio at 0 time was 0.2± 0.01 
(n=3) and for the ice control 1.32 ± 0.1 (n=3). Therefore, the T/M ratio at 0 time was 
1.05% of the total [3H]5-HT T/M ratio and at 0 ̊C was 6.75% of the total [3H]5-HT T/M 
ratio. Total non-specific T/M ratio was subtracted from the total [3H]5-HT T/M ratio in 
each experimental section before further analysis. 
Specific [3H]5-HT uptake was calculated for each D-amphetamine concentrations of 
1(n=6), 10 (n=6) and 100 (n=6) µM. 
There was a statistically significant concentration-related effect of amphetamine on 
[3H]5-HT uptake inhibition in cortical sections in the presence of pargyline (one way 
ANOVA, F (3,20) = 29.1 p < 0.001; Figure 3.9). However, a two-way mixed analysis of 
variance showed no significant main effect of pargyline (Two-way ANOVA, F (3, 38) 








































Figure 3.9 The effect of pargyline on [3H]5-HT uptake in the presence of 
amphetamine in rat cortical brain sections. Sections were incubated with D-
amphetamine (0 – 100 µM) and [3H]5-HT for 30 min at 4°C under O2/CO2 atmosphere. The 
uptake is expressed as a percentage of [3H]5-HT uptake in control sections Amph.post 
represents the experiments after optimisation. Amph+pg represent the experiments with the 
addition of 10 µM pargyline. Each point represents mean ± SEM of 3 experiments. 
 
The D-amphetamine and pargyline experiment was repeated in hippocampal sections.  
In the presence of pargyline. 
In the absence of D-amphetamine, the average T/M ratio for hippocampal sections 
incubated for 30 min in aCSF at 34 ̊C was 15.27 ± 0.83 (n=6), the T/M ratio at 0 time 
was 0.2± 0.03 (n=3) and for the ice control 1.03 ± 0.2 (n=3). Therefore, the T/M ratio 
at 0 time was 1.38% of the total [3H]5-HT T/M ratio and at 0 ̊C was 6.79% of the total 
[3H]5-HT T/M ratio. Total non-specific T/M ratio was subtracted from the total [3H]5-HT 
T/M ratio in each experimental section before further analysis. 
Specific [3H]5-HT uptake was calculated for each D-amphetamine concentrations of 
1(n=6), 10 (n=6) and 100 (n=6) µM. 
There was a statistically significant concentration-relate effect of amphetamine on 
[3H]5-HT uptake inhibition in hippocampal sections in the presence of pargyline 
(Kruskal-Wallis H test, X 2,3=19.46; p< 0.001; Figure 3.10). ). A two way ANOVA 









































Figure 3.10  The effect of pargyline on [3H]5-HT uptake in the presence of 
amphetamine in rat hippocampal brain sections. Sections were incubated with D-
amphetamine (0 – 100 µM) and [3H]5-HT for 30 min at 4°C under O2/CO2 atmosphere. The 
uptake is expressed as a percentage of [3H]5-HT uptake in control sections Amph represents 
the experiments without pargyline. Amph+pg represent the experiments with the addition of 10 
µM pargyline to the aCSF. Each point represents mean ± SEM of 3 experiments. 
The results after optimization showed there was reduction in [3H]5-HT uptake 
variability. Therefore, these results suggest that the use of this method can be applied 
successfully to evaluate the effect of SCRAs on 5-HT uptake. 
3.4.3 Effect of JWH-018 [3H]5-HT uptake. 
JWH-018 was chosen as an example of an indole derivative SCRAs to assess its ability 
to inhibit [3H]5-HT uptake on hippocampus.  
In the absence of JWH-018, the average T/M ratio for hippocampal sections incubated 
for 30 min in aCSF at 34 ̊C was 15.73 ± 1.7 (n=18), the T/M ratio at 0 time was 0.23± 
0.02 (n=7) and for the ice control 1.25 ± 0.32 (n=7). Therefore, the T/M ratio at 0 time 
was 1.44% of the total [3H]5-HT T/M ratio and at 0 ̊C was 7.9% of the total [3H]5-HT 
T/M ratio. Total non-specific T/M ratio was subtracted from the total [3H]5-HT T/M ratio 
in each experimental section before further analysis. 
Specific [3H]5-HT uptake was calculated for each JWH-018 concentration of 0 (n = 18), 






































There was no statistically significant effect of JWH-018 concentrations on [3H]5-HT 
uptake inhibition in hippocampal sections (Kruskal-Wallis H test X (2,5) =4.53, p>0.05; 
Figure 3.11). 
 
Figure 3.11  Effect of JWH-018 on [3H]5-HT uptake on rat hippocampal sections. 
Sections were incubated with JWH-018 (0 – 10 µM) and [3H]5-HT for 30 min at 4°C under 
O2/CO2 atmosphere. The uptake is expressed as a percentage of [3H]5-HT uptake in control 
sections. Each point represents mean ± SEM of 9 experiments.  
 
To determine if an alternative mechanism of action was counteracting 5-HT uptake, 
additional experiments were conducted in the presence of CB1 antagonist rimonabant 
with monoamine oxidase inhibitor pargyline to decrease 5-HT degradation. 
In the absence of JWH-018 and rimonabant, the average T/M ratio for hippocampal 
sections incubated for 30 min in aCSF at 34 C̊ was 21.47 ± 1.19 (n=12), the T/M ratio 
at 0 time was 0.27± 0.04 (n=6) and for the ice control 0.98 ± 0.2 (n=6). Therefore, the 
T/M ratio at 0 time was 1.24% of the total [3H]5-HT T/M ratio and at 0 ̊C was 4.5% of 
the total [3H]5-HT T/M ratio. Total non-specific T/M ratio was subtracted from the total 










































Specific [3H]5-HT uptake was calculated for JWH-018 in absence of rimonabant (0.01 
µM (n=4), 10 (n=10)), JWH-018 in the presence of 1 µM rimonabant (0.01 (n=4), 10 
µM (n=4)) and 1 µM rimonabant (n=8).  
The addition of rimonabant did not affect [3H]5-HT uptake in the eight groups of 
treatment (Kruskal Wallis X (2,7) =2.15, p>0.05; Figure 3.12). 
 
Figure 3.12 The effect of the CB1 receptor antagonist rimonabant on [3H]5-HT 
uptake in rat hippocampus brain sections. Sections were incubated with JWH-018 
(0.01 and10 µM) in the presence of 1 µM rimonabant and [3H]5-HT for 30 min at 4°C under 
O2/CO2 atmosphere. The uptake is expressed as a percentage of [3H]5-HT uptake in control 
sections. Each point represents mean ± SEM of 6 experiments. 
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3.4.4 Effect of CP 55,940 on [3H]5-HT uptake 
The effect of the non-indole cannabinoids CP 55,940 on 5-HT uptake was investigated 
in the presence and absences of 1 µM CB receptor antagonist rimonabant. 
In the absence of CP 55,940 and rimonabant, the average T/M ratio for hippocampal 
sections incubated for 30 min in aCSF at 34 C̊ was 18.15 ± 2.3 (n=8), the T/M ratio at 
0 time was 0.22± 0.05 (n=4) and for the ice control 0.63 ± 0.15 (n=4). Therefore, the 
T/M ratio at 0 time was 1.19% of the total [3H]5-HT T/M ratio and at 0 ̊C was 3.4% of 
the total [3H]5-HT T/M ratio. Total non-specific T/M ratio was subtracted from the total 
[3H]5-HT T/M ratio in each experimental section before further analysis. 
Specific [3H]5-HT uptake was calculated for 10 µM CP 55,940 (n=11) and 10 µM CP 
55, 940 in the presence of 1 µM rimonabant (n=10).  CP 55,940 has no significant 
effect on [3H]5-HT uptake in the presence or absence of rimonabant (Kruskal Wallis X 
(2,1) =0.97, p>0.05; Figure 3.13). 
 
Figure 3.13 The effect of CP 55,940 [3H]5-HT uptake in the presence and absence 
of the CB1 receptor against rimonabant. Sections were incubated with 10 µM CP55, 
940 in the presence and absence of 1 µM rimonabant and [3H]5-HT for 30 min at 4°C under 
O2/CO2 atmosphere. The uptake is expressed as a percentage of [3H]5-HT uptake in control 




In summary, these results showed that the SCRAs JWH-018 and CP55, 940 did not 
inhibit 5-HT uptake, while this experimental model was able to demonstrate that the 
SSRI Fluoxetine significantly inhibited 5-HT uptake (Figure 3.14).  
 
Figure 3.14 Comparison of [3H]5-HT uptake of Fluoxetine, JWH-018 and CP 
55,940. The Hippocampal Slices were incubated with 3H-5HT for 30 min at 34 ̊C in the 
presence or absence of 10 µM JWH-018, CP 55,940 and fluoxetine. Each point represents the 
mean± SEM of 3-5 experiments. 
 
 
3.5 Discussion  
The objective of these experiments was to assess the effect of an indole-containing 
SCRA, represented by JWH-018, and non-indole containing SCRA, represented by 
CP 55,940, on 5-HT uptake. 
3.5.1 Rat brain slice method  
Previous published studies examining 5-HT uptake have used either synaptosomes 
(Whittaker et al., 1964), cultured neurones (Buc-Caron et al., 1990) or rodent brain 
slices (Shaskan and Snyder, 1970). Synaptosomes, produced from brain tissue 
homogenate, have proven to be a good model for studying the molecular mechanisms 
of synaptic transmission. Although, synaptosomes should be fairly uniform during the 
preparation there may be a loss in functional integrity or low protein yield (Whittaker, 
1993, Dunkley et al., 1986). In addition, there are several serotonergic models that 
have been characterized.  For instance, blood platelets have been used as a reliable 
model to study 5-HT release and uptake, but they lack the ability to synthesis 5-HT (Da 
Prada et al., 1988). In addition many cell line models have been used such as NG108-
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15 hybrid cells (Hilibrand et al., 1987), the medullary thyroid carcinoma (MTC) cell line 
(Tamir et al., 1989), and the CGP cell line derived from human carcinoids cells 
(Debons-Guillemin et al., 1982). None of these, however, displays a full serotoninergic 
phenotype such as active 5-HT uptake, storage, and metabolism (Buc-Caron et al., 
1990). On the other hand isolated rat brain slices maintain many “in vivo” functions for 
several hours when maintained in a suitable medium (Collingridge, 1995). Moreover, 
brain slices provide a highly regulated ex-vivo setting while maintaining large parts of 
the complicated cellular integrity, including cellular barrier and intact circuits. This 
results in a more comparable ex-vivo setting to the in-vivo brain in term of pH gradients, 
active transport systems and cell-cell interaction (Loryan et al., 2013). However, the 
limitations of this method are the restricted number of slices taken from each brain and 
the need to keep the slices intact. The rat brain slice method was selected to study the 
effect of SCRAs on 5-HT uptake as this keeps most of the localised cellular intact. This 
method also provides a more “realistic” assessment of the effect of SCRA on 
transmission without excluding the effect of SCRA on other functions.   
3.5.2 Development and Validation of the rat brain slice method 
To validate the rat brain slice method for 5-HT uptake assessment, non-labelled 5-HT 
was used (Figure 3.5). These results obtained were consistent with published studies 
which reported that incubation with increasing concentrations of the non-labelled 5-HT 
inhibited [3H]5-HT uptake as it increased competition (Blackburn et al., 1967, Hyttel, 
1978).To validate the rat brain slice method for 5-HT uptake inhibition, the 5-HT uptake 
inhibitor fluoxetine was used (Wong et al., 1995). Data obtained showed that fluoxetine 
inhibited 5-HT uptake in hippocampal rat brain slices in a dose dependent manner 









  Fluoxetine concentration Percentage* 






   
Table 3.2  [3H]5-HT uptake in hippocampal slices. *percentage of uptake based on 
100% of control uptake.  
 
The different incubation times and the 5-HT concentrations used could account for the 
slight observed differences in uptake inhibition between different studies (Wong et al., 
1975, Owens et al., 2001). The effect of amphetamine on 5-HT uptake is more complex 
than the effect of fluoxetine on uptake. In the current study amphetamine inhibits 5-HT 
uptake, which is consistent with previous studies (Raiteri et al., 1975, Wong et al., 
1973). However, the percentage uptake inhibition varied between different 
concentrations in a non-concentration dependent manner. This variation in uptake 
inhibition may be due to different mechanisms of amphetamine increasing 5-HT 
concentration in the synaptic cleft. Amphetamine has been shown to have monoamine 
releasing effects (Rothman et al., 2001), i.e. release of 5-HT from serotonergic 
presynaptic terminals. A drug that influences neurotransmitter release, and at the same 
time blocks uptake, may promote release of some of the 5-HT previously taken up, 
making it appear that there is no inhibition.  
3.5.3 Ex-vivo brain slice experiment optimization 
In the previous experiments, it was noticed that there was substantial variability in 5-
HT uptake between the replicates, as demonstrated by large standard deviations. To 
reduce variability a number of modifications were made to the method prior to SCRA 
assessment. The slice dissection was conducted in aCSF instead of the sucrose slush; 
the slices were oxygenated during dissection as transport of 5-HT is enhanced by 
oxygen (Perez and Andrews, 2005). The slices were dissected before transportation; 
the time between the dissection and starting the experiment was reduced as longer 
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incubation times are associated with increased shredding of cells within the slices 
which might contribute to the variability of data.  
Furthermore, the addition of pargyline (MAO inhibitor) significantly increased 5-HT 
uptake (Table 3.3), because pargyline inhibits the degradation of 5-HT (Ross and 
Renyi, 1969). In conclusion, the rat brain slice uptake assay was established 








Table 3.3 [3H]5-HT uptake in aCSF slices incubated with and without pargyline. 
However, there are some limitations related to the rat brain slices method, first a 
metabolic shaker should be used instead of in house made apparatus (Figure 3.4) to 
provide more consistence control over the temperature, rate of shaking and oxygen 
pressure. Secondly, due to the low sensitivity of the method to 5-HT uptake inhibition 
a more simple and sensitive method such as synaptomsomal preparation could be 
used. Synaptosomes could be used to optimise the concentrations used of the tested 
SCRA, before being applied to the rat brain slice method. Thirdly, the underlying 
reasoning for this part of research was based on the hypothesis that cannabinoids may 
increase serotonergic activity reported in some clinical cases from SCRA intoxication, 
however, there is contradictory evidence from a variety of mechanistic studies (Section 
1.5). It might have been better to initially start with studying it in animals (murine model) 
and measuring the level of serotonin directly such as micro dialysis studies.  
3.5.4 Effect of JWH-018 and CP55, 940 on [3H]5-HT uptake  
The results of this study demonstrate that both JWH-018 and CP 55,940 at the 
concentrations tested, do not affect [3H]5-HT uptake in rat hippocampus, a brain region 
receiving serotonergic innervation and possessing 5-HT presynaptic terminals 
 (T/M) ratio Number of slices 
Cortical sections incubated 
in aCSF without pargyline 
10 ± 1.03 6 
Cortical sections incubated 
in aCSF with 10 µM 
pargyline 
19 ± 3.14 6 
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(Palkovits et al., 1977). These obtained results indicate that that the 5-HT transporter 
is unaffected by these SCRAs. 
Little information is known about the effects of SCRA on serotoninergic systems in the 
brain. The understanding of the impact of cannabinoids on SERT function could help 
to understand the interaction between the two systems. Velenovská et al. (2007) 
investigated the effect of cannabinoids on 5-HT function on platelets from chronic 
cannabis smokers (Velenovská and Fišar, 2007). They reported that high 
concentrations of cannabinoids (∆9 THC, anandamide and WIN 55,212-2) can inhibit 
SERT activity acutely. This inhibition is non- competitive, which indicates that 
cannabinoids indirectly inhibited SERT activity through the changes on membrane 
lipids.  Although studying 5-HT uptake using platelets models has been shown to be a 
successful method (Stahl and Meltzer, 1978, Lesch et al., 1993),  it  does not represent 
the complexity of the brain where there is an integration and interaction between 
different receptors, neurotransmitters and /or transporters. In addition, Velenovská 
noted that high concentrations of tested cannabinoids are required to induce 5-HT 
uptake inhibition.  In contrast, this study tested 5-HT uptake in rat brain hippocampus, 
where most of the serotonergic features are expressed. In addition, the concentrations 
range of JWH-018 used in the experiments was chosen to span the expected blood 
concentrations after inhalation of smoke. Poklis et al. (2012) reported that the blood 
concentration in mice after 20 min exposure to JWH-018 was 42-160 ng/ml, equivalent 
to 0.12-0.45 µM (Poklis et al., 2012). Therefore, following the information from Poklis 
et al. (2012), a concentration range from 0.0001-10µM was used for both JWH-018 
and CP55, 940 in this study. Unfortunately, the results of this study suggested that 
neither JWH-018 nor CP55, 940 affected the uptake of [3H] 5-HT in rat hippocampus. 
This further suggests that the 5-HT transporter is unaffected. 
The initial results show that the indole core structure present in JWH-018 does not act 
a substrate to compete with 5-HT for SERT binding site. However, to determine this in 
detail more SCRAs containing the indole core structure would need to be analysed.   
3.5.5  The effect of CB1 agonist rimonabant  
It has been suggested that CB1 receptors might be located presynaptically on 
serotonergic neurons (Nakazi et al., 2000). In addition, Lau et al (2008) reported the 
co-expression of CB1 receptors with protein markers for re-uptake and monoamine 
95 
 
release on serotonergic neurons (Lau and Schloss, 2008). Hence, many studies 
suggested the role of CB1 receptor in modulation of 5-HT release and uptake. 
Therefore, rimonabant; a potent CB1 receptor antagonist (Rinaldi-Carmona et al., 
1994); was used to exclude a direct effect of CB1 receptor activation on 5-HT uptake. 
Kenney et al. (1999) suggested that CB1 receptors could be involved in the regulation 
SERT function (Kenney et al., 1999). They reported that SERT function is decreased 
in human placenta cells after exposure to the CB1 agonist WIN 55,212-2. It was 
proposed that the reduction in SERT activity was indirectly through lowering 
intracellular Ca++, which plays a role in regulation of SERT activity (Turetta et al., 2002). 
Steffens and Feuerstein(2004), however, reported the inhibitory effect of cannabinoids 
on 5-HT uptake mediated by a reduction of Na+/K+-ATPase activity rather than CB1 
activation (Steffens and Feuerstein, 2004).   
Nakazi et al. (2008) had reported that the activation of the CB1 receptor lead to 
relatively small 5-HT release inhibition (20% inhibition) (Nakazi et al., 2000). Kleijn et 
al. (2011) stated that the acute stimulation of the CB1 receptor counteracted the effect 
of selective serotonin reuptake inhibitor citalopram on increasing 5-HT levels in rat 
prefrontal cortex (Kleijn et al., 2011). The blocking of CB1 by rimonabant moderately 
stimulates 5-HT release in the rat prefrontal cortex (Tzavara et al., 2003). Taken 
together, the effect of CB1 activation could inhibit 5-HT release, but this could lead to 
reduced 5-HT available for uptake and this might mask the inhibition of SERT function. 
However the results in this study suggested that the blocking of CB1 receptor had no 
effect on 5-HT uptake as it did not change 5-HT uptake either by itself or in combination 
with the tested SCRA. 
In summary, the results of this study did not explain the occurrence of serotonergic 
adverse events seen clinically in SCRA users. It was important to test the hypothesis 
that indole-containing cannabinoids may have a direct effect on SERT function. 
However, the results suggested that if SCRAs are causing a serotonergic effect this 
may be via another indirect mechanism. The study tested the parent compound JWH-
018, but not metabolites, which are proven to retain activity on CB receptors (Brents 
et al., 2011). Therefore, we cannot exclude the possibility that these metabolites, which 
can still contain the indole core, may have an effect on SERT function or other 
serotonergic receptors that might contribute to a serotoninergic effect. 
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Finally, this experiment tested JWH-018 and CP55, 940, but, there are diverse 
preparations or products that have been shown to contain different SCRAs such as 
AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-
ADB-PINACA, ADBICA, and 5F-ADBICA (Banister et al., 2015). These may exert 
effects directly on the serotonergic or other monoaminergic systems but so far remain 
uncharacterised. Further investigation into these continually evolving substances 





















  Neurotoxic analysis of NPS 
 
4.1 Introduction 
The abuse of NPS, in particular herbal products that contained SCRAs, are an 
important issue with potential serious consequence for public health. These 
substances have been perceived as a “safe and legal” alternative to the widely 
recreationally abused herb “cannabis”, especially in the younger population (UNDOC, 
2018). Most SCRAs have the ability to pass blood brain barrier due to their lipophilic 
properties, and they bind to CB1 receptor with different affinities. Most SCRAs have 
shown to have binding affinity and agonist activity to CB1 receptor many times higher 
than ∆9-THC (Banister et al., 2016, Banister et al., 2015, Sachdev et al., 2018). SCRAs 
are a diverse group of compounds with various chemical structures which bind to 
cannabinoid receptors with different affinities (Castaneto et al., 2014) resulting in 
different potencies, metabolism and toxicological profile. Although SCRAs have been 
shown to have psychotropic effects similar to cannabis (Gunderson et al., 2012), more 
toxic and serious adverse health effects have been reported with SCRA users. It has 
been estimated that SCRA users are 30 times more likely to seek hospital admission 
than cannabis users (Zaurova et al., 2016, van Amsterdam et al., 2015, Winstock et 
al., 2015). 
Over the last 10 years, the number of SCRAs encountered has continually increased, 
with 179 being notified to the EU early warning system since 2008, (EMCDDA, 2018). 
The pharmacological effects of this rapidly expanding group of substances is not fully 
understood, despite there being studies on the structure-activity relationships, binding 
affinities and pharmacokinetic profile for some SCRAs. Information on the toxicological 
effects of SCRAs for both short and long-term exposure is still scarce and few studies 
have been published in the literature regarding the underlying molecular mechanisms 
of toxicity in human cells (Koller et al., 2014, Tomiyama and Funada, 2011, Ferk et al., 
2016, Koller et al., 2013).  
The herbal products which are marketed as NPS vary in type and composition of NPS, 
rendering NPS users unware what they have exactly taken as they consume branded 
products with different names (Brunt et al., 2017). Zuba et al. (2011) reported that there 
is a significant difference in the composition of some available branded products 
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regarding synthetic cannabinoids. He reported that some products contain one SCRA, 
while other products contain more than two SCRA (Zuba et al., 2011). These findings 
have been confirmed by other authors, such as Uchiyama et al. (2014), who stated 
that 60 different combination patterns were detected in 104 products, with 1-7 
compounds per product being present. In addition, these compounds belong to 
different NPS categories for instance SCRA, phenylethylamines and cathinone 
derivatives (Uchiyama et al., 2014). Alongside this, drugs users’ use NPS with other 
traditional drug of abuse for example MDMA, which instigate to co-administration of 
multiple drug of abuse that results in adverse effect (Heikman et al., 2016). 
Therefore, the evaluation of the toxicological properties of SCRAs, in particular the 
neurotoxic effects of these widely used substances, is needed.   
4.1.1 SCRAs 
Although over 179 SCRAs have been identified not all are currently being taken for 
recreational use therefore for this study two currently in-use SCRAs (taken from the 
NPIS data), a SCRA analogue and one of the first SCRAs identified in herbal products 
were examined.  
4.1.1.1 JWH-018 
JWH-018 (1-pentyl-3-(1-naphthoyl) indole) (Figure 4.1) was chosen as it is one of the 
first identified SCRAs in herbal products (Auwarter et al., 2009). It is a synthetic 
cannabinoid receptor agonist from the aminoalkylindoles group. It was developed by 
the chemist John W Huffman as a potential ∆9-THC alternative for therapeutic uses 
with less addictive properties (Huffman et al., 1994). It is a potent agonist with high 
binding affinity for the  CB1 (Ki= 9 nM) and CB2 receptors (Ki= 3 nM), which is more 
potent than ∆9-THC for either receptor (Ki=40.4 nM at CB1 and 36.4nM at CB2 
receptor) (Aung et al., 2000). Wintermeyer et al. (2010) reported that phase I 
metabolism of JWH-018 produced at least nine hydroxylated, N-dealkylated, 
dehydrated and carboxy metabolites (Wintermeyer et al., 2010). Further studying of 5 
of the hydroxylated metabolites and the carboxy metabolite revealed that the 5 tested 
monohydroxylated metabolites, but not the carboxy product, had high activity and 
affinity at CB1 receptors when tested both in vivo and in vitro (Brents et al., 2011). 
Furthermore, these monohydroxylated metabolites also demonstrated nanomolar 
affinity and acted a potent agonists at CB2 receptors (Rajasekaran et al., 2013). In 
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contrast the main phase II metabolite, JWH-018-N-(5-hydroxypentyl) β-D-glucuronide 
(018-gluc) does not have activity on CB1 receptor and antagonises the parent drug 
activity on the same receptor (Seely et al., 2012a). The human blood concentration of 
JWH-018 has been shown to decrease rapidly over 3 hours after inhalation through 
smoking (Teske et al., 2010). JWH-018 was detected in 18 out of 45 post-mortem blood 
samples analysed in the range of 0.1-199 ng/ml (Shanks et al., 2012b). In a controlled 
inhalation study conducted by Toennes et al. (2017) concentrations of 2.9 to 9.9 ng/ml 
were measured in blood (Toennes et al., 2017). Even with low serum concertation, 
JWH-018 still causes neurocognitive impairment and the euphoric feelings of ‘high’ 
(Theunissen et al., 2018). 
Animal studies have shown that JWH-018 produces antinociception, catalepsy, 
hypothermia, hypo-mobility and increased anxiety (Wiebelhaus et al., 2012, Macrì et 
al., 2013) and induces myoclonus, convulsions and hyperreflexia (Ossato et al., 2015). 
Moreover, Cha et al. (2015) suggested that JWH-018 and JWH-012 might be induce 
neurotoxicity through distortion of the nuclear membrane and nuclei in the NA core 
shell and inducing neuronal cell damages (Cha et al., 2015). In addition, JWH-018 
reduced K+ evoked glutamate and GABA release from hippocampal slices and 
inhibited short and long term memory together with its halogenated analogues in mice 
(Barbieri et al., 2016). These neurological changes observed in SCRA exposure may 
reflect the direct or indirect effects of SCRA-induced cytotoxicity and neuronal 
dysfunction. However, the cytotoxic effect of SCRAs at a cellular level and the 
mechanisms by which they induce toxicity or molecular changes after acute and 
chronic exposure in human neuronal cells has not been described previously. 
4.1.1.2 MDMB-CHMICA 
MDMB-CHMICA (2-[[1-(cyclohexylmethyl) indole-3-carbonyl] 3, 3-dimethylbutanoate, 
(Figure 4.1) is an indole core SCRA which was detected in Europe and reported to the 
EMCCDA for the first time in September 2014 (EMCDDA, 2017b). It is a potent CB1 
and CB2 receptor agonist with EC50 values of 10 and 71 nM respectively (Banister et 
al., 2016). MDMB-CHMICA users reported that MDMB-CHMICA is stronger than other 
SCRAs; this might be due its higher CB1 receptor potency (WHO and Meeting, 2017). 
MDMB-CHMICA undergoes extensive phase I metabolism producing 31 metabolites 
that have been identified in human urine samples (Franz et al., 2017), with 
monohydroxylated metabolites identified as proven biomarkers to detect consumption 
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(Gaunitz et al., 2018). The adverse effects of MDMB-CHMICA, such as agitation, 
vomiting, delirium and respiratory depression have been self-reported by users and 
taken from case reports of acute intoxication that required hospitalization, with some 
leading to fatalities (Vucinic et al., 2018, Hermanns-Clausen et al., 2018, Abouchedid 
et al., 2017, Hill et al., 2016, Adamowicz, 2016). However, limited data regarding the 
cytotoxicity and genotoxicity of MDMB-CHMICA was found in the literature.  
4.1.1.3 5F-ADB 
5F-ADB, also known as 5F-MDMB-PINACA (methyl-[2-1(fluoropentyl)-1H-indazole-3-
carboxamido)-3,3-dimethylbutanoate], (Figure 4.1) is an indazole core SCRA which 
was reported to EMCCDA for the first time in 2015 (EMCDDA, 2017a). It is a potent 
CB1 and CB2 receptor agonist with EC50 values of 0.59 nM and 7.5 nM respectively 
(Banister et al., 2016). Kusano et al. reported that 5F-ADB undergoes phase I 
metabolism to produce several metabolites (Kusano et al., 2018); however, there is 
limited literature available on the pharmacokinetics of 5F-ADB. This SCRA has been 
reported to be responsible for poisoning and fatalities in several cases/users (Kraemer 
et al., 2019, Hasegawa et al., 2015, Angerer et al., 2017, Barceló et al., 2017). Like 
MDMB-CHMICA, no studies were identified in the literature that have examined the 
cellular toxicity of 5F-ADB. 
4.1.1.4 MMB-CHMICA 
MMB-CHMICA, also known as AMB-CHMICA (methyl 2-[[1-(cyclohexylmethyl) indole-
3-carbonyl]amino]-3-methyl-butanoate,  Figure 4.1) is structurally related to MDMB-
CHMICA, having an additional methyl group at the butanoate group. It has been shown 
to be metabolised by hydroxylation and O-demethylation (Mardal et al., 2018). It is a 
potent SCRA which binds to CB1 and CB2 receptors with EC50 values of 3.5 and 12 








Mephedrone (4-methylmethcaininoe) is a cathinone stimulant (Figure 4.2). It was first 
synthesised in 1929, but appeared as recreational drug in the mid-2000s (EMCDDA, 
2011). It acts by enhancing monoamine release and blocking monoamine reuptake 
through the inhibition of monoamine transporters in the brain (Papaseit et al., 2017). It 
is metabolised by phase I metabolism into six metabolites (Meyer et al., 2010). There 
is considerable evidence of severe acute intoxication and fatalities relating to 
mephedrone (Busardò et al., 2015, Schifano et al., 2011). The data in the literature as 
yet does not clearly describe the mechanism of action and toxicity of mephedrone 
(Pantano et al., 2017).   
4.1.2.2 25I-NBOMe 
25I-NBOMe (4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl) phenethylamine) is a 
stimulant hallucinogen (Figure 4.2). It was synthetized in 2003 as radiolabelled 25I-
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NBMOE to study 5-HT receptors, and was first reported to EMCDDA as a recreational 
drug in 2012 (EMCDDA, 2014).  25I-NBOMe is a potent 5-HT2A receptor agonist with 
Ki = 0.44 nM (Braden et al., 2006). It undergoes extensive phase I and phase II 
metabolism (Leth-Petersen et al., 2016). Severe intoxication cases and fatalities have 
been reported with 25I-NBOMe (Hill et al., 2013, Walterscheid et al., 2014, Poklis et 
al., 2014). Like other NPS, limited data areavailable about the pharmacology and 
toxicology of 25I-NBOMe in humans.   
4.1.3 Classical drugs of misuse 
4.1.3.1  Delta-9-tetrahydrocannabinol (∆9-THC)  
∆9-THC is the psychoactive ingredient of the plant Cannabis sativa and it is responsible 
for the psychoactive effects of cannabis (Gaoni and Mechoulam, 1964). It acts as a 
partial agonist on CB1 (Ki=40.4 nM) and at CB2 receptor (Ki 36.4nM) (Aung et al., 
2000). In addition, it acts on other receptors such as the opioid and benzodiazepine 
receptors and interacts with protein and nucleic acid metabolism and the prostaglandin 
pathway (Burstein et al., 1982, Cichewicz, 2004, Grotenhermen, 2003). Unlike SCRA, 
∆9-THC is well studied. Briefly, it is highly lipid soluble and rapidly absorbed after 
inhalation, reaching peak concentrations in blood after 5-7 minutes (Ohlsson et al., 
1980). Once absorbed, ∆9-THC is metabolised by oxidation by CYP2C9 and CYP3A4 
to produce hydroxylated active metabolite, which undergoes oxidation to add several 
carboxylic groups and produce inactive 11-nor-9-carboxy-Δ9-THC metabolite. Then 
this inactive metabolite undergoes conjugation with glucuronic acid, which is regarded 
as the main metabolite (Bornheim et al., 1992, Yamamoto et al., 1987). In mice ∆9-
THC, produce antinociception, hypothermia, catalepsy, impairment of memory and 
learning and aggressive behaviour (Wiley and Martin, 2002). 
4.1.3.2 MDMA 
MDMA (3, 4-methylenedioxy-methamphetamine), commonly known as ‘ecstasy’ 
(Figure 4.2) is a stimulant and entactogenic recreational drug chemically related to 
amphetamine. It was first synthesised in 1912 and used for psychotherapy, then 
subsequently misused as recreational drug (Benzenhöfer and Passie, 2010). It acts by 
directly increasing the release of noradrenaline and dopamine as well as blocking the 
serotonin transporter (Kalant, 2001). Most MDMA users are poly-drug users, 
combining MDMA use with substances such as alcohol, cannabis, cocaine, heroin or 
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LSD (Wish et al., 2006). MDMA is metabolised in the liver mainly by CYP2D6 to several 
metabolites, some of which retain pharmacological activity (Kalant, 2001) MDMA can 
cause acute and chronic toxicity, and this is not limited to neurotoxicity (Meyer, 2013, 
Kalant, 2001).  
 
Figure 4.2  Chemical structure of novel stimulants (25I-NBOMe and mephedrone) 
and classical drug of abuse (∆9-THC and MDMA). 
 
4.1.4 Use of cell cultures in toxicity testing 
Toxicology offers many in vivo and in vitro test techniques. While animal 
experimentation has played a critical role in toxicology, a progression towards an 
alternative in vitro toxicology using cell-based assays is needed. Cell culture provides 
a method of studying animal or human cells in a controlled environment. This can 
include cell biology such as metabolic studies and the study of the effect of drugs and 
toxic substances on physiological pathways, for example protein synthesis and 
interactions between cells. 
Cell culture has the advantage of allowing the control of physicochemical environment. 
Experiments are easily performed at relatively low cost and are appropriate for toxicity 
testing of a variety of chemicals, allowing multiple replicates (Philippeos et al., 2012). 
Advances in stem cell toxicology testing provided a propitious platform for predictive 
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studies. Stem cells have the advantage of the ability to extensively proliferate without 
transformation or differentiate into different cell types making them suitable for 
functional toxicity and developmental tests (Liu et al., 2017). 
In this study, a human neuronal progenitor stem cell model (hNPSC) was used. This 
has been used successfully as a model to investigate the cytotoxicity of other 
compounds (Nisar et al., 2015). The use of human neuronal stem cell model provides 
a further advantage of avoiding the need to extrapolate results across species (Breier 
et al., 2010, Scott et al., 2013).  
4.1.5  Cell viability assay 
There are several cytotoxicity assays widely used in pharmacology and toxicology to 
evaluate the impact of drugs and chemicals in the cells, such as MTT, XTT, and the 
Alamar blue reduction assay. In this study the Alamar blue reduction assay was 
employed to evaluate cell viability (Page et al., 1993). This reagent is not toxic to the 
cell, and does not require cell death to obtain measurements, allowing the continuous 
monitoring of the same cell cultures over time. In addition this method is more sensitive 
than MTT (Hamid et al., 2004, O'Brien et al., 2000, Ahmed et al., 1994, Rampersad, 
2012). 
The Alamar blue reduction assay is a sensitive, simple, non-toxic test that can be 
applied to high throughput toxicity testing. It measures metabolic properties of the cell 
through monitoring the oxidation-reduction of the active ingredient Resazurin. 
Resazurin is water soluble, stable in aqueous media and cell membrane permeable 
(Rampersad, 2012). Resazurin is a blue low fluorescent dye that is reduced by 
nicotinamide adenine dinucleotide NADH into the pink highly fluorescent dye called 


















4.1.6 RNA sequencing 
The information for protein translation is stored in genes as DNA which is transcribed 
into RNA and ultimately translated into proteins. The transcription of a subset of genes 
into corresponding RNA molecules denotes the cell's identity and controls its biological 
activities. These RNA molecules are crucial for explaining and understanding the 
genome function in development and changes induced during disease (Kukurba and 
Montgomery, 2015). The assessment of protein expression is important to understand 
any modifications at cellular level in response to internal or external stimuli. However, 
it is difficult and time consuming to investigate all the changes that may occur in protein 
expression. Therefore, studying protein–encoding messenger RNA expression 
(transcriptome) might be informative as a proxy for envisaging protein expression (Guo 
et al., 2008). Understanding mRNA expression helps to associate the information on 
genome with its functional protein expression. 
RNA sequencing has been employed as an unbiased genomic approach for 
identification and quantification studies of messenger RNA molecules in a biological 
samples and is a valuable tool for investigating cellular responses (Haque et al., 2017). 
RNA sequencing techniques facilitate the profiling of the whole set of the transcribed 
genes or all types of RNA (transcriptomes), in addition to quantifying the modifications 
in expression levels of each transcript in response to various conditions (Wang et al., 
2009, Whitley et al., 2016) RNA sequencing was employed in this study to detect any 
changes in gene expression after treatment with SCRAs and to compare the effect of 
SCRA usage with ∆9-THC. 
4.1.7 Pathway analysis 
To understand the RNA sequencing data generated Ingenuity Pathway Analysis (IPA) 
software can be employed. IPA enables scientists to analyse data generated from 
microarrays, RNA-sequencing, proteomics and PCR. IPA’s data analysis facilitates 
identification of the significance of data or target(s) of interest in relation to bigger 
biological systems. IPA enables scientists to investigate more information about 
proteins, genes and how different drugs and chemical induce these changes (Jiménez-
Marín et al., 2009, Zeng et al., 2016). It helps to build ‘interactive models of 
experimental systems’. Importantly, canonical pathways are a set of pre-built pathways 
curated from numerous sources including the literature. Canonical pathway analysis of 
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IPA explains how pathways are affected significantly, taking into account the number 
of molecules shared between a user identifiable set and a pathway.  
4.1.8 Western blotting  
Proteins are complex molecules that play an important role in regulation of cell function, 
they are responsible for most of the cell physiological function, including cell shape, 
structure, catalysing metabolic reaction, transport, etc. Therefore, any changes in 
cellular protein levels can have an impact on the health and function of cells and the 
brain itself.  
To study potential changes in protein expression in the neuronal cells exposed to 
SCRA western blotting was performed. Western blotting is used to detect and 
recognise proteins of interest from a protein lysate/homogenate extracted from cells or 
tissue. It can also be used semi-quantitatively to determine the level of protein 
expression change in comparison to a control (health) sample/donor, (Mahmood and 
Yang, 2012). The principle of western blotting relies upon the separation of protein 
according to their molecular weight by using sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE).  All of the separated proteins are then transferred 
onto a nitrocellulose membrane producing and the protein of interest is then detected 
by immuno-reaction with a specific primary antibody targeted to the protein of interest. 
This primary antibody is then subsequently detected by a secondary labelled antibody. 
The protein of interest is detected as band at the correct molecular weight by either 
chemiluminescent or near infrared imaging. The band intensity is related  to the level 
of protein present within a specific linear range (Ma and Shieh, 2006) and is compared 
between samples to determine a ratio for protein expression change in conjugation 








The present study aimed to examine the acute and chronic neurotoxicity of selected 
SCRAs and comparing them to ∆9-THC, MDMA and selected synthetic stimulants 
using human neuronal stem cell models. 
4.3 Materials and Methods 
4.3.1 Cell culture  
Human neuronal precursor stem cell (hNPSC) line N1997 forebrain (generated in 
house), were cultured  in growth medium consisting of Advanced DMEM/F12 (Life 
Technologies) supplemented with 5μg/ml Amphotericin B (Gibco), 1% N-2 (Life 
Technologies),  2% B27 (Life Technologies), 1% Insulin-Transferrin-Selenium 
supplement (Life Technologies), 1% penicillin-streptomycin-L-glutamine (Sigma), 1% 
MEM non-essential amino acids (Gibco), 1.5% D-glucose (Sigma), 2% sodium 
bicarbonate (Sigma), 3.5 µg/ml ascorbic acid (Sigma), 5μg/ml heparin (Sigma), 
10ng/ml leukaemia inhibitor factor (Santa Cruz), 20 ng/ml basic fibroblast growth factor 
(R&D Systems) and 20 ng/ml epidermal growth factor (R&D Systems). Cells were 
cultured in T75 flasks coated with 1% Geltrex™ (Life Technologies) in a humidified 
incubator at 37 ̊C with 5% CO2. Growth medium was replenished at 2-3 day intervals 
by replacing 60% of the existing medium with fresh medium.   
The cells were grown to 80-90% confluency before passaging, approximately every 5-
7 days. For cell passaging, the medium was removed, and cells were incubated with 
5ml (for T75 flask) of Trypsin/EDTA to detach cells for 3-5 minutes. The trypsin was 
diluted by adding growth medium to the cell suspension. Cells were collected in 15 ml 
tubes and centrifuged at 250g for 5 minutes. The supernatant was discarded, and cells 
were re-suspended in fresh growth medium. Then cells were counted using a 
haemocytometer and seeded into T75 cm2 flasks (for maintenance) or multi-well plates 
(subsequent experiments). 
To differentiate the hNPSC into mature neuronal cells, the hNPSC were seeded into 
plates coated with 1% Geltrex™ (Life Technologies) prepared in DMEM (Life 
Technologies) and grown for 3 days in growth medium. The growth medium was 
replaced with differentiating medium containing Advanced DMEM/F12 supplemented 
with 10% heat inactivated foetal bovine serum (FBS) (Sigma), 1% N2 ( Life 
Technologies), 2% B27 (Life Technologies), 1% penicillin-streptomycin-L-glutamine 
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(Sigma), 5 μg/ml Amphotericin B (Gibco), 1% MEM non-essential amino acids (Gibco), 
2% sodium bicarbonate (Sigma),  1.5% D-glucose (Sigma), 3.5 µg/ml ascorbic acid 
(Sigma), 1% Insulin-Transferrin-Selenium Supplement (Life Technologies) and 5μg/ml 
heparin (Sigma). Cells were differentiated for 14 days to allow maturation into neuronal 
cells and the differentiating medium was replenished every other day. The cells 
allowed to differentiated for 14 days because the alternative splicing of microtubule-
associated genes such as EML4 (echinoderm microtubule associated protein like 4), 
MAP2 (microtubule-associated protein 2), KIF2A (microtubule-depolymerizing kinesin) 
appeared after 6-10 days of differentiation. These genes are the key indicator in stem 
cell differentiation (Madgwick et al., 2015).  
4.3.2 Cell viability assays  
Human neuronal progenitor stem cells (hNPSC) were seeded into 48 well plates, at a 
density of 50,000 cells/well, coated with 1% Geltrex in DMEM and cultured for 3 days 
with growth medium. Cells were either tested directly as immature progenitor stem 
cells or differentiated into mature neuronal cells by replacing the growth medium with 
differentiating medium. Cells were differentiated for 14 days to allow maturation into 
neuronal cells with the medium being replaced every other day prior to treatment. 
The cytotoxicity of NPS was evaluated using the Alamar Blue reduction assay by 
repeatedly exposing the hNPSC and mature neuronal cells with JWH-018 (0-10 µM, 
Tocris), 5F-ADB (0-10 µM, Chiron AS Trondheim), MMB-CHMICA (0-10 µM, Chiron 
AS Trondheim), MDMB-CHMICA (0-10 µM, Chiron AS Trondheim), Mephedrone (0-
10µM, Sigma) and 25I-NBOMe (0-10 µM, LGC Standards). The tested substances 
have a limited solubility in aqueous solutions (see logP values, Table 4.1), therefore 















Table 4.1 LogP values of the tested chemical compounds.  
 
Cell viability was tested after 24 hours, 7 and 14 days exposure by the addition of 
Alamar Blue reagent. Resazurin sodium salt (Sigma) was dissolved in Dulbecco’s 
Phosphate Buffered Saline (dPBS; Sigma Aldrich) at a concentration of 1 mg/ml. Then 
the stock solution was diluted to 100 µg/ml with either growth or differentiation media 
to give 10% Alamar blue reagent. The growth/differentiation media was removed and 
350 µl of 10 % Alamar blue in the relevant media was transferred into each well of the 
48 well plates. The plates were incubated for 1 hour (for mature cells) and 1.5-4 hours 
(for immature cells) before duplicates of 100 µl Alamar blue reagent from each well 
were transferred into a 96 well plate. Alamar Blue reduction was measured by 
fluorescence at an excitation wavelength of 530 nm, and the emission at 590 nm. 
Plates were returned to the incubator after the remaining Alamar Blue solution was 
removed from the wells of the 48 well plate and the cells exposed again to the same 
concentration of NPS in fresh media. The cells were continually exposed for 14 days 
and the Alamar Blue reduction assay repeated after 24 hours, 7 days and 14 days 
exposure. Control cultures were treated with an equivalent amount of vehicle (DMSO).  















 1 2 3 4 5 6 7 8 
A 10 µM 10 µM 10 µM 10 µM 5 µM 5 µM 5 µM 5 µM 
B 2 µM 2 µM 2 µM 2 µM 1 µM 1 µM 1 µM 1 µM 
C 0.5 µM 0.5 µM 0.5 µM 0.5 µM 0.1 µM 0.1 µM 0.1 µM 0.1 µM 
D 0.05 µM 0.05 µM 0.05 µM 0.05 µM 0.01µM 0.01 µM 0.01 µM 0.01 µM 
E 0.005µM 0.005µM 0.005µM 0.005µM DMSO DMSO DMSO DMSO 
F Media Media Media Media H2O2 H2O2 H2O2 H2O2 
 
Table 4.2 Layout of the 48 well and the treatment used. 
 
To examine the effect of multiple NPS exposure and the effect of combinations of NPS 
with other drugs of abuse (poly drug exposure), Immature and mature cell were 
exposed to combinations of the SCRAs MDMB-CHMICA which is denoted as (A) and 
5F-ADB which is denoted as (B) in addition to the conventional drug of abuse MDMA 
(ecstasy) which is denoted as (C) at concentrations of 1,3,10 and 20 nM each. The 
combination of exposure included MDMB-CHMICA & 5F-ADB (A+B), MDMB-CHMICA 
& MDMA (A+C), 5F-ADB & MDMA (B+C) in three concentrations (1, 3 and 10 nM) and 
MDMB-CHMICA & 5F-ADB & MDMA (A+B+C) in 1,3,10 and 20 nM.  
Table 4.3 shows the concentrations used in a typical plate layout. The cells were 


































































































Table 4.3 Lay out of the 48 well and the combination treatment used. A = MDMB-
CHMICA, B =5F-ADB and C =MDMA (ecstasy). 
 
 
4.3.3 RNA sequencing to determine gene expression changes due to NPS 
exposure 
hNPSC were seeded into six well plates coated with 1 % Geltrex in DMEM and grown 
for 3 days in growth medium at a density of 300,000 cells/well. The medium was 
replaced with differentiating medium and the cells were differentiated for 14 days to 
allow maturation into neuronal cells, with the medium being replaced every other day. 
The mature cells were exposed separately to 10 nM of MDMB-CHMICA, 5F-ADB, ∆9-
THC and DMSO control (n=4 per treatment). The cells were exposed to this treatment 
for 14 days and the medium along with the corresponding drug being replenished every 
other day. 
4.3.3.1 RNA extraction and purification  
The culture medium was aspirated and 1 ml Trizol (Life Technologies) was added to 
each well of the 6-well plates. Cells were scraped and transferred to micro-centrifuge 
tubes, after which 50 µl of 4-Bromoanisole (Sigma-Aldrich) was added and the tubes 
were mixed for 15 seconds by vigorously shaking by hand and incubated at room 
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temperature for 2-3 minutes. The tubes were then centrifuged at 12,000 g for 15 
minutes at 4°C. The upper aqueous layer that contains the RNA was transferred to a 
clean RNase-free tube. Equal volumes of 70% ethanol (prepared from 200 proof 
molecular biology grade ethanol, Sigma Aldrich) were added to obtain a final ethanol 
concentration of 35%. The tube was vortexed to mix well and then inverted to disperse 
any visible precipitate. RNA was further purified using the Pure Link® RNA Mini Kit, 
Invitrogen. The solution was transferred into spin cartridges (with collecting tubes) in 
700 µl volumes and was centrifuged at 12,000 g for 15 seconds at room temperature. 
The flow-through was then discarded and the remaining solution filtered prior to the 
addition of 700 µl washing buffer I (Pure Link® RNA Mini Kit, Invitrogen) and 
centrifuged at 12000 x g for 15 seconds at room temperature. The flow-through was 
discarded and the spin cartridge was inserted into a new collection tube. 500 µl of 
washing buffer II was added and the tube centrifuged at 12,000 g for 15 seconds at 
room temperature. The flow through was discarded and the washing with buffer II was 
repeated. The tube then centrifuged at 12000 x g for 1 minute, then the spin cartridge 
was inserted into a recovery tube and 50µl of RNase free water was added to the 
centre of the spin cartridge. The tube incubated for 1 minute at room temperature and 
centrifuged for 2 minutes at 12000 x g at room temperature. The purified RNA was 
collected in the collection tube.     
The initial RNA concentrations were determined by measuring absorbance at 260 nm 
using a Nano Drop spectrophotometer (2000 Thermo Scientific) using Nuclease-free 
water as a blank. Purity of the samples was measured as a ratio of A260/A280 
(Absorbance at 260nm and 280nm) ratio between 1.8 and 2.0 generally suggesting a 
pure nucleic acid sample whereas lower ratios suggests protein contamination 
(Desjardins and Conklin, 2010). 
4.3.3.2 RNA sequencing 
The extracted RNA samples were sent to the Genomics Core Facility (Newcastle 
University, UK). All the samples were assessed for quality and quantity using an Agilent 
Tape station 4200 with RNA Screen Tapes and were sequenced using an Illumina 
NextSeq 500 platform. The sequencing parameters were 76bp single read and dual 
8bp index reads. The samples were prepared using the TruSeq stranded mRNA library 
preparation kit (Illumina). 
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4.3.3.3 Bioinformatics information 
Bioinformatics analysis to ascertain gene expression changes between exposed and 
non-exposed cells was conducted at Bioinformatics Support Unit (Newcastle 
University). 
4.3.4  Determination of Proteomic changes that occur due to NPS exposure 
hNPSC were seeded into six well plates coated with 1 % Geltrex in DMEM and grown 
for 3 days in growth medium at density 300,000 cells/well. After which the growth 
medium was replaced with differentiating medium. Cells were differentiated for 14 days 
to allow maturation into neuronal cells with the medium being replaced every other 
day. 
The mature neuronal (differentiated) cells were exposed separately to 10 nM of 
MDMB-CHMICA, 5F-ADB, MMB-CHMICA, ∆9-THC and MDMA (ecstasy), in addition 
to a combination of NPS and ecstasy (3 nM 5F-ADB combined with 3 nM MDMB-
CHMICA and 3nM MDMA). Control cultures were treated with the equivalent amount 
of vehicle (DMSO). The cells were exposed to this treatment for 14 days, the medium 
with the correspondent drug being replaced every other day. All treatments were 
carried out in quadruplicate and the whole experiment repeated three times. 
4.3.4.1 Protein lysate preparation of cells  
The culture medium was aspirated, and cells were washed twice with dPBS. 250 µl of 
native lysis buffer (1% Tris-buffered saline (TBS), 0.27 M Sucrose, 1 % Triton X-100, 
and protease inhibitor (Roche)) was added. The cells were then scrapped and left on 
ice for 30 mins. Finally, the cells were scraped again, and the cell lysate was collected 
and stored at -20°C. 
4.3.4.2  Determination of protein concentration by the Bradford assay 
Bovine serum albumin (BSA, sigma) was used to plot a standard curve of known 
protein concentration in the range of 0 to 1mg/ml prepared in diluted native lysing 
buffer. The samples were diluted 1:20 with MilliQ water prior analysis. 5 µl of each 
diluted sample and standard were pipetted onto 96-well plates in triplicate. 250 µl of 
Bradford reagent (Sigma) was added to each well and left to incubate for 15 mins at 
room temperature. Absorbance was measured at 595 nm using a plate reader 
(TECAN, Infinite 200 Pro reader, infinite M NANO+). Protein concentration was 
calculated using the standard curve produced from the absorbance of the BSA 
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concentration samples and the linear regression equation was used to quantify the 
protein of the unknown samples. 
4.3.5   Western blotting  
Protein samples were prepared at 1 µg/µl with 4X LDS NuPAGE LDS sample buffer 
(Invitrogen, UK) and 10X NuPAGE sample reducing agent (Invitrogen, UK). Samples 
were sonicated for 8-10 seconds, and the proteins denatured by heating for 10 minutes 
at 70 ̊C. 
10 µg (10µl) of protein was loaded into each well of NuPAGE 4-12% Bis-Tris Gel 
(Invitrogen) and 5µl See Blue molecular weight marker (Invitrogen) was added to the 
gel. The gel was electrophoresed in NUPAGE MOPS SDS running buffer containing 
NuPage Antioxidant (Invitrogen) at 120 V for 20 minutes and then at 160 V for one 
hour. The proteins were then electrotransferred onto nitrocellulose membrane using 
iBlot Gel transfer stacks (Invitrogen) at 20 V for 8 minutes in an iBlot device 
(Invitrogen). Proteins on the membrane were then stained with Ponceau S solution 
(Sigma) to check if the transfer was successful. Then the membrane was appropriately 
cut and labelled before they were washed for 10 minutes three times with Tris buffered 
saline with 0.2% Tween 20 (TBS-T). 
The membranes were blocked with odyssey blocking buffer (TBS) (Li-COR) for 1 hour 
at room temperature to block non-specific antibody binding. Membranes were then 
incubated with specific primary antibodies (Table 4.4) diluted in odyssey blocking 
buffer containing 0.2% Tween 20 overnight at 4  ̊C. The following day excess antibody 
was removed by washing the membranes 3 times with TBS-T for 5 minutes each. 
Membranes were then incubated with the respective secondary antibody (Table 4.4) 
in blocking buffer for 60 minutes at room temperature followed by several washes with 
TBS-T (3 times 5 minutes each). Membranes were incubated with GAPDH antibody 
conjugated to Alexa Flour® 680 at room temperature for 1 hour. The membranes were 
then washed with TBS-T twice for 5 minutes each, followed by 3 washes with TBS. All 
incubations and washings were done with continuous shaking. The membranes were 
imaged with an Odyssey near- infrared imaging system (LI-COR odyssey FC). 
GAPDH was used to normalise the results and the ratio of mean protein of 
interest/GAPDH were calculated for all samples. The primary and secondary 
antibodies used in the study are listed in Table 4.4. 
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Antibodies Species Dilutions Source 
Catalogue 
number 
AHR Rabbit Polyclonal 1:1000 Gene Tex GTX 129013 
BIP (HSPA5) Rabbit Polyclonal 1:500 Abnova PAB2462 
Beta III -tubullin  Mouse Monoclonal 1:500,000 
R&D 
Biotechnology MAB-1195 
CB1  Rabbit Polyclonal  1:1000 Gene Tex GTX 100219 
COX Va Mouse Monoclonal 1:500 Mitoscience MS409 
CYP2E1 Rabbit polyclonal  1:500 Abcam ab 28146 
CYP3A4 Rabbit polyclonal  1:500 Cypex PAP011  
CYPOR (G-5) Mouse Monoclonal 1:200 Santa Cruz sc-25263 
Cytochrome C (A8) Mouse Monoclonal 1:1000 Santa Cruz sc-13156 
DARPP-32 Rabbit Polyclonal 1:1000 GeneTex GTX61337 
GFAP (F-2) Mouse Monoclonal 1:1000 Santa Cruz sc-166481 
GSTP1 (Fl-210) Rabbit Polyclonal 1:2000 Santa Cruz sc-134469 
MTCO1 Mouse Monoclonal 1:250 Abcam ab14705 
NDUFA9 Mouse Monoclonal 1:500 Mitoscience MS111 
NDUFS1 (E-20) Goat Polyclonal 1:500 Santa Cruz sc-50132 
PDI (C-2) Mouse Monoclonal 1:1000 Santa Cruz Sc-74551 
Phospho Erk 1/2 Rabbit Polyclonal 1:1000 Cell Signalling 9101 S 
SR-2A (A-4) Mouse Monoclonal 1:1000 Santa Cruz sc-166775 
UGT1A1 Rabbit polyclonal  1:1000 Abcam ab194697 
UGT1A6 Rabbit polyclonal  1:1000 Abcam ab97646 
VDAC1 Mouse Monoclonal 1:500 Abcam ab14734 
GAPDH Antibody (G-




secondary antibody Goat Polyclonal 1:15000 LI-COR 926-32210 
IRDye® anti-rabbit 
secondary antibody Goat Polyclonal 1:15000 LI-COR 926-32211 
IRDye® anti-goat 
secondary antibody Donkey Polyclonal 1:15000 LI-COR 926-32214 
 
 
Table 4.4 Specifications and source of primary and secondary antibodies. 
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4.3.6 Preliminary NPS effect on metabolism in the brain analysis 
The RNA sequencing data showed changes in some metabolizing enzymes; therefore, 
the following method was done to test the effect of SCRA on drug metabolism. Human 
neuronal progenitor stem cells (hNPSC) were seeded into six well plates coated with 
1 % Geltrex in DMEM and grown for 3 days in growth medium at density 300,000 
cells/well. The medium was replaced with differentiating medium and the cells were 
differentiated for 14 days to allow maturation into neuronal cells, with the medium being 
replaced every other day. The mature cells were exposed separately to 10 nM of 
MDMB-CHMICA, 5F-ADB, ∆9-THC and DMSO control (n=6 per treatment). The cells 
were exposed to this treatment for 14 days and the medium along with the 
corresponding drug being replenished every other day. 
4.3.6.1 Paracetamol metabolism exposure 
The culture media was aspirated from all 6 wells of each treatment group, to 3 wells 
from each group 1 µg/ml of paracetamol diluted in differentiation media was added for 
48 hours. The remaining 3 wells per group had the differentiation medium replaced 
(without NPS treatment) for 48 hours to allow the cells to recover from SCRA exposure. 
After 48 hours the paracetamol treated cells were lysed and collected together with the 
corresponding media and kept at -20 C°. The remaining 3 wells, which were allowed 
to recover from NPS treatment, were then treated with 1 µg/ml of paracetamol in 
differentiation media for 48hrs, after which the cells were lysed and collected along 
with the media. 
4.3.6.2 Cell and media collection/preparation  
The culture medium was aspirated and transferred into 15 ml tube and 150 µl 
transferred to vials for the mass spectrometer. 250 µl of sterile culture water was added 
to the wells of the plate, then then cells were scrapped and the cell lysate was 
collected. The cell lysate was sonicated for 8 seconds and centrifuged for 15 minutes 
at 20,000 rpm. 150 µl of the supernatant was transferred to mass spectrometer vials 
for analysis. 
4.3.6.3 Liquid chromatography–mass spectrometry (LC-MS) 
Cell lysate and the corresponding medium were sent to the Northern Institute for 
Cancer Research Chromatography lab (NICR), Newcastle University for analysis. 
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4.3.7  Statistical analysis 
The statistical evaluation of the results of experiments was performed with the SPSS 
software system (V24; IBM SPSS Statistics USA). Results were reported as means ± 
standard deviations (SD).  
Normality of the data distribution was assessed by the Shapiro-Wilko test. The results 
of the viability assays were analysed by one-way ANOVA followed by the Dunnett's 
multiple comparison test (when data followed normal distribution) or by the Kruskal-
Wallis test. All other analyses were performed with the Student’s-test; p-values ≤ 0.05 
were considered as statistically significant. 
4.4 Results  
4.4.1 Cytotoxicity assay of New psychoactive substances 
The cytotoxicity of new psychoactive substances on human neural precursor stem cells 
was evaluated using the Alamar blue assay. 
4.4.1.1  Synthetic cannabinoids  
To determine the toxicity of SCRAs, hNPSC cells were treated with nine different 
concentrations of SCRAs ranging from 0.05 to 10µM then assessed for toxicity after 
24 hours, 7 and 14 days of exposure. The results showed a statistically significant 
reduction in cell viability in immature stem cells over a concentration range 5-10 µM as 
shown in Figure 4.5, with each drug exhibiting different toxicities.  
MDMB-CHMICA significantly reduced cell viability by 14% at Day 7 (10 µM, p=0.017) 
and up to 20% after 14 days of exposure (10 µM, p=0.005, Figure 4.5 A). MMB-
CHMICA, the structural analogue of MDMB-CHMICA, was shown to be toxic to cells 
after 7 days, inducing 13% cell death (5 µM, p=0.024). Further cell death was observed 
with both 5 µM (23%, p=0.046) and 10 µM (17%, p=0.004) after 14 days of exposure 
(Figure 4.5 B). 5F-ADB significantly reduced cell viability by 22% at after 14 days 
exposure (10µM, p=0.038, Figure 4.5 C).In contrast, the data from the Alamar Blue 
reduction assay on mature cells treated with synthetic cannabinoids (JWH-018, 5F-
ADB, MMB-CHMICA and MDMB-CHMICA) showed no significant effect (p>0.05) with 
less than 10% cell death shown after 2 weeks exposure for all the SCRAs 
analysed (Figure 4.6).  JWH-018 was the one of the first SCRA to be abused in the 




Figure 4.5 The effect of SCRAs on cell viability on immature stem cells. The results 
show percentage reduction in cell viability in immature forebrain cultures treated with different 
SCRAs. (A) MDMB-CHMICA, (B) MMB-CHMICA and (C) 5F-ADB (0.005 to 10 μM), using 
0.1% DMSO as a control. Cytotoxicity was measured using the Alamar blue reduction assay. 
Data are presented as Mean ±SD from quadruplicate samples (assay repeated n=3). Statistical 
significance was evaluated with ANOVA at day 1, 7 and 14 time points. * represents p <0.05, 
















Figure 4.6 The effect of SCRAs on cell viability on mature stem cells. The results show percentage reduction in cell viability in mature 
forebrain cultures treated with different SCRAs. (A) MDMB-CHMICA, (B) MMB-CHMICA, (C) 5F-ADB and (D) JWH-018 (0.005 to 10 μM), using 
0.1 % DMSO as a control. Cytotoxicity was measured using the Alamar blue reduction assay. Data are presented as Mean ±SD from quadruplicate 






































4.4.1.2 Combined exposure (poly drug use) 
To explore the potential interaction of two synthetic cannabinoids, with one of the 
commonly co-administered conventional drugs of abuse, MDMA.  Mature hNPSC were 
exposed to a concentration 1000-fold lower than the highest concentration tested in 
viability assays. The cytotoxicity of MDMA was tested first at the same concentrations 
range of the synthetic cannabinoids (0.005 to 10 µM) on both mature and immature 
cells. The results showed that MDMA reduced cell viability slightly (p<0.05) at a 
concentration range 1 to 5 µM on mature cells after 7 days of treatment as shown in 
Figure 4.7 A, but interestingly the cells recovered viability at day 14. However, MDMA 
was not toxic to immature cells at the same concentration range (Figure 4.7 B). 
To determine the toxicity of the combined exposure of MDMB, 5F-ADB and MDMA the 
three drugs were analysed in combinations containing 1,3,10 and 20 nM of each. They 
were also examined in pairs as shown in Figure 4.8. The Alamar blue cell viability 
assay showed that the combination at these tested concentrations were not toxic to 
































Figure 4.7 The effect of MDMA on cell viability on mature and immature stem 
cells. (A) The results show percentage reduction in cell viability in mature forebrain cultures 
treated with MDMA (0.005 to 10 μM), using 0.1% DMSO as a control. (B) The percentage of 
cell viability in immature forebrain cultures treated with MDMA (0.005 to 10 μM), using 0.1% 
DMSO as a control. Cytotoxicity was measured using the Alamar blue reduction assay. Data 
are presented as Mean ± SD from quadruplicate samples (assay repeated n=3). Statistical 
significance was evaluated with ANOVA at day 1, 7 and 14 time points. * represents p <0.05 
and ** represent p<0.01 when compared to DMSO treated cells.  
  
















































Figure 4.8 The effect of combined on cell viability on mature stem cells. The results 
show percentage reduction of cell viability in mature forebrain cultures treated with combination 
of A= MDMB-CHIMCA, B=5F-ADB and C=MDMA. The numbers represent concentration in 
nanomolar for each chemical substance. Cytotoxicity was then measured using the Alamar 
blue assay. Data are presented as Mean ± SD from triplicate samples (assay repeated n=3) 
for combined exposure. Statistical significance was evaluated with ANOVA at day 1, 7 and 14 
time points. 
 
4.4.1.3  Mephedrone and 25I-NBOMe    
To compare the cytotoxic effect of SCRA with other types of NPS, two stimulants from 
different groups were chosen. Mephedrone (4-methyl methcathinone), a stimulant from 
the Cathinone family and 25I-NBOMe, a substituted phenethylamine hallucinogen. 
The treatment of mature hNPSC cultured cells with mephedrone induced toxicity in a 
dose dependant manner after 24-hours exposure (Figure 4.9A), with a 5.6% reduction 
in cell viability at 2 µM (p= 0.045), increasing to 6.1% reduction in cell viability at 5 µM 













































































exposure mephedrone reduced cell viability by 10.8% at 5 µM and 10.2% at 10 µM 
(p=0.011 and 0.017 respectively). While after 2 weeks exposure mephedrone reduced 
cell viability significantly at 5 µM only (p=0.004). Mephedrone induced acute toxicity 
after 24 hours of exposure, the cells seems to recover as after 14 days of exposure to 
mepherdrone the percentage of cells death decreased to 4.7% at 10 µM and 8.9% at 
5 µM. However, the cytotoxic activity of mephedrone was not observed on immature 
cells after 2 weeks exposure at the same concentration range (0.005 to 10µM) (Figure 
4.9 B). 
25I-NBOMe did not induce significant cell death on mature cells (Figure 4.10 A), but it 
did induce an early death (24%) to immature cells after 24 hours of exposure at 10 µM 
only, and the cell viability was reduced by 85% after 7 days of exposure at 10 µM, 













Figure 4.9 The effect of mephedrone on cell viability on mature and immature 
stem cells. (A) The results show percentage reduction in cell viability in mature forebrain 
cultures treated with mephedrone (0.005 to 10 μM), using 0.1% DMSO as a control. (B) The 
percentage of cell viability in immature forebrain cultures treated with mephedrone (0.005 to 
10 μM) and 0.1% DMSO as a control. Data are presented as Mean ± SD from quadruplicate 
samples (assay repeated n=3). Statistical significance was evaluated with ANOVA at day 1, 7 






Figure 4.10 The effect of 25I-NBOMe on cell viability on mature and immature 
stem cells. (A) The results show percentage reduction in cell viability in mature forebrain 
cultures treated with 25I-NBOME (0.005 to 10 μM), using 0.1% DMSO as a control. (B) The 
percentage of cell viability in immature forebrain cultures treated with 25I-NBOMe (0.005 to 10 
μM) and 0.1% DMSO as a control. Data are presented as Mean ± SD from quadruplicate 
samples (assay repeated n=3). Statistical significance was evaluated with ANOVA at day 1, 7 
and 14 time points. * represents p <0.05, ** represent p<0.01 when compared to DMSO treated 




The results from the cytotoxicity assays for NPS have shown that different drugs have 
different patterns of cytotoxic effects. The SCRAs tested were toxic to immature cells 
but not to mature cells. In contrast to mephedrone which was toxic to mature cells but 
not immature cells. Whereas the novel hallucinogen 25I-NBOMe showed greatest 
toxicity to immature cells by killing more than 90% of the cells.  
4.4.2 Gene expression changes due to NPS exposure 
To gain an insight into SCRA usage at a molecular level on the human brain, MDMB-
CHMICA and 5F-ADB were further investigated along with it ∆9-THC the psychoactive 
ingredient of the plant cannabis. These changes were assessed by changes in gene 
expression, protein expression and metabolic changes. 
The potential gene expression changes due to NPS exposure were examined using 
RNA sequencing. The first step in the analysis of the gene expression data areto 
examine the sample distance and conduct a principal component analysis (PCA) to 
emphasise variations. The sample distance analysis and PCA showed that the MDMB 
-CHMICA, ∆9-THC and control (DMSO) samples were clustered together well in 
groups, suggesting that the responses to exposure between the quadruplicates were 
consistent (Figure 4.11). However, the 5F-ADB samples showed variance between 
samples which might indicate the 10 nM used was not enough to exhibit a full response 




Figure 4.11  PCA and samples distance between samples. (A) The PCA plot coloured 
by treatment (DMSO, 5F-ADB, ∆9-THC and MDMB). (B) The heatmap shows distances 






4.4.2.2 Differential Gene Expression 
Differential gene expression analysis was carried out with the R package DESeq2. 
DESeq2 provides methods to test for differential expression by use of negative 
binomial generalized linear models (Lovell et al., 2019).  
Genes with the absolute log 2-Fold Change higher than 1 (meaning the linear-scale 
fold change is greater than 2), with Benjamini-Hochberg adjusted p-values less than 
0.05 have been classified as significant genes. A mean normalised count threshold of 
10 has also been applied to exclude genes with very small counts across samples 
comparison. 
To explore the effect of SCRA exposure on hNPSC derived neurones, a comparison 
between MDMB-CHMICA, 5F-ADB and ∆9-THC and the control cells treated with 
DMSO was conducted. The gene expression analysis revealed that 154 genes were 
significantly changed in MDMB-CHMICA treated cells, with 98 genes significantly down 
regulated, and 56 significantly upregulated. In 5F-ADB treated cells, 20 genes were 
significantly changed including 9 downregulated and 11 upregulated genes. For ∆9-
THC, 50 genes were significantly changed with 22 genes were downregulated and 28 






Figure 4.12 The volcano plot of the differently expressed genes. (A) Represents the 
differential expression MDMB-CHMICA treated cells versus control, (B) represents the of 5F-
ADB treated cells differential expression of versus control and (C) represent differential 
expression of ∆9-THC treated cells versus control. Black dots indicate non-statistically 





The 20 most statistically significant genes are shown in Table 4.5 (which shows the  
significant genes in MDMB-CHMICA treated cells), Table 4.6 (which shows the 
significant genes in 5F-ADB treated cells and Table 4.7 (which shows the significant 
genes in ∆9-THC treated cells) arranged according to the adjusted p adjusted value 











Mitochondrially encoded tRNA 
isoleucine 
1.99 1.08E-76 2.01E-72 MT 
ENSG00000261326 LINC01355 
Long intergenic non-protein coding 
RNA 1355  
-2.28 2.29E-38 1.42E-34 1 
ENSG00000105708 ZNF14 Zinc finger protein 14  -1.14 4.22E-29 1.31E-25 19 
ENSG00000252690 SCARNA15 Small Cajal body-specific RNA 15 -1.52 3.90E-28 1.04E-24 15 
ENSG00000120738 EGR1 Early growth response 1  1.08 1.20E-27 2.78E-24 5 
ENSG00000210195 MT-TT 
Mitochondrially encoded tRNA 
threonine  
1.34 1.95E-27 4.04E-24 MT 
ENSG00000278864   Novel transcript  -1.02 7.32E-24 1.24E-20 17 
ENSG00000233937   Uncategorized gene.  -1.56 3.31E-23 5.14E-20 5 
ENSG00000273373   Novel transcript  -1.88 4.48E-22 5.96E-19 1 
ENSG00000142871 CYR61 
Cysteine rich angiogenic inducer 
61  
1.13 2.11E-20 2.46E-17 1 
ENSG00000272540   Novel transcript  1.88 6.09E-20 6.67E-17 6 
ENSG00000250251 PKD1P6 
Polycystin 1, transient receptor 
potential channel interacting 
pseudogene 6  
1.00 7.04E-18 6.24E-15 16 
ENSG00000210107 MT-TQ 
Mitochondrially encoded tRNA 
glutamine  




ZKSCAN2 divergent transcript  -1.58 4.82E-17 3.45E-14 16 
ENSG00000210077 MT-TV 
Mitochondrially encoded tRNA 
valine  
1.53 4.61E-16 2.60E-13 MT 
ENSG00000271533   Novel transcript  -1.11 7.32E-16 3.78E-13 X 
ENSG00000275180   Novel transcript  -1.79 3.09E-14 1.34E-11 12 
ENSG00000210196 MT-TP 
Mitochondrially encoded tRNA 
proline  
1.22 7.75E-14 3.14E-11 MT 
ENSG00000215493   
Kelch-Like 12 (Drosophila) 
(KLH12) Pseudogene  
-1.45 1.43E-12 4.92E-10 22 
ENSG00000210112 MT-TM 
Mitochondrially encoded tRNA 
methionine  
1.48 2.83E-11 7.21E-09 MT 
Table 4.5 Top 20 most differential expressed gene changes for MDMB-CHMICA 
treated cells. The cells were treated with 10 nM MDMB-CHMICA in comparison to DMSO 
treated cells (control). The negative values in log2 Fold Change values refer to the gene being 
downregulated and the positive values refer that the gene being upregulated.
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Ensembl_gene_id hgnc_symbol Description 
log2Fold 





tRNA isoleucine  1.17 4.8E-26 7.8E-22 MT 
ENSG00000210107 MT-TQ 
Mitochondrially encoded 
tRNA glutamine  1.06 4.4E-10 1.8E-06 MT 
ENSG00000269378 ITGB1P1  
integrin subunit beta 1 
pseudogene 1  1.50 4.6E-06 2.5E-03 19 
ENSG00000196167 COLCA1 
Colorectal cancer associated 
1  -1.92 7.8E-06 3.2E-03 11 
ENSG00000144045 DQX1 
DEAQ-box RNA dependent 
ATPase 1  -4.12 3.2E-05 7.4E-03 2 
ENSG00000184343 SRPK3 SRSF protein kinase 3  1.33 7.6E-05 1.4E-02 X 
ENSG00000196218 RYR1 ryanodine receptor 1 1.31 1.0E-04 1.6E-02 19 
ENSG00000183018 SPNS2 sphingolipid transporter 2  1.05 1.2E-04 1.7E-02 17 
ENSG00000171700 RGS19 
regulator of G protein 
signalling 19  2.05 1.3E-04 1.8E-02 20 
ENSG00000081479 LRP2 LDL receptor related protein 2 1.13 1.4E-04 1.8E-02 2 
ENSG00000108231 LGI1 
leucine rich glioma inactivated 
1  -1.24 1.3E-04 1.8E-02 10 
ENSG00000150667 FSIP1 
fibrous sheath interacting 
protein 1  2.66 2.2E-04 2.4E-02 15 
ENSG00000109255 NMU Neuromedin U -1.68 3.3E-04 3.3E-02 4 
ENSG00000255326 
 
Nnovel transcript -1.00 4.0E-04 3.7E-02 11 
ENSG00000099725 PRKY 
Protein kinase, Y-linked, 
pseudogene  -4.32 4.7E-04 4.0E-02 Y 
ENSG00000118972 FGF23 Fibroblast growth factor 23  -1.09 4.8E-04 4.0E-02 12 
ENSG00000163694 RBM47 RNA binding motif protein 47  -2.97 4.9E-04 4.0E-02 4 
ENSG00000181790 ADGRB1 
Adhesion G protein-coupled 




subunit  -1.20 5.9E-04 4.5E-02 1 
ENSG00000121101 TEX14 
Testis expressed 14, 
intercellular bridge forming 
factor  1.88 6.5E-04 4.7E-02 17 
Table 4.6  Top 20 most differential expressed gene for 5F-ADB treated cells. The 
cells were treated with 10 nM 5F-ADB in comparison to DMSO treated cells (control). The 
negative values in log 2Fold Change values refer to the gene being downregulated and the 
















1.37 2.78E-16 9.03E-13 MT 
ENSG00000252690 SCARNA15 
small Cajal body-
specific RNA 15 
-1.07 2.28E-16 9.03E-13 15 




-1.02 1.39E-12 1.62E-09 8 
ENSG00000261326 LINC01355 
long intergenic non-
protein coding RNA 
1355 





1.45 6.09E-11 3.96E-08 MT 
ENSG00000210077 MT-TV 
Mitochondrially 
encoded tRNA valine 
1.21 2.31E-10 1.21E-07 MT 
ENSG00000214402 LCNL1 Lipocalin like 1 1.03 2.29E-10 1.21E-07 9 
ENSG00000187122 SLIT1 Slit guidance ligand 1 -1.39 5.31E-09 2.01E-06 10 
ENSG00000167202 TBC1D2B 
TBC1 domain family 
member 2B 
-1.01 4.95E-08 1.44E-05 15 




-1.02 1.77E-07 3.73E-05 3 
ENSG00000272540  Antisense To TUBB 1.10 2.20E-07 4.32E-05 6 
ENSG00000269399  Novel Transcript -1.03 2.33E-07 4.51E-05 19 
ENSG00000108231 LGI1 
Leucine rich glioma 
inactivated 1 




1.37 7.57E-07 0.000123 8 
ENSG00000210156 MT-TK 
Mitochondrially 
encoded tRNA lysine 
1.19 3.01E-06 0.000363 MT 
ENSG00000153902 LGI4 
Leucine rich repeat LGI 
family member 4 





1.20 4.31E-06 0.00047 MT 
Table 4.7 Top 20 most differential expressed gene for ∆9-THC treated cells. The 
cells were treated with 10 nM ∆9-THC in comparison to DMSO treated cells (control). The 
negative values in log 2 Fold Change values refer to the gene being downregulated and the 




It is noteworthy, that the most significantly changed group of genes across the 3 groups 
were mitochondrial tRNA genes (MT-tRNA). All of these were upregulated with fold 
changes between 1.17 and 1.99. In addition, mitochondrially encoded tRNA isoleucine 
(MT-TI) was the highest significantly changed gene in the 3 groups. In MDMB-CHMICA 
treated cells, there were 9 MT-tRNA significantly changed genes, whereas there were 
2 and 6 MT-tRNA significantly changed gene in 5F-ADB and ∆9-THC treated cells 
respectively. There were 4 common genes that were significantly changed among 3 
groups (Table 4.8).  
 hgnc_ 
symbol Description 
MDMB-CHMICA 5F-ADB ∆9-THC 
log2Fold 
padj log2Fold padj log2Fold padj 










1.41 3.18E-14 1.06 1.80E-06 1.37 9.03E-13 
LGI1 leucine rich glioma 





-3.28 1.29E-02 -4.12 7.40E-03 -3.2 2.80E-02 
 
Table 4.8 The common genes changed among MDMB-CHMICA, 5F-ADB and ∆9-
THC. 
 
Although, there were only 4 changes that were commonly changed in all 3 treatment 
groups, there were greater overlaps in gene expression changes between treatment 
groups when analysed in pairs (Figure 4.13). The direction of changes in all genes 
across the 3 groups follow the same patterns in term of activation or inhibition. The full 






Figure 4.13 Diagram indicating the number of differentially expressed genes 
identified in MDMB-CHMICA, 5F-ADB and ∆9-THC, including the number of 
genes that overlapped between exposed groups.  
 
4.4.2.3  Ingenuity Pathway Analysis (IPA) 
To explore, the canonical pathways, functional gene networks, and biological 
functions, all the expressed gene sets were analysed by IPA software (Ingenuity 
Pathways Analysis, Redwood City, USA; (Qiagenbioinformatics.com, 2019). The p 
value of 0.05 was set as a cut off value for further analysis. The p value is an arithmetic 
value used to arrange networks according to how relevant they are to the genes in the 
input dataset. Nevertheless, it may not imply of the significance or the quality of the 
pathway. The values take into consideration the number of focus genes in the pathway 
and the extent of the network to estimate how related this network is to the original list 
of focus genes. IPA has a library of canonical pathways and the canonical pathway 




In order to interrogate the particular canonical pathways modified with the treated cells, 
IPA was conducted on the MDMB-CHMICA, 5F-ADB and ∆9-THC treated cells versus 
DMSO treated cells (control). IPA identified that there were 34 canonical pathways 
significantly changed in MDMB-CHMICA treated cells, 25 pathways for cells exposed 
to 5F-ADB and 17 pathways for ∆9-THC exposure at p<0.05. The canonical pathway 
analysis predicts the activity of pathways either activated or inhibited or where no 
prediction can be made. Table 4.9 showed the activated and inhibited pathways after 
exposure to MDMB-CHMICA, 5F-ADB and ∆9-THC. The full lists of canonical 



















MDMB vs DMSO 5F-ADB vs DMSO ∆9-THC vs DMSO 
Inhibited Canonical pathways 
Inhibited Canonical 
pathways 
Inhibited Canonical pathways 
Sumoylation Pathway   Wnt/β-catenin Signalling 
Sirtuin Signalling pathways   EIF2 Signalling 
Chondrotin Sulfate degradation   Ephrin B signalling 
    Aryl hydrocarbon receptor 
signalling 
    D-myo-inositol (1,4,5,6)-
Tetrakisphosphate Biosynthesis 
    D-myo-inositol (3,4,5,6)-
tetrakisphosphate Biosynthesis 
Activated Canonical pathways 
Activated Canonical 
pathways 
Activated Canonical pathways 
EIF2 Signalling p53 Signalling 








Signalling In Dorsal 
Horn Neurons 
  
BMP signalling pathway NGF Signalling   
TGF-β Signalling     





Thrombin Signalling     
Wnt/β-catenin Signalling     
Phospholipase C Signalling     
IL-8 Signalling     
Protein Kinase A Signalling     
Mouse Embryonic Stem Cell 
pluripotency 
    
 
Table 4.9 Canonical pathways significantly changed in MDMB-CHMICA, 5FADB 
and ∆9THC treated cells. 
 
The pathway analysis revealed that the main molecular and cellular function affected 
in MDMB-CHMICA treated cells includes gene expression, protein synthesis, cellular 
development, cellular growth and proliferation and RNA post-translational modification. 
The overlapped canonical pathways which were detected as significant are displayed 






Figure 4.14 Overlapping canonical pathways maps altered pathways and representing shared biology among them in 
MDMB-CMICA versus control treated cells. RNAseq dataset based on pathway analysis using the Ingenuity Pathway Analysis software. 
Mature neuronal cells treated with 10 nM MDMB-CHMICA. Each link corresponds to connected pathways shared one or more genes in common. 
The brighter the red colour correspond the larger the –log p values.
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The MDMB-CHMICA IPA analysis showed that the SUMOylation pathway (Figure 
4.15) and sirtuin pathway Figure 4.16). SUMOylation is a process in which a member 
of the small ubiquitin-like modifier (SUMO) family of proteins is conjugated to the lysine 
residues in target proteins as part of post-translational modification. It is involved in 
many biological processes for example transcription, DNA repair, nuclear transport and 
chromosome segregation (Schorova and Martin, 2016, Gareau and Lima, 2010). It is 
also a main element in many extra nuclear neuronal mechanisms and has been 
involved in broad spectrum of neuropathological circumstances such as Huntington’s 
disease and Neuronal intra-nuclear inclusion disease (NIID) (Martin et al., 2007). 
Sirtuin are NAD+-dependent histone deacetylases enzymes controlling many metabolic 
pathways in prokaryotes and eukaryotes. The seven sirtuin members play an important 
role in many biological processes such as cell survival, senescence, proliferation, 
apoptosis, DNA repair, cell metabolism, and cellular response to stress (van de Ven et 
al., 2017). The canonical analysis showed also that EIF2 (Figure 4.17), Notch, mTOR 
signalling (Figure 4.18), BMP and TGF had been activated in MDMB-CHMICA 
exposed cells. The EIF2 (eukaryotic initiation factor 2) protein plays a vital role in 
protein synthesis regulation, through its involvement in the unfolded protein response 
(UPR) (Cao and Kaufman, 2012). Under stress EIF2 either alleviates cellular injury or 
induces apoptosis as an alternative (Wek et al., 2006). Notch is a signalling pathway 
that plays an essential role in the specification of cell fates that take place over local 
cell interactions in different tissues and organisms. It plays an important role in neural 
development (Artavanis-Tsakonas et al., 1999). mTOR (mechanistic target of 
rapamycin) pathway has a vital role in controlling protein synthesis and ultimately 
proliferation and cell growth (Laplante and Sabatini, 2012). 
The BMP signalling pathway (Bone morphogenetic proteins) was initially recognized 
as osteo inductive elements in bone extracts, but is now known to play significant roles 
in a broad range of procedures during the creation and maintenance of multiple parts 
of the body including cartilage, bone, muscle, kidney, and blood vessels (Katagiri and 
Watabe, 2016). The TGF-B (transforming growth factor β) family play an important role 
in the regulation of cell proliferation and survival together with other related family 
member such as BMPs proteins (Zhang et al., 2017). From the changes in pathways, 
MDMB-CHMICA exposure tend to affect gene expression, metabolic diseases and 





Figure 4.15 Effects on SUMOylation pathway in MDMB-CHMICA treated cells. The SUMOylation pathway was inhibited by MDMB-
CHMICA in mature stem cells.Genes that are highlighted in red are considered upregulated and the one highlighted in blue are downregulated. 





Figure 4.16 Effect on Sirtuin pathway in MDMB-CHMICA treated cells. The Sirtuin pathway was inhibited by MDMB-CHMICA in mature 
stem cells.Genes that are highlighted in red are considered upregulated and the one highlighted in blue are downregulated. Canonical pathways 




Figure 4.17 Effect on EIF2 signalling pathway in MDMB-CHMICA treated cells. EIF2 was activated by MDMB-CHMICA in mature 
stem cells.Genes that are highlighted in red are considered upregulated and the one highlighted in blue are downregulated. Canonical 





Figure 4.18 Effect on mTOR pathway in MDMA-CHMICA treated cells. mTOR was 
activated by MDMB-CHMICA in mature stem cells. Genes that are highlighted in red are 
considered upregulated and the one highlighted in blue are downregulated. Canonical 





Figure 4.19 Gene- gene network generated by IPA software depicting the Gene 
Expression, Metabolic Disease, Protein Synthesis network in MDMB-CHMICA 
treated cells. The red colour represented upregulated genes and the blue colour 
representing predicted inhibition. Solid lines indicated direct interaction and dashed line 
indicated indirect interaction. 
 
In cells exposed to 5F-ADB, the pathway analysis revealed that the main molecular 
and cellular function affected in 5F-ADB treated cells includes protein synthesis, gene 
expression, cell cycle, cellular movement and cell death and survival. The overlapped 




Figure 4.20 Overlapping canonical pathways maps altered pathways and representing shared biology among them in 5F-
ADB versus control treated cells. RNAseq dataset based on pathway analysis using the Ingenuity Pathway Analysis software. Mature 
neuronal cells treated with 10 nM 5F-ADB. Each link corresponds to connected pathways shared one or more gene in common. The brighter the 
red colour correspond the larger the log p value.
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The IPA analysis indicated that p53, actin cytoskeleton signalling pathway, neuropathic 
pain signalling in dorsal horn neurons, nerve growth factor (NGF) and adrenomedullin 
signalling pathway signalling have been activated in 5F-ADB treated cells. 
The p53 (Figure 4.21) is a tumour suppressor gene in human cancers; activated p53 
induces apoptosis by transactivating pro-apoptotic genes and direct binding to anti-
apoptotic mitochondrial proteins to successfully provoke apoptosis (Ranjan and 
Iwakuma, 2016). The actin cytoskeleton signalling pathway (Figure 4.22) regulates 
many biological function and acts as a mediator of cellular motility and changes in cell 
shape during the cell cycle in consequence to extracellular stimuli. It also organises 
the cytoplasm and produces mechanical forces within the cell. As well as acting as a 
mediator initiator of apoptosis signalling (Desouza et al., 2012, Schmidt and Hall, 
1998). Finally, NGF (Nerve growth factor) is essential for maintenance, growth, and 
survival of neurons. In particular sympathetic and sensory neuron which undergo 
apoptosis in the lack of NGF (Kristiansen and Ham, 2014). It can be noticed that the 
activated pathways in 5F-ADB treated cells are related to increases in apoptosis and 
consequently cell death. 
From the changes in pathway analysis, 5F-ADB affects gene expression, metabolic 


















Figure 4.21  Effect on  P53 pathway in 5F-ADB treated cells. P53 pathway was 
activated by 5F-DDB in mature stem cells. Genes that are highlighted in red are 
considered upregulated and the one highlighted in blue are downregulated. Canonical 
pathways were identified and depicted by Ingenuity Pathway Analysis software.  






Figure 4.22 Effect on Actin cytoskeleton signalling pathway in 5F-ADB treated cells. Actin cytoskeleton signalling pathway was 
activated by 5F-ADB in mature stem cells. Genes that are highlighted in red are considered upregulated and the one highlighted in blue are 







Figure 4.23 Gene- gene network generated by IPA software depicting the Gene 
Expression, Metabolic Disease, Protein Synthesis network in 5F-ADB treated 
cells. The red colour represented upregulated genes and the blue colour representing 
predicted inhibition. Solid lines indicated direct interaction and dashed line indicated indirect 
interaction. 
In cells exposed to ∆9-THC, the pathway analysis revealed that the main molecular 
and cellular function affected in ∆9-THC treated cells includes cellular development; 
cellular growth and development; cellular assembly and organisation; cellular function 
and maintenance and gene expression. The overlapped canonical pathways which 






Figure 4.24 Overlapping canonical pathways maps altered pathways and representing shared biology among them in ∆9-
THC treated cells versus control treated cells. RNAseq dataset based on pathway analysis using the Ingenuity Pathway Analysis software. 
Mature neuronal cells treated with 10 nM 5F-ADB. Each link corresponds to connected pathways shared one or more genes in common. The 
brighter the red colour correspond the larger the –log p value. 
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The IPA analysis indicated that Wnt/β-catenin signalling (Figure 4.25) and EIF2 (Figure 
4.26), ephrin B signalling (Figure 4.27) and aryl hydrocarbon receptor signalling (Figure 
4.28) have been inhibited in ∆9-THC treated cells. 
Wnt/β-catenin signalling plays a role in cell proliferation regulation, differentiation and 
cell fate determination, it acts through transmitting the signal across the cell 
membrane. As a consequence, Wnt mutations are often associated with birth defects 
in humans, cancer and other illnesses such as neurodegeneration and osteoporosis 
(Kim et al., 2013). Ephrin B is involved in regulation of many physiological process, 
such as regulation of cytoskeletal rearrangements, formation of topographic maps and 
controls cell migration in neurons, allowing the cells to reach their final destination 
(Kania and Klein, 2016). The Aryl hydrocarbon receptor signalling has a role in 
xenobiotic metabolism as a regulator of metabolising enzymes such as cytochrome 
P450s. Also, it is involved in the regulation of gene expression and plays a role in 
immunity regulation and cellular differentiation (Esser and Rannug, 2015, Gutiérrez-
Vázquez and Quintana, 2018).  
From the changes in pathway analysis, ∆9-THC affects neurological disease, 




















Figure 4.25 Effect on Wnt/β-catenin Signalling pathway in ∆9-THC treated cells.  
The Wnt/β-catenin was inhibited by ∆9-THC in mature stem cells. Genes that are highlighted 
in red are considered upregulated and the one highlighted in blue are downregulated. 











Figure 4.26 Effect on EIF2 signalling pathway in ∆9-THC treated cells. The EIF2 signalling pathway was inhibited by ∆9-THC in mature 
stem cells. Genes that are highlighted in red are considered upregulated and the one highlighted in blue are downregulated. Canonical pathways 




Figure 4.27 Effect on ephrin B Signalling pathway in ∆9-THC treated cells. The 
ephrin B Signalling pathway was inhibited by ∆9-THC in mature stem cells. Genes that are 
highlighted in red are considered upregulated and the one highlighted in blue are 










Figure 4.28 Effect on Aryl hydrocarbon receptor signalling pathway in ∆9-THC 
treated cells. The Aryl hydrocarbon receptor signalling pathway was inhibited by ∆9-THC in 
mature stem cells. Genes that are highlighted in red are considered upregulated and the one 
highlighted in blue are downregulated. Canonical pathways were identified and depicted by 




Figure 4.29 Gene- gene network generated by IPA software depicting the Gene 
Expression, neurological disease, organismal injury and abnormalities 
psychological disorders in ∆9-THC treated cells. The red colour represented 
upregulated genes and the blue colour representing predicted inhibition. Solid lines indicated 
direct interaction and dashed line indicated indirect interaction. 
 
The RNA sequencing analysis suggests that the tested SCRAs and ∆9-THC modulate 
gene expression at the molecular level that could lead to serious side effects, the most 
prominent effect being the induction of ER stress. MDMB-CHMICA induced more 
changes (154 genes) in comparison with 5F-ADB (20 genes) and ∆9-THC (50 genes) 
which might suggest that MDMB-CHMICA is potentially induce more changes at 
cellular level and hence might be more harmful, albeit having the same toxic effect at  
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10 µM (Figure 4.6). However, 5F-ADB response was inconsistence ( Figure 4.11) that 
would affect the statistical gene changes analysis and the higher effective 
concentration used  (17 times the EC50 of 5F-ADB at CB1 receptor) might be 
responsible for triggering more cell death pathways than MDMB-CHMICA. Therefore, 
it was not possible to draw a conclusive comparison between 5F-ADB and MDMB-
CHMICA. The increases in MT tRNA expression across the 3 groups indicates that the 
cells were stressed. In addition, the difference in response can be seen as in EIF2 
signalling pathway activated in MDMB-CHMICA treated cells it was inhibited in ∆9-
THC treated cells.  
4.4.3 Proteomic changes due to NPS exposure 
To investigate the functional significance of the changes in protein level after chronic 
exposure to SCRAs and ∆9-THC, western blotting was performed on mature neuronal 
cells treated with 10 nM of MDMB-CHMICA, 5F-ADB and ∆9-THC for 2 weeks. 
4.4.3.1 CB1 receptor expression in hNPSC cells  
CB1 receptor expression was investigated because it is the receptor via which 
cannabinoids produce their major psychoactive effects. Western blot analysis of CB1 
showed 3 bands at the expected molecular weights at 53 kDa (CB1), 49 kDa (CB1b) 
and 46 kDa (CB1a) as shown in Figure 4.30. The isoform CB1a was the only isoform 
analysable due to low fluorescent signal of the other isoforms. There were no statistical 
differences in CB1a expression between the control and treated cells in all exposures 
(p>0.05), with percentage changes ranging from a 7% decrease in MDMB-CHMICA 





Figure 4.30  Expression of the CB1a isoform receptor in mature cells treated with 
SCRA and ∆9- THC. Western blot for the expression of CB1 receptor in mature neuronal 
cells treated with 10 nM of MDMB-CHMICA (A), 5F-ADB (B) and ∆9-THC (C) for 14 days. Data 
presented as Mean ± SD from quadruplicate samples (assay repeated n=3) (D). Statistical 
significance was evaluated by independent sample t-test.  
4.4.3.2  Neuronal and astrocytic marker expression 
To assess the effect of exposure to MDMB-CHMICA or 5F-ADB on neurons and 
astrocytes, the proteins β III – tubulin and glial fibrillary acidic protein (GFAP) were 
examined respectively. The cytoskeletal protein β III - tubulin is expressed in neuronal 
cells, but not glial cells (Sullivan, 1988). GFAP is the astrocytic marker glial fibrillary 
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acidic protein (GFAP) which is noted to increase in gliosis as a response to brain injury 
or stress (Nolte et al., 2001). 
Western Blot analysis showed a single band at approximately 50 kDa for β III -tubulin, 
as shown in Figure 4.31 and this was not significantly different  between treatment 
groups and control (p>0.05). 
Two bands were shown for GFAP between 40-50 kDa (Figure 4.32), the top and 
bottom band were analysed and are subsequently referred to as GFAP isoform 1 and 
2, respectively. GFAP isoform 1 & 2 were not statically different for MDMB-CHMICA or 
5F-ADB treated cells compared to controls (p>0.05).  Following ∆9-THC treatment, 
however isoform 1 expression was significantly increased by 20% (p= 0.003) but there 
was no significant effect for GFAP isoform 2 for the same cells (p=0.27). Similarly, the 
sums of the 2 isoforms showed that total GFAP expression was higher in ∆9-THC 
treated cells compared to controls (p=0.003) but there was no effect with MDMB-





Figure 4.31 Expression of 𝜷𝐈𝐈𝐈-tubulin in mature cells treated with SCRA and ∆9-
THC. Western blot for the expression of β-tubulin in mature neuronal cells treated with 10 nM 
of MDMB-CHMICA (A), 5F-ADB (B) and ∆9-THC (C) for 14 days. Data presented as Mean ± 
SD from quadruplicate samples (assay repeated n=3) (D). Statistical significance was 





Figure 4.32 Expression of GFAP in mature cells treated with SCRA and ∆9-THC. 
Western blot for the expression of GFAP in mature neuronal cells treated with 10 nM of MDMB-
CHMICA (A), 5F-ADB (B) and ∆9-THC (C) for 14 days. Data presented as Mean ± SD from 
quadruplicate samples (assay repeated n=3) (D). Statistical significance was evaluated by 
independent sample t-test. ** represent P<0.01.  
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4.4.3.3  Mitochondrial markers expression 
The differential gene expression analysis showed that the most significant changes 
were in mitochondrial tRNA (MT-tRNA) across SCRA and ∆9-THC. MT-tRNA are 22 
genes that are encoded by MT-DNA which are required for protein synthesis in the 
mitochondria (Suzuki et al., 2011). Mitochondrial proteins are necessary to produce 
the key machinery of the oxidative phosphorylation system. This is especially important 
in organs with high energy consumption, such as the brain.  Defects in MT-tRNA genes 
lead to mitochondrial dysfunction and numerous pathologies such as brain 
malformation and many metabolic defects (Kanungo et al., 2018, Bohnsack and Sloan, 
2018). Mutations in MT-tRNA affect the mitochondrial respiratory chain because the 
mutation will lead to no, or incorrect, amino acid integration into complex I, III, IV, and 
V proteins. The most affected proteins will be those that are dependent on the affected 
MT-tRNA. In addition, MT-tRNA are often positioned adjacent to a subunit gene, and 
the mutation may influence the polycistronic transcript processing that might affect 
respiratory complexes (Triepels et al., 2001). 
The most significant change in the 3 treatment groups affected mitochondrially 
encoded tRNA isoleucine (MT-TI), and mutations in this gene are related to complex 
IV deficiency. Therefore, analysis of potential mitochondrial protein changes focused 
respiratory complexes I and IV.  
Mitochondrial complex I NADH-ubiquinone oxidoreductase subunit A9 (NDUFA9) and 
NADH-ubiquinone oxidoreductase subunit (NDUFS1) which are located in the inner 
membrane of the mitochondria were investigated. They are responsible for electron 
transfer to the respiratory chain from nicotinamide adenine dinucleotide (NADH) 
(Pagniez-Mammeri et al., 2012). 
Complex I NDUFA9 (Figure 4.33) showed a single band at approximately 37 kDa with 
no significant differences between the treated cells and DMSO treated cells (controls) 
in the MDMB-CHMICA and 5F-ADB treated cells. There was a 16% reduction in 
NDUFA9 expression in ∆9-THC treated cells with respect to control, but this was not 




Figure 4.33 Expression of NDFA9 in mature cells treated with SCRA and ∆9-THC. 
Western blot for the expression of NDFA9 in mature neuronal treated with 10 nM of MDMB-
CHMICA (A), 5F-ADB (B) and ∆9-THC (C) for 14 days. Data presented as Mean ± SD from 
quadruplicate samples (assay repeated n=3) (D). Statistical significance was evaluated by 
independent sample t-test. 
 
Western Blot analysis showed a single band at approximately 75kDa for NDUFS1 and 






Figure 4.34 FS1UExpression of ND  in mature cells treated with SCRA and ∆9-
THC. Western blot for the expression of NDFS1 in mature neuronal cells treated with 10 nM 
of MDMB-CHMICA (A), 5F-ADB (B) and ∆9-THC (C) for 14 days. Data presented as Mean ± 
SD from quadruplicate samples (assay repeated n=3) (D). Statistical significance was 
evaluated by independent sample t-test. 
   
Cytochrome c oxidase subunit 5a (CoxVa) and mitochondrially encoded cytochrome c 
oxidase I (MTCO1) subunits of the electron transport chain of the mitochondria 
(complex IV) were also verified using western blotting.  
Western blotting analysis detected COX Va at approximately 14 kDa. COX Va was 
30% significantly higher in MDMB-CHMICA treated cells compared to control (p= 
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0.028), while no significant change was observed in 5F-ADB and ∆9-THC treated cells 
compared to control (Figure 4.35). 
 
 
Figure 4.35 Expression of COX Va in mature cells treated with SCRA and ∆9-THC. 
Western blot for the expression of COX Va in mature neuronal cells treated with 10 nM of 
MDMB-CHMICA (A), 5F-ADB (B) and THC (C) for 14 days. Data presented as Mean ± SD 
quadruplicate samples (assay repeated n=3) (D). Statistical significance was evaluated by 




MTCO1 was demonstrated as single band at approximately 33 kDa. MTCO1 was 14% 
higher in MDMB-CHMICA treated cells compared to control, but this change was not 
statistically significant (P>0.05). There was also no significant difference in MTCO1 
expression among the 5F-ADB and ∆9-THC with respect to control as shown in Figure 
4.36. 
 
Figure 4.36 Expression of MTCO1 in mature cells treated with SCRA and ∆9-THC. 
Western blot for the expression of MTCO1 in mature neuronal treated with 10 nM of MDMB-
CHMICA (A), 5F-ADB (B) and ∆9-THC (C) for 14 days. Data presented as Mean ± SD from 
quadruplicate samples (assay repeated n=3) (D). Statistical significance was evaluated by 
independent sample t-test.             
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Voltage-dependent anion channel 1 (VDAC1) was assessed by western blotting. 
VDAC1 is located in the mitochondrial outer membrane and plays an important role in 
controlling calcium homeostasis and apoptosis (Shoshan-Barmatz et al., 2018). A 
single band at approximately 30 kDa was demonstrated for VDAC1. There was no 
significant differences between MDMB-CHMICA, 5F-ADB and ∆9-THC with respect to 
control (p>0.05), but there was a trend of increment with synthetic cannabinoids 
MDMB-CHMICA and 5F-ADB of 11% (p=0.07) and 14% (p=0.09), respectively, while 
with ∆9-THC it was less than 1% increment as shown in Figure 4.37.
 
Figure 4.37 n ofExpressio VDAC1 in mature cells treated with SCRA and ∆9-THC. 
Western blot for the expression of VDAC1 in mature neuronal cells treated with 10 nM of 
MDMB-CHMICA (A), 5F-ADB (B) and ∆9-THC for 14 days (C). Data presented as Mean ± SD 
quadruplicate samples (assay repeated n=3) (D). Statistical significance was evaluated by 
independent sample t-test.   
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4.4.3.4  Endoplasmic- reticulum (ER) stress markers 
The IPA analysis showed that the cells exposed to 10 nM of MDMB-CHMICA, 5F-ADB 
and ∆9-THC have increased protein synthesis acting through different pathways such 
as the inhibition of SUMOylation pathway, the activation of EIF2 signalling and Notch 
signalling. The increase in protein synthesis may trigger ER stress. To investigate the 
effects on ER stress, the markers binding immunoglobulin protein (BiP), ER resident 
protein disulphide isomerase (PDI) and C/EBP homologous (CHOP) were examined. 
BiP which acts as a chaperone positioned in the ER lumen and interacts with newly 
synthesised proteins and plays an important role in the protein folding process during 
ER response (Ni and Lee, 2007), was demonstrated as a single band at approximately 
62 kDa. There were no significant differences in BIP expression among the 3 treatment 
group (p>0.05) despite a 12% increase in BIP protein expression in MDMB-CHMICA 
treated cells, as shown in Figure 4.38.  
ER resident protein disulphide isomerase (PDI),  which has an essential role in protein 
folding quality control (Bottomley et al., 2001), was demonstrated as single band at 55 
kDa. There were no significant differences in PDI expression among the 3 treatment 
groups (p>0.05) (Figure 4.39). Unfortunately, CHOP antibody did not work when tested 
by western. 
The extracellular signal-regulated protein kinases 1 and 2 phospho (ERK1/2), which 
mediate cell proliferation and cell death (Mebratu and Tesfaigzi, 2009), were also 
investigated. Western blotting analysis showed 2 bands at approximately 42 and 44 
kDa (Figure 4.40); the top bands were too weak to be analysed and these correspond 
to phospho-ERK2. The bottom band which corresponds to phospho-ERK1, was 
analysed. Phospho-ERK1 was not statistically significant in the 3 treatment groups with 





Figure 4.38 Expression of BIP in mature cells treated with SCRA and ∆9-THC. 
Western blot for the expression of BIP in mature neuronal cells treated with 10 nM of MDMB-
CHMICA (A), 5F-ADB (B) and ∆9-THC (C) for 14 days. Data presented as Mean ± SD from 
quadruplicate samples (assay repeated n=3) (D). Statistical significance was evaluated by 







Figure 4.39 Expression  of PDI in mature cells treated with SCRA and ∆9-THC. 
Western blot for the expression of PDI in mature neuronal cells treated with 10 nM of MDMB-
CHMICA (A), 5F-ADB (B) and ∆9-THC (C) for 14 days. Data presented as Mean ± SD 
quadruplicate samples (assay repeated n=3) (D). Statistical significance was evaluated by 









Figure 4.40 Expression of phospho-Erk1 in mature cells treated with SCRA and 
∆9-THC. Western blot for the expression of ERK1 in mature neuronal cells treated with 10 nM 
of MDMB-CHMICA (A), 5F-ADB (B) and ∆9-THC (C) for 14 days. Data presented as Mean ± 
SD from quadruplicate samples (assay repeated n=3) (D). Statistical significance was 







4.4.3.5 Metabolic enzymes 
The RNA sequencing analysis demonstrated that exposure to cannabinoids can have 
an effect on the levels of metabolising enzymes. In MDMB-CHMICA treated cells the 
enzymes CYP17A1 and CYP27B1 were 2-3 times upregulated with p value of 0.04 
and 0.03 respectively (appendix I). In ∆9-THC treated cells CYP17A1 was 4 times 
upregulated (p =0.004) and the enzyme glutathione S-transferase mu 4 (GSTM4) was 
slightly upregulated (p= 0.04). Therefore, it was decided to investigate potential 
changes in metabolising enzymes, since these substances might be metabolised into 
toxic metabolites or affect the metabolizing enzymes involved in biotransformation of 
other substances.  
NADPH-cytochrome P450 reductase (CYPOR) is an endoplasmic reticulum enzyme 
responsible for the metabolism of drugs and xenobiotic through its role in supplying 
electrons to microsomal P450 and other proteins such as heme oxygenase (Pandey 
and Flück, 2013).  CYPOR was demonstrated as a single band at approximately 70 
kDa (Figure 4.41). There was no significant difference in CYPOR expression among 
the 3 treatment group in comparison to DMSO vehicle treated cells (p>0.05).  
Cytochrome P450 3A4 (CYP3A4) and Cytochrome P450 2E1 (CYP2E1) are phase I 
metabolising enzymes that are involved in xenobiotic and drugs metabolism (Rendic 
and Carlo, 1997). UDP-glucuronosyltransferase 1-1 (UGT1A1) and UDP-
glucuronosyltransferase 1-6 (UGT1A6) are phase II metabolising enzymes that are 
responsible of detoxification of many drugs and hormones by conjugation with 
glucuronide to increase water solubility ad enhance excretion (Tukey and Strassburg, 
2000). CYP3A4, CYP2E1, UGT1A1 and UGT1A6 enzymes were tested but, 
unfortunately it did not work due to poor quality antibodies. 
Glutathione-S-transferases (GSTs) are a group of phase II metabolising enzymes that 
are involved in the metabolism of xenobiotic by catalysing the conjugation of 
glutathione via a sulfhydryl group to a substrate to make the compound more water 
soluble (Boyer, 1989). GSTP1 was demonstrated as a single band at approximately 
23 kDa (Figure 4.42). GSTP1 expression decreased in MDMB-CHMICA, 5F-ADB and 
∆9-THC treated cells compared to control. ∆9-THC treated cells showed a significant 
39% reduction (p= 0.007), but the reduction of 8% was not significant for both MDMB-
CHMICA and 5F-ADB (p>0.05). 
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The Aryl hydrocarbon receptor (AHR), which is a transcription factor that regulates the 
gene expression of xenobiotic metabolising enzymes for example cytochrome P450 
family 1 (Nebert, 2017), was investigated as AHR pathway was inhibited in ∆9-THC 
exposed cells. AHR was demonstrated as a single band at approximately 96kDa 
(Figure 4.43). There was no significant difference in AHR expression among the 3-
treatment group in comparison to DMSO vehicle treated cells (p>0.05). 
 
Figure 4.41  Expression of CYPOR in mature cells treated with SCRA and ∆9-
THC. Western blot for the expression of CYPOR in mature neuronal cells treated with 10 nM 
of MDMB-CHMICA (A), 5F-ADB (B) and ∆9- THC(C) for 14 days. Data presented as Mean ± 
SD from quadruplicate samples (assay repeated n=3) (D). Statistical significance was 




Figure 4.42 Expression of GSTP1 in mature cells treated with SCRA and ∆9- 
THC. Western blot for the expression of GSTP in mature neuronal cells treated with 10 
nM of MDMB-CHMICA (A), 5F-ADB (B) and ∆9- THC (C) for 14 days. Data presented as 
Mean ± SD from quadruplicate samples (assay repeated n=3) (D). Statistical significance 







 Figure 4.43  Expression of AHR in mature cells treated with SCRA and ∆9-
THC. Western blot for the expression of AHR in mature neuronal cells treated with 10 nM 
of MDMB-CHMICA (A), 5F-ADB (B) and ∆9-THC (C) for 14 days. Data presented as Mean 
± SD from quadruplicate samples (assay repeated n=3) (D). Statistical significance was 
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4.4.4  Neurotransmission 
There is little known about the direct effect of SCRA on other neurotransmitters.  
Therefore, the effect of the 3 synthetic cannabinoids (MDMB-CHMICA, MMB-
CHMICA and 5F-ADB) as well as ∆9-THC, MDMA, and the combined exposure of 
MDMA and SCRA was investigated. Since the serotonergic system might 
contribute to SCRA adverse effects. 5-HT2A receptor and monoamine enzymes 
(MAO) were investigated.  
The 5-HT2A receptor is distributed in the CNS and has a role in cognitive 
impairment in mental disorders such as schizophrenia and depression and 
mediates the psychoactive effects of the phenylisopropylamine hallucinogens 
(Kroeze and Roth, 1998, Titeler et al., 1988).  
The 5-HT2A was demonstrated as a single band at approximately 50 kDa (Figure 
4.44). There was no significant difference in 5-HT2A expression among the 6 
treatment groups in comparison to DMSO vehicle treated cells (p>0.05). It is 
noteworthy that there was a 10-15 % reduction in 5-HT2A protein expression across 
the 3 SCRA treatment groups and the mixed exposure cells, whereas ∆9-THC 
treated cells showed 1% reduction only.  
MAO A and MAO B were tested; MAO A antibody was not reactive, with no bands 
detected by western blotting, while MAO B demonstrated a band at approximately 
59 kDa as shown in Figure 4.45. There was a general increase in MAO B 
expression among all the treated cells (more than 10%); the mixed exposure 
treated cells (MDMB-CHMICA, 5F-ADB and MDMA) showed the highest increase 
of up to 26% compared with control but was not statistically significant (p>0.05).  
Dopamine- and cAMP-regulated neuronal phosphoprotein (DARRP 32), which is a 
protein phosphatase inhibitor and acts as a key target  for dopamine neuronal 
signalling (Fernandez et al., 2006), was also tested. 
DARRP 32 was demonstrated as four bands between 42 and 32 kDa (Figure 4.46). 
All the bands were analysed and will subsequently be referred as DARRP 32 
isoforms 1, 2, 3 and 4 respectively. There were no significant difference in DARRP 
32 expression among the 6 treatment groups in comparison to DMSO vehicle 




Figure 4.44 Expression of SR2A receptor in mature cells treated with SCRA, 
∆9-THC MDMA and mixed exposure. Western blot for the expression of SR2A 
receptor in mature hNPSC cells treated with separately to 10 nM of 10 nM MDMB-
CHMICA, 5F-ADB, 10 nM MMB-CHMICA, 10 nM ∆9-THC, 10 nM MDMA (ecstasy) and to 
a combination of SCRA and MDMA  (3 nM 5F-ADB combined with 3 nM MDMB-CHMICA 
and 3nM MDMA) for 14 days. Data presented as mean ± SD from triplicate samples (assay 
repeated n=3). Statistical significance was evaluated by independent sample t-test. 





Figure 4.45 Expression of MAO B in mature cells treated with SCRA, ∆9-THC 
ecstasy and mixed exposure. Western blot for the expression of MAO B in mature 
hNPSC cells treated with separately to 10 nM of 10 nM MDMB-CHMICA, 5F-ADB, 10 nM 
MMB-CHMICA, 10 nM ∆9-THC, 10 nM MDMA (ecstasy) and to a combination of SCRA 
and MDMA  (3 nM 5F-ADB combined with 3 nM MDMB-CHMICA and 3nM MDMA) for 14 
days. Data presented as Mean ± SD from triplicate samples (assay repeated n=3). 








Figure 4.46 Expression of DARRP 32 in mature cells treated with SCRA, ∆9-
THC ecstasy and mixed exposure. Western blot for the expression of DARRP 32 in 
mature hNPSC cells treated with separately to 10 nM of 10 nM MDMB-CHMICA, 5F-ADB, 
10 nM MMB-CHMICA, 10 nM ∆9-THC, 10 nM MDMA (ecstasy) and to a combination of 
SCRA and MDMA  (3 nM 5F-ADB combined with 3 nM MDMB-CHMICA and 3nM MDMA) 
for 14 days.. Data presented as Mean ± SD from triplicate samples (assay repeated n=3). 
Statistical significance was evaluated by independent sample t-test. 
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4.4.5 Preliminary metabolism experiments 
The RNAseq results showed changes in some cytochrome metabolising enzymes 
such as CYP17A1 and western blotting showed a significant reduction in GSTP1 
protein expression. Therefore, the elucidation of the role of SCRA in inhibiting or 
activating metabolising enzymes is important from a clinical and toxicological point 
of view. To examine this a commonly prescribed and routinely examined painkiller 
(paracetamol) was examined for its metabolism profile after cells were exposed to 
cannabinoids. Therefore, paracetamol was used to examine if cannabinoid use can 
affect the metabolism of commonly used pharmaceuticals. Paracetamol is 
metabolised through both phase I and phase II pathways as Figure 4.47 briefly 
illustrates (Mazaleuskaya et al., 2015).  
 
Figure 4.47 Summary of paracetamol metabolism. Where SULT is 
Sulfotransferase enzymes, UGT is UDP-glucuronosyltransferase, CYP is cytochrome 
P450 and NAPQI is N-acetyl-p-benzoquinone imine, the paracetamol toxic metabolite.  
The analysis aimed to measure paracetamol concentration and the paracetamol 
metabolites sulphate, glucuronide and glutathione conjugates in both culture media 
and in cell lysate. Unfortunately, complete results were not obtained due to 
technical issues with the spectrometry unit due to blockage of the liquid 
chromatography column. Therefore, only paracetamol concentration in cell culture 
media was measured. 
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The preliminary data for paracetamol showed reductions in paracetamol 
concentration in MDMB-CHMICA, 5F-ADB and ∆9-THC treated cells compared to 
non –cannabinoids treated cells (control). 
The paracetamol concentration in the media of non-treated cells was higher than 
the treated cells both immediately after cannabinoid exposure and after 48 hours 
wash out as shown in Table 4.10. Paracetamol concentration was decreased by 
32% in MDMB-CHMICA, 80.5% in 5FADB and 85% in ∆9-THC treated cell culture 
media, in cells exposed to paracetamol immediately after cannabinoids treatment. 
However, it was only statistically significant in ∆9-THC exposed cells in comparison 
to non-cannabinoid treated cells (p= 0.028) (Figure 4.48). Paracetamol 
concentration was decreased by 78.9% in MDMB-CHMICA, 77.8% in 5FADB and 
88.1% in ∆9-THC treated cell culture media, in cells exposed to paracetamol after 
48 hours (wash-out) after cannabinoids treatment. However, it was only statistically 
significant in ∆9-THC exposed cells in comparison to non-cannabinoid treated cells 
(p= 0.024) (Figure 4.48).  
 
 Paracetamol concertation in different treated cell 
media (ng/ml) 




201 136 39 30 
After 48 hours 
(wash-out) 
185 39 41 22 
 
Table 4.10 Paracetamol concentrations in culture media after exposure to 
MDMB-CHMICA, 5F-ADB and∆9-THC. Paracetamol concentration was measured 
either directly after the cells been exposed to cannabinoids for 14 days or after 48 hours 






Figure 4.48 level of paracetamol concentration in culture medium of mature 
cells treated with SCRA and ∆9-THC. Paracetamol concentration in culture medium 
of mature hNPSC cells treated with 10 nM of MDMB-CHMICA, 5F-ADB and ∆9-THC for 
14 days, then treated with 1µg/ml paracetamol either immediately after cannabinoid 
exposure or 48 hour (wash-out) after cannabinoids exposure. Statistical significant was 
evaluated by Kruskal-Wallis test. * represents p <0.05.  
 
The decreases in paracetamol concentration in all 3 treatment groups might 
suggest that cannabinoids increase paracetamol metabolism, with the highest 
effect been seen in ∆9-THC. The reduction in 5F-ADB was greater than for MDMB-
CHMICA but slightly less than the reduction with ∆9-THC. The concentration of 
paracetamol was lower in cells exposed to paracetamol after 48 hours wash out 









4.5 Discussion  
The objective of this study was to investigate the potential neurotoxicity of SCRAs 
and try to characterise the mechanisms that might be involved, using human 
neuronal stem cells.  
4.5.1 Cytotoxicity assay 
This study investigated the neurotoxicity of SCRAs utilising a human stem cell brain 
model. Since SCRA are psychoactive substances and their major site of action is 
the human brain, the human neuronal stem cell model provides a good model to 
simulate the effects of SCRA neurotoxicity. The SCRAs and other comparative 
NPS were tested on both neuronal progenitor cells and mature neuronal 
(differentiated) cells. The neuronal progenitor cells are classed as an immature 
model of the human brain (developing). They were used to model the potential 
effects of NPS, in particular SCRAs use by young individuals or by potential breast 
feeding or pregnant women where there is the possibility of passive exposure. The 
mature (differentiated) neuronal model is used to study the response of the adult 
brain to NPS exposure. 
The human neuronal precursor stem cell model (hNPSC) line N1997 used in this 
study offers advantage of using human cells over using animal cells. Hence, 
avoiding the need to extrapolate results across species (Breier et al., 2010, Scott 
et al., 2013). In addition, other human cell lines have many limitations such as 
HEK293 lack neuronal phenotype; SHSY5Y cell lines (that is derived from human 
neuroblastoma cells) are hard to differentiate into mature dopaminergic state 
(Schlachetzki et al., 2013). Moreover, hNPSC cells has been used successfully as 
a model to investigate the cytotoxicity of other compounds and to study brain 
development & neurodegeneration (Nisar et al., 2015, Kurzawa-Akanbi et al., 
2012, Madgwick et al., 2015). Although hNPSC display and maintain functional 
features close to brain cells, it has some limitations. hNPSC is a 2-dimensional 
model which does not reflect the in vivo where the vascular perfusion continuously 
supplies nutrient and remove metabolic waste products. Also, it  lacks the 
interaction between the cell and its matrix, and between adjacent cells (Haycock, 
2011). Furthermore, differentiation into specific types of neurons with high purity 
might vary between experiments (Zhao and Moore, 2018). The immature and 
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mature stem cells were exposed daily to the tested compounds, as many users 
used it regularly on a daily bases (Cooper, 2016, Macfarlane and Christie, 2015).  
The toxicity studies show that MDMB-CHMICA, 5F-ADB and MMD-CHMICA were 
toxic to immature cells at 5-10 µM after 7-14 day of exposure, with MMB-CHMICA 
showing higher toxicity. The cytotoxicity of these SCRAs at 5-10 µM which is more 
than 1000 time higher the range of their binding affinities to both CB1 and CB2 
receptors (0.59-10 nM for CB1 and 7.5-71 nM for CB2 receptors). i.e all receptors 
sites will be occupied, and the maximum effect will occur. In addition to the other 
potential binding with non-CB receptors, transporters and metabolising enzyme. 
Thus, the high binding affinities of SCRAs when compared to ∆9-THC can be 
responsible for unusual severe effects due to CB receptors overstimulation. 
The differences in cytotoxicity might be attributed to the differences in SCRA 
potencies to CB1 receptor and its potential interaction with other neurotransmitter 
or activation/inhibition of signalling pathways on the brain.  
These finding are in line with Tomiyama et al. (2014) who proposed that the 
cytotoxicity may depend upon the role of CB1 receptor rather than the chemical 
structure of SCRA (Tomiyama and Funada, 2014). 
The results obtained from the Alamar Blue on the mature neuronal model assay in 
the presences of JWH-018 did not show a significant reduction in cell viability, 
suggesting that JWH-018 is not cytotoxic over the range of concentrations tested. 
These results are consistent with those of Couceiro et al. (2016), who 
demonstrated that JWH-018 did not decrease cell viability in SH-SY5Y and 
HEK293T cell lines. Similarly, Koller et al. (2013) investigated the toxicological 
profiles of some SCRAs including JWH-018 at concentrations up to 100 µM and 
24 hours incubation, using MCF-7 (breast) and TR146 (buccal) cells. These 
SCRAs and did not show mitochondrial damage or changes lysosomal activity or 
protein synthesis (Koller et al., 2013).  
Tomiyama et al. (2014) examined mice forebrain neuronal culture and concluded 
that the tested SCRAs (including JWH-018) were toxic between 10 and 30 µM. In 
addition, they concluded that the toxicities of tested SCRA were reversible when 
the cells were pre-incubated with CB1 receptor blocker but not CB2 receptor 
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blocker (Tomiyama and Funada, 2014). Interestingly, the N-(3-hydroxypentyl) 
JWH-018 metabolite was shown to cause a substantial reduction in cell viability at 
concentrations higher than 25 µM (Couceiro et al., 2016). Moreover, 5F-ADB, 
MDMB-CHMICA and MMD-CHMICA did not reduce cell viability of mature 
neuronal cells, suggesting that these SCRA are not overtly toxic at the 
concentrations tested (0.005-10µM). Recently, a study published regarding 
cytotoxicity of 5F-ADB and MDMB-CHMICA which utilised a lung carcinoma cell 
line A549 and buccal carcinoma cell line TR146 only showed toxicity was induced 
at concentrations higher than 25µM (Grafinger et al., 2019).  
So far, there have been few studies published which have investigated the 
cytotoxic properties of SCRA, probably due to the diversity of the group and the 
continuous appearance of new compounds (Wojcieszak et al., 2016). 
There is limited data available on the bioavailability of SCRA in human blood. Most 
of the available data are either from post-mortem analysis, emergency department 
admissions, police forensic samples or pharmacokinetic studies (summarised in 
Table 4.11). One limitation of these data are the lack of the knowledge of the actual 
dose being taken by the user and the time between the consumption of SCRA and 
blood measurement being taken, which varies widely. In addition, the blood 
concertation usually does not reflect the exact amount introduced into the system 
as SCRA rapidly disappear from the circulation either due extensive tissue 
distribution or rapid metabolism (Teske et al., 2010, Toennes et al., 2017). Some 
of the metabolites may also be more potent than the original parent compound 
ingested. Moreover, SCRA are highly lipophilic compounds and when they pass 
through the blood brain barrier, they might accumulate in a concentration higher 








SCRA Concentration Condition Sample type Ref. 
JWH-018 (n=18) 292.8 pM-582.8  nM Post-mortem Blood (Shanks et al., 2012b) 
JWH-018(n=1) 123.0 nM Case study Blood (Hermanns-Clausen et al., 2018) 
 JWH-018 (n=6) 8.4 nM – 28.9nM Pharmacokinetic study Blood 
(Toennes et al., 
2017) 
(JWH-018 (n=2)  23.7 nM-29.2865  nM  Pharmacokinetic study Serum (Teske et al., 2010) 
JWH-073 (n=8) 305.4  pM–208.5nM Post-mortem Blood (Shanks et al., 2012b) 
 5F–ADB 503.3  pM Post-mortem Blood (Kusano et al., 2018) 
5F-ADB n=4 291.3  pM–5.0 nM Post-mortem Blood (Usui et al., 2017) 
5F-ADB  50.33 pM Case history Urine (Minakata et al., 
2017) 
MDMB-CHMICA 14.5644 nM Post-mortem Blood (Adamowicz, 2016) 
MDMB-CHMICA 6.762 nM Post-mortem Brain (Adamowicz, 2016) 
MDMB-CHMICA  3.6nM Post-mortem Serum (Westin et al., 2015) 
MDMB-CHMICA  8.84-224.70 nM Case study blood 




2.3 - 16.9 nM Driving under influence of drug Blood (Karinen et al., 2015) 
APINACA (n=3) 656.6 pM- 67.03nM Driving under influence of drug Blood (Karinen et al., 2015) 
UR-144 (n=2) 671.7 pM-1.4 nM Driving under influence of drug Blood (Karinen et al., 2015) 
 
Table 4.11 Examples of some SCRA levels found from pharmacokinetics 
studies, forensics and post-mortem cases. 
 
The available literature suggests that the concentrations of SCRA present in 
human samples after consumption is lower than the levels examined in toxicity 
publications. Therefore, the SCRA concentrations range examined in this study 
were lower to more closely mimic the levels found clinically.     
The molecular mechanisms that underlies SCRA cytotoxicity remain to be 
elucidated. Tomiyama et al. (2014), reported that CB1 cannabimimetic induce 
apoptosis through a caspase 3 dependant mechanism (Tomiyama and Funada, 
2014) and this is the same mechanism suggested for ∆9-THC by increasing 
cytochrome c release and caspase-3 activity (Campbell, 2001). On the other hand, 
the cytotoxicity of the CB2 agonist JWH-133 was not mediated by activation of the 
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CB2 receptor or apoptotic pathways (Wojcieszak et al., 2016). Bologov et al. (2011) 
indicated that cannabimimetics significantly reduce cell viability when the cells 
were cultured under stressful conditions (glucose and serum deprived medium), 
but the same compounds did not affect viability for the same type of cell when 
cultured under optimal conditions. This raises a possible effect of the environment 
in potentiating toxicity by mechanisms such as hypoxia (Bologov et al., 2011).  
It is worth mentioning that the SCRA used in this study were reference standard 
quality chemicals and the actual SCRA misused by users are usually in the form 
of herbal preparations sprayed with chemical that may contain adulterants or 
contaminants that might also be cytotoxic. Granfinger et al. (2019) examined the 
cytotoxicity of 5C-AKB 48, ADB-CHMINACA, MDMB-CHMICA, 5F-ADB and NM-
2201 in form of reference standards, as smoke condensate and herbal extract 
preparation. They showed that the cytotoxic effects of 5C-AKB48, 5F-MDMB-
PINACA, and MDMB-CHMICA were augmented by plant material (Grafinger et al., 
2019). In addition, the cells were continuously exposed to the test compound which 
is might not reflect the actual exposure, together with the not taking into 
consideration the effect of blood brain barrier and the metabolic changes that might 
activate or deactivate the tested chemicals. 
The cytotoxicity of tested SCRA was prominent in immature cells but not mature 
cells. It may be that immature cells are more sensitive to apoptotic effects than 
mature cells (Downer et al., 2007) and mature cells are more resistant to cell death 
than immature cells (Kole et al., 2013). In addition, the mechanisms of apoptosis 
vary between immature and mature neurons (Lesuisse and Martin, 2002).  
The natural cannabinoids ∆9-THC was not tested in this study; however, effects of 
∆9-THC on viability have been studied previously using the same cell lines and 
methodology in-house (unpublished data). The results showed that ∆9-THC was 
not toxic to both mature and immature neuronal cells in a concertation range of up 
to 20 µM. This would suggest that tested SCRAs are more toxic than ∆9-THC.  
To compare the toxicities of SCRA with other NPS, the novel stimulants 
mephedrone and 25I-NBOMe hallucinogen were investigated for cell viability. The 
viability experiments showed that mephedrone induced toxicity in a concentration 
dependant manner for the first seven days. However, the cell viability recovered 
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after day 14, suggesting that this may be because the concentrations used were 
stressing the cells rather than killing them. The data in the literature regarding 
mephedrone induced neurotoxicity is contradictory, for example some studies 
reported that mephedrone can cause a reductions in dopamine and 5-HT 
transporters, while others showed no destruction of dopamine nerve endings and 
no significant changes in monoamine levels in the brain (den Hollander et al., 2014, 
Martinez-Clemente et al., 2014, López-Arnau et al., 2015, Motbey et al., 2012, 
Angoa‐Pérez et al., 2012). However, due to discrepancies in experimental design, 
doses and type of cells used, it is difficult to compare the results or draw a final 
conclusion about mephedrone action (Pantano et al., 2017). 25I-NBOMe showed 
early neurotoxic effect on immature cells and showed high cytotoxicity after 
repeated exposure. The high toxicity might because it is a potent 5-HT2A agonist, 
as suggested by Braden et al 2006 (Braden et al., 2006). Currently, all the data in 
the literature about 25I-NBOMe relates to case report studies and some 
pharmacokinetics studies (Hill et al., 2013). No literature has been found about the 
mechanism of toxicity and this study is the first study in vitro to be reported.   
To compare the toxicity of SCRA with conventional drug of abuse, the synthetic 
stimulant MDMA (ecstasy) was examined for cell viability. The viability experiments 
showed a reduction in cell viability was noticed after 7 days of MDMA exposure at 
1, 2 and 5 µM but not 10 µM and the cells retained viability after further exposure. 
The variability in cell response might be due to that MDMA stressing the cell at the 
mitochondrial level without killing the cell and later revive from stress (Fulda et al., 
2010). Similar to that seen in mephedrone as the cells recovered after 14 days 
from exposure. 
It has been noticed from the NPIS data and published literature that drug abusers 
usually consume more than one drug of abuse (poly-abuse). This poly-abuse might 
lead to interactions between different drugs that might lead to different effects when 
compared to single drug toxicity evaluation. Therefore, a combination of MDMB-
CHMICA, 5F-ADB and the conventional drug of abuse MDMA at lower and more 
clinically relevant concentrations were investigated for effects on cell viability. The 
combination of MDMB-CHMICA, 5F-ADB and MDMA did not affect viability, the 
tested concentrations might not affect cell survival, but might induce changes on 
cellular level that manifest as adverse health effect. 
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Overall, the viability results suggested that SCRA are toxic to immature cells but 
not to mature cells. This suggests that the abuse of SCRA by young users or 
pregnant women may severely affect the young developing brain. Nevertheless, 
the lack of overt cytotoxic effect in mature cells does not exclude potential changes 
induced by continued exposure to SCRA. Therefore, additional investigations were 
done to understand the molecular and cellular changes arising from repeated use. 
Finally, the different types of NPS can produce different modes of intoxication 
which require further investigation. 
4.5.2 Gene Expression Changes 
This is the first investigation using RNA sequencing to assess the impact of SCRA 
and ∆9-THC using human neuronal stem cell models. In drug discovery and 
development, RNA sequencing provides a high-throughput tool for simultaneously 
evaluating the patterns of expression/changes of thousands of genes and 
identifying relevant functional gene pathways (Khatoon et al., 2014).  
To elucidate the molecular changes that occur following repeated exposure to 
SCRA (MDMB-CHMICA and 5F-ADB) and ∆9-THC, mature neuronal cells were 
exposed to 10 nM concentrations for 2 weeks. This concentration was chosen in 
the knowledge that SCRA showed minimal toxicity at 1000 time higher 
concentrations (10µM), to span the cannabinoids levels reported in the literature 
(Table 4.11) and to be close in concentration to the EC50 of the selected 
cannabinoids. Therefore, we selected 10 nM to investigate early changes caused 
by SCRA rather than nonspecific changes associated with cell death.  
At the mRNA level, gene changes detected involved genes that belong to very 
different functional categories. The number of genes differentially changed in 
comparison to control after MDMB-CHMICA exposure was 154 genes, while the 
equivalent for 5F-ADB was only 20 genes. The lower number of genes changed 
for 5F-ADB is may be due to the variance in response shown by the 4 replicates 
as shown by the PCA (Figure 4.11). The variation of response might be because 
of the concertation used (10nM) was not enough to elicit the full response of 5F-
ADB, although, the EC50 of 5F-ADB was 0.59 nM. This might suggests that 5F-
ADB action is not limited to the CB1 receptor alone. It could also be due to receptor 
desensitisation that represents a protective mechanism against chronic receptor 
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overstimulation that limits the response to a full agonist (Ferguson, 2001). 
Comparing MDMB-CHMICA to ∆9-THC, the magnitude of changes due to the 
synthetic cannabinoid MDMB-CHMICA was 3 times higher than for ∆9-THC (50 
genes significantly changed) suggesting that SCRA might induce more changes in 
gene expression due to frequent exposure than natural cannabis. Previous studies 
on the effect of ∆9-THC have been conducted in mice or rats. These transcriptome 
studies usually target certain aspects like changes in rat cerebellum on chronic use 
(Colombo et al., 2009) or changes in brain lipidome in mice (Leishman et al., 2018) 
therefore it is not possible to accurately compare the results to this current study.  
The common differential changed genes among the 3 groups were 2 mitochondrial 
tRNAs, LGI1 and DQX1. It can be noticed that the changes in expression of these 
genes are in the same direction in the 3 groups, i.e. they are either upregulated or 
down regulated in all groups. In addition, the fold change was relatively similar. The 
results showed that two of the genes common to all 3-treatment groups that were 
upregulated were the mitochondrially encoded tRNA isoleucine (MT-TI) and 
mitochondrially encoded tRNA glutamine (MT-TQ). They are responsible for 
transferring the amino acids isoleucine and glutamine, respectively, to the 
polypeptide chain at the ribosome site of protein synthesis during translation. 
Mutation of MT-TI leads to many clinical diseases. These include MERRF, which 
is characterised by, epilepsy, dementia cerebellar ataxia, myoclonus and abnormal 
cells called ragged red fibers (RRF) (Lorenzoni et al., 2014). Cardiomyopathy and 
deficiency in complex IV of the mitochondrial respiratory chain have also been 
shown (Kaido et al., 1995, Taylor et al., 2003). Mutation of MT-TQ is one of the 
genetic causes of mitochondrial encephalomyopathy, lactic acidosis, and stroke-
like episodes (MELAS). It is worth mentioning that the mitochondrial tRNA were 
the most affected genes. In MDMB-CHMICA treated cells there were 9 MT-tRNA 
genes significantly changed. The significant genes should have p value less than 
0.05 and a fold change more than 1, but it was noticed that there were 8 MT-tRNA 
genes were significantly changed in p value but did not pass the fold change cut-
off value. The same changes in MT-tRNA genes in 5F-ADB treated cells were 
noticed as 2 TM-tRNA genes were significantly changed in addition to 8 other 
genes that have been a significant p value but the not the fold change value. In ∆9-
THC there were 6 MT-tRNA significantly changed and 6 genes that have been a 
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significant p value only. These changes in MT-tRNA indicated the adverse effects 
of cannabinoids in the mitochondria as they are affecting more than 50% MT-tRNA 
that play an important role in mitochondrial function. The tRNA are non-coding 
RNAs that helps ribosomes in protein synthesis by decoding mRNA genetic code 
and translate protein. Recent studies have shown that tRNA play a role in the 
cellular response to stress (Kirchner and Ignatova, 2015). Cytosolic t-RNA and MT-
tRNA bind to cytochrome c; (cytochrome c acts as initiator of apoptosis and 
caspase activation); this binding will impair the activation of caspase and act as a 
protective mechanism against cell death (Mei et al., 2010, Huber et al., 2019). In 
the mitochondria, the MT- tRNA plays important roles in allowing effective, precise, 
and dynamic protein synthesis (Bohnsack and Sloan, 2018). Mutations in MT-tRNA 
are responsible for many genetic diseases such as myoclonic epilepsy with 
ragged-red fiber disease (MERRF) and mitochondrial encephalomyopathy, lactic 
acidosis, and stroke-like episodes (MELAS) (Goto et al., 1991, Shoffner et al., 
1990). The increase in MT-tRNA expression might be a response to the stress 
induced by MDMB-CHMICA, 5F-ADB and ∆9-THC. The perturbation in MT-tRNA 
gene expression might indicate changes in mitochondrial protein synthesis, and 
any disruption or abnormal protein synthesis may affect the components of the 
mitochondrial respiratory chain or may boost ATP production. In addition, these 
changes may impact other mitochondrial functions such as involvement in 
metabolic pathways, apoptosis and reactive oxidative species signalling (Pearce 
et al., 2017, Bohnsack and Sloan, 2018, Xu et al., 2016). 
The consequence of increase or decrease in protein synthesis will lead to a 
respiratory chain complex defect. This defect will trigger mito-nuclear signalling 
mechanisms that allow mitochondria to interact with the nucleus and reprogram 
nuclear gene expression. These signalling mechanisms include mitochondrial 
proteolytic response, UPR and heat shock response pathways. Therefore, 
mitochondrial stress in neuronal cells reprogram gene expression and metabolism 
and consequently regulating neuronal function (Hunt et al., 2019, Khacho et al., 
2019). Furthermore, the disruption of mitochondria function, impact the glial cells 
as well. The induction of UPR in mitochondria and activation of glial stress 
response pathway have been reported in many neurogenerative diseases 
(McAvoy and Kawamata, 2019). However, the mechanisms by which Mt-tRNA 
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affect mitochondrial function are poorly understood. Therefore, prediction of MT-
tRNA effect on the neuronal function and clinical outcome extremely difficult; as 
McFarland et al, reported that “We understand little of the factors determining the 
pathogenicity of specific MTt-tRNA mutations, making prediction of clinical 
outcome extremely difficult” (McFarland et al., 2004). Therefore, further 
investigation about the effect of SCRA on mitochondrial function, neuron 
mitochondria biogenesis and the proteins and pathways implicated in oxidative-
phosphorylation function is required. 
The other significantly changed gene was leucine rich glioma inactivated 1 (LGI1). 
This gene is highly expressed in brain; the exact function in the CNS is still unclear, 
but evidence shows that it encodes proteins that could regulate the activity of 
voltage-gated potassium channels and it may be involved in neuronal growth 
regulation and cell survival. In addition, it regulates synaptic transmission of 
glutamatergic synapses in the hippocampus (Zhou et al., 2009, National Center for 
Biotechnology Information). Recent research showed that presence of LGI1 
antibodies in encephalitis patients related to structural damage of the hippocampus 
that causes impairments of verbal and visuospatial memory (Finke et al., 2017). 
LGl1 has also been linked with faciobrachial dystonic seizures (FBDS), a form of 
epilepsy which is illustrated by frequent, short-term seizures affecting the arm and 
face (Plantone et al., 2013).   
It can be noticed that the mutations in MT-tRNA and LGI1 are associated with 
seizures, cardiac side effects and memory loss which are also some of the features 
of cannabinoid toxicity (Gurney et al., 2014). It can be postulated that the changes 
in these genes contribute to SCRA adverse effects. 
The final commonly differentially changed gene for all 3 groups was DEAQ-box 
RNA dependent ATPase (DQX1). This gene is related to the RNA-dependent 
ATPases and plays a role in RNA metabolism. However, the clinical significance 
and biological role of DQX1 has not been explored. 
It can be noticed that there are overlaps in differentially expressed genes among 
the 3 groups and the direction of change of all of these genes are the same. This 
might indicates that these changes are mediated through the activation of CB1 
receptor. The MDMB-CHMICA induced more changes compared to ∆9-THC might 
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be explained by MDMB-CHMICA being a more potent and a full agonist on CB1 
receptor in comparison to less potent and partial agonist ∆9-THC (Paronis et al., 
2012). Therefore, it can be proposed that synthetic cannabinoids are more toxic 
than cannabis.   
The canonical pathway analysis by IPA showed that MDMB-CHMICA, 5F-ADB and 
∆9-THC induced a variety of different gene expression changes. MDMB-CHMICA 
treatment of neuronal cells inhibited both SUMOylation and Sirtuin signalling 
pathways. Recently, SUMOylation has been identified as a vital posttranslational 
modification capable of changing stability, regulation of genes, subcellular 
localization of proteins, and protein-protein interactions. Also, it plays a vital role in 
cellular processes, for example oncogenesis, cell cycle control, apoptosis, and 
response to viral infection (Gareau and Lima, 2010). Therefore, any disturbances 
in the SUMOylation pathway may lead to changes in cellular function (Zhou et al., 
2004). The change in SUMOylation pathway may be as a result in changes reactive 
oxygen species (ROS) production, which has been suggested to be an important 
regulator of the SUMOylation pathway. Bossis et al reported that SUMO-
conjugating enzymes Inactivation may be an early phase in cellular response to 
oxidative stress and they can be regarded as ROS sensors (Bossis and Melchior, 
2006). During oxidative stress, the SIRT1 enzyme (part of the sirtuin signalling 
pathway) becomes inhibited (Salminen et al., 2013). These findings indicate that 
MDMB-CHMICA might slightly increase oxidative stress in the cells by increasing 
the levels of ROS production. The increase in ROS level and loss of antioxidant 
balance impacts the cell through oxidative damage to cellular proteins, lipids and 
genetic material. Since the brain is a highly metabolic organ, any disruption to the 
ROS system will have substantial effects on it (Sies, 1997, Islam, 2017). Any 
increase in ROS production may be due increase in protein synthesis as shown by 
increased expression of the MT-tRNA in MDMB-CHMICA treated cells (Han et al., 
2013). 
The current study showed that MDMB-CHMICA activated the EIF2 signalling 
pathway, which is an initiator of protein synthesis (Kimball, 1999). The activation 
of EIF2 signalling might indicate the increase in protein synthesis which is 
complemented by the activation of mTOR signalling which also indicate increase 
in protein synthesis. Previous studies showed that continued activation of neuronal 
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PI3-K/Akt/mTOR signalling can be an early feature of Alzheimer disease due to the 
accumulation of tau protein (O' Neill, 2013). In addition, TGF-β/ and BMP signalling 
pathways are involved in many processes at a cellular level and any disruption in 
their activity lead to many defects. It has been shown that activation of these 
pathways has a protective effect on the cells (Shan et al., 2018, Guo and Wang, 
2009), but cross-talk signalling between these is very complex and data should be 
interpreted with caution. Taken together, these changes suggest that MDMB-
CHMICA activates oxidative stress responses, increases protein synthesis which 
in turn activates the unfolded protein response. Therefore, further investigation is 
required to measure the oxidative stress induced by MDMB-CHMICA such as Mito-
SOX to measure mitochondria-derived O2‾ and redox prob dichlorodihydro 
fluorescein (DCFH) to measure intracellular H2O2‾. In addition to studying changes 
in mitochondrial transmembrane potential (Δ ψm). 
In comparison 5F-ADB showed different canonical pathway changes, with the 
activation of only 5 pathways and no predictions for inhibition which might attributed 
to the sample variation mentioned earlier. The activation of p53 induces apoptosis 
by transactivating pro-apoptotic genes and direct binding to anti-apoptotic 
mitochondrial proteins, thus successfully provoking apoptosis (Ranjan and 
Iwakuma, 2016). Whereas, the activation of actin cytoskeleton suggested initiation 
of apoptosis, as actin cytoskeleton acts as mediator, initiator in apoptotic pathways 
(Desouza et al., 2012). On the other hand, the activation of NGF and 
adrenomedullin signalling pathway may reflect a protective response from the 
neuronal cells. The NGF is a potent pro-survival factor that protects the cells from 
apoptosis (Mnich et al., 2014), together with the neuroprotective effect of 
adrenomedullin activation that improves the survival and migration of astrocytes 
and inhibits apoptosis by eliminating oxidative stress-mediated signals (Xia et al., 
2004). It can be noticed that the activated pathways in 5F-ADB treated cells are 
related to increase apoptosis and consequently cell death. Thus, it is important to 
understand the mechanisms by which 5F-ADB initiate or trigger apoptosis and 
hence identify the effects on human brain and how it is translated into clinical 
manifestations  and any long-lasting damages it might cause. This can be done by 
investigating the effect of 5F-ADB on membrane asymmetry (analysis of annexin 
V binding), caspase activation markers, and DNA fragmentation. 
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The gene expression changes induced by ∆9-THC were different and even 
contradictory to those of MDMB-CHMICA as shown by EIF2 signalling and Wnt/β-
catenin signalling being inhibited by ∆9-THC, whereas they were activated by 
MDMB-CHMICA. As mentioned previously, changes in EFI2 activity arise in 
response into a broad spectrum of cellular stress and lead to increase in protein 
synthesis. The reduction in its activity reflects the reduction in protein synthesis 
(Wek et al., 2006). Furthermore, ∆9-THC inhibited aryl hydrocarbon receptor 
signalling which plays an important role in the regulation of xenobiotic metabolism, 
such as the induction of CYP1A1 and CYP1A2. It was also shown to affect the 
glutathione S-transferase Mu 4 (GSTM4) gene expression. GSTM4 enzyme plays 
a role in metabolism of various xenobiotic such as drugs, environmental toxins and 
products of oxidative stress (Denson et al., 2006). The inhibition of phase II 
metabolism will reduce the detoxification of other drugs and xenobiotic and may 
enhance their effects, potentially leading to adverse effects and toxicity. In the 
nervous system, Ephrin signalling is involved in the proliferation of neuronal 
progenitor cells, the control of axonal growth cones to their synaptic targets and 
synapse development (Kania and Klein, 2016). In addition, Ephrin-B2 expressed 
in astrocytes of the hippocampal stimulates EphB4 forward signalling in neural 
stem cells and, through activation of β-catenin, promotes neuronal differentiation 
but not proliferation (Ashton et al., 2012). The inhibition of Ephrin-B2 signalling and 
Wnt/β-catenin signalling in the hippocampus might affect memory and cognition.  
Taken together, IPA analysis provides evidence for the potential role of SCRA in 
cellular stress. The changes induced by MDMB-CHMICA, 5F-ADB and ∆9-THC 
varied in the targeted pathways, but it can be noticed that affected pathways were 
related to increase protein synthesis that potentially triggers stress pathways in the 
cells such as ROS production, activation of unfolded protein response and changes 
in metabolising enzymes. In addition, there was a difference in responses between 
the 2 synthetic cannabinoids MDMB-CHMICA and 5F-ADB; as MDMB-CHMICA 
showed signs of increase cell stress while 5F-ADB triggered apoptotic pathways. 
This might be attributed to the 10nM concentration used which was similar of 
MDMB-CHMICA EC50 at CB1 receptor, whereas the EC50 of 5F-ADB at CB1 
receptor (0.59nM).The higher 5F-ADB effective concentration and the continuous 
exposure for 14 days may be responsible for driving different pathways from 
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MDMB-CHMICA in particular apoptotic pathway. In addition to the inconsistent 
responses from the quadruplicate samples compromised the IPA analysis and 
hence different effects on physiological pathways.  It should be noted that all these 
changes are triggered by the relatively low concentration of 10 nM (compared to 
10 µM toxic concentration) which was not enough to kill the cells, but enough to 
induce changes that may help explain some of the neurotoxic effects seen in 
cannabinoids use. 
4.5.3 Proteomic changes due to NPS exposure  
The CB1 receptors are the main receptors responsible for the psychotropic effects 
of cannabinoids. The CB1 receptor expresses 3 isoforms (Bagher et al., 2013), but 
due to low fluorescence intensity on the western blot only the CB1a isoform was 
analysable.   
Neither MDMB-CHMICA and 5F-ADB or ∆9-THC did not significantly change CB1a 
protein expression.  It is well established that repeated exposure to an agonist can 
cause down-regulation of receptors expression (Tsao and von Zastrow, 2000). 
Therefore, down regulation in CB1 receptors might be anticipated after repeated 
exposure to cannabinoids. Hirvonen et al. (2012) reported that there was down 
regulation of CB1 receptors selectively in the cortical brain region in chronic 
cannabis users. This down regulation was reversed after 4 weeks of discontinuing 
cannabis use (Hirvonen et al., 2012). In addition, the potent CB1 receptor agonist 
WIN 55,212-3 induced significant down regulation of CB1 receptors in a 
concentration dependant manner starting from 10 nM (Blair et al., 2009). This down 
regulation will contribute to development of tolerance to their pharmacological 
effects (Martin et al., 2004). It can be noticed that MDMB-CHMICA followed the 
trend in CB1 expression reduction from the previous studies. Interestingly, 5F-ADB 
increased CB1 receptor protein expression by 19%. Laprairie et al. (2013) reported 
that endocannabinoids; arachidonyl-2-chloroethylamide, anandamide and 
methanandamide; can increase CB1 receptor protein expression in a neuronal cell 
culture model by activation of transcription such as NF-κB. A final conclusion on 
the effect of the studied cannabinoids on CB1 expression cannot be drawn, 
because only one isoform was analysed and this represents only a proportion of 
the CB1 receptor pool. In addition, the CB1 isoform (53 kDa) is the most abundant 
isoform and was not quantified. 
197 
 
To investigate whether MDMB-CHMICA, 5F-ADB and ∆9-THC induce 
morphological changes or neuronal injury to mature neuronal cells, β III – tubulin 
and GFAP were assessed. The tested cannabinoids did not affect neuronal 
cytoskeletal β III – tubulin, but ∆9-THC significantly increased GFAP expression. 
GFAP overexpression is characteristic of astrogliosis in which the astrocyte 
become reactive in response to insults such as trauma, genetic disorder, disease 
and chemical injury (Eng et al., 2000). However, there are 2 distinctive types of 
astrocytes, named A1 and A2. The A1 type might be neurotoxic, because they 
upregulate many genes that suggested to be destructive to the synapses. In 
contrast to A2 astrocytes, which promote neuronal survival and tissue repair 
(Liddelow and Barres, 2017); therefore it would be useful to look again with more 
specific markers to A1 and A2 to see if the response is damaging or protective 
response.  
This result is in agreement with other studies that have showed that ∆9-THC 
significantly increases GFAP in the rat hippocampus after chronic exposure 
(Lopez‐Rodriguez et al., 2014, López-Gallardo et al., 2012). Furthermore, GFAP 
expression increased in rat hippocampus during acute and chronic administration 
of ∆9-THC (Suliman et al., 2018). Another study indicated that twice daily exposure 
to the SCRA WIN 55,212-2 for 14 days did not induced significant changes in 
GFAP expression, although there was a significant change in NF-160, NF-200 and 
MAP-2 neuronal cytoskeletal proteins in rat brain (Tagliaferro et al., 2006). These 
results highlight that ∆9-THC could induce brain injury which might contribute to 
the chronic effects of cannabis use. 
The overexpression of MT-tRNA suggests an increase in protein synthesis in the 
mitochondria, including proteins that comprise the OXPHOS system. MT-tRNA is 
involved in the synthesis of critical subunits of Complexes I, III , IV and two subunits 
of complex V, depending on the type of amino acid incorporated (Triepels et al., 
2001). The Complex I subunits NDUFA9 and NDUFS1 showed non-significant 
changes in protein expression with 16% reduction of NDUFA9 in ∆9-THC treated 
cells. Impairment in NDUFA9 expression in mitochondria might lead to an increase 
in ROS production as it has a proposed role in preventing ROS generation 
(Abruzzo et al., 2010, Bause and Haigis, 2013). Increased ROS production harms 
cells by lipid peroxidation and by modification of nucleic acid and protein structures. 
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In a study by Wolff et al. (2015), showed that ∆9-THC inhibited mitochondrial 
respiratory chain complexes I, II, and III as well as increasing ROS production in 
mitochondria extracted from rat brain (Wolff et al., 2015). In the current research, 
the ∆9-THC effect on NDUFA9 was not statistically significant, but the reduction in 
expression might lead to increase ROS production and this might induce damage 
to brain cells during longer term exposure. 
MDMB-CHMICA increased Cytochrome c oxidase subunit 1 (MTCO1) expression 
by 14% and significantly increased Cytochrome c oxidase subunit 5a (CoxVa) by 
30%. Cytochrome c oxidase consists of 13 subunits, located in the inner 
mitochondrial membrane. Cytochrome c oxidase catalyses the last step of the 
electron transfer chain in mitochondrial oxidative phosphorylation which accounts 
for 90% of cellular ATP production, in addition to its role as a proton pump together 
with complex I and III to control ATP synthesis (Little et al., 2018). This suggests 
that MDMB-CHMICA induces mitochondrial biogenesis, which is a complicated 
process by which the cell increases the number of mitochondria present to adapt 
to different physiological and environmental conditions. Therefore, the 
overexpression indicates an increase in ATP production. The increase Cytochrome 
c oxidase in MDMB-CHMICA treated cells might be as a compensatory mechanism 
to a reduction in ATP synthase. Havlíčková Karbanová et al. (2012) reported 
reduction in inner mitochondrial protein TMEM70 resulting in 30 % reduction in 
ATP synthase activity and this lead to marked and significant increases in cellular 
protein content of the subunits of respiratory chain complex III and complex IV 
(Havlíčková Karbanová et al., 2012). TMEM70 gene expression was significantly 
inhibited (p= 0.01) as shown in the differential gene expression data for MDMB-
CHMICA treated cells, but not 5F-ADB or ∆9-THC exposed cells. The 11 % 
increase VDAC1 expression in MDMB-CHMICA treated cells might further 
suggests that MDMB-CHMICA increases ROS levels in neuronal cells. It has been 
suggested that elevated levels in ROS increase cell death observed with VDAC 
overexpression (McCommis and Baines, 2012). These findings suggests MDMB-
CHMICA might lead to increase ROS production to levels that might cause the 
inhibition of the SUMOylation pathway, Sirtuin pathways and upregulate of mTOR 
activity (Jang and Sharkis, 2007). 
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Evidence from the literature proposed that oxidative stress and ROS are correlated 
to ER stress and represent an essential element of UPR (Bhandary et al., 2013, 
Zeeshan et al., 2016). UPR generally operates to offset ROS accumulation 
stimulated by different stresses to protect cells from cell death (Xue et al., 2005). 
The tested SCRA (MDMB-CHMICA and 5F-ADB) and ∆9-THC did not significantly 
change PDI and BiP protein expression, but in MDMB-CHMICA treated cells BIP 
expression increased by 12%. BiP plays a pivotal role as a key ER chaperone with 
anti-apoptotic properties; it also has the capability to control the initiation of UPR 
signalling (Lee, 2005).  
In addition, phospho Erk1/2 was investigated, given the association between ROS 
and ER stress (Santos et al., 2009). Phosphorylation of Erk1/2 acts as a cell 
survivor factor to protect the cells from ER stress- induced apoptosis (Darling et 
al., 2017). The results showed no significant increase, but there were 14% increase 
in phospho-Erk1 expression in 5F-ADB. This might indicate that the level of stress 
induced by 5F-ADB was not enough to activate Erk1 expression. Unfortunately, 
phospho-Erk2 was not analysed due to low fluorescent signal.  
RNA sequencing analysis noted many metabolic enzyme changes, it shows 
changes in some cytochrome P450 such as CYP17A1 which was 3-4 times 
significantly upregulated in MDMB-CHMICA and ∆9-THC treated cells. Therefore, 
both phase I (CYP3A4, CYP2E1 and CYPOR) enzymes and Phase II (UGT1A1, 
UGT1A6 and GSTP1) enzymes were examined for changes in protein expression. 
Unfortunately, the CYP’s and the UGTs did not produce clear bands on the western 
blot for analysis. Interestingly, the results showed that phase II enzyme GSTP1 
was significantly inhibited in ∆9-THC treated cells whereas the inhibition was non-
significant in SCRA treated cells (less than 10%). Glutathione-S-transferase is vital 
in the metabolism of xenobiotic and endogenous substances and clearance of 
oxidative stress products (Higgins and Hayes, 2011). There is also recently 
growing evidence that GSTP can inhibit kinase function and suppress apoptosis 
through association in the regulation kinases signalling involved in cellular stress, 
such as Jun N-terminal kinase (JNK), apoptosis and signal-regulating kinase 
(ASK1) (Tew, 2007, Wu et al., 2006, Elsby et al., 2003). The reduced expression 
of GSTP1 might modify the capacity to detoxify other chemical and substances 
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and thus may be causal to other toxicities. This can lead to aggravated intoxication, 
in particular with poly-drug users.  
It is well documented that AHR is involved in xenobiotic metabolism through the 
induction of cytochrome P450 enzymes. The differential gene expression analysis 
showed that there are upregulation of some phase I and phase II metabolising 
enzymes in MDMB-CHMICA and ∆9-THC treated cells such as CYP17A and some 
GSTs. However, SCRA and ∆9-THC did not directly affect AHR protein expression, 
but MDMB-CHMICA and ∆9-THC increase AHR expression by 10 % and 6% 
respectively.  
In Summary, the investigated protein changes complement the RNA sequencing 
data. The increase in Mt RNA might indicate increase in protein synthesis such as 
the increased expression in MTCO1 and CoxVa in MDMB-CHMICA treated cells. 
Further proteomic investigation in particular mitochondrial respiratory subunits will 
be useful to elucidate the effect of SCRA exposure on neuronal cell. In addition, it 
highlights the effects of cannabinoids on the metabolism enzymes and how these 
changes can be translated into clinical manifestations. 
 
4.5.4 Neurotransmission 
The effect of SCRA on neurotransmission in the brain in particular serotonergic 
transmission was investigated, because many of the clinical presentations of 
SCRA users are similar to that of serotonin syndrome. Moreover, numerous 
behavioural studies on animals reported that cannabinoids might regulate 5-HT 
neurotransmission (Darmani, 2001, Hill et al., 2006, Franklin and Carrasco, 2013).  
In this study, the western blotting analysis of 5-HT2A, showed that there were no 
significant changes in 5-HT2A expression in the cannabinoid, MDMA and combined 
exposure groups. In this context, previous studies showed that chronic exposure 
to the potent cannabimimetic agent HU-210 might upregulate 5-HT2A receptors but 
causes down regulation of 5-HT1A receptors (Hill et al., 2006). In addition, Franklin 
and co-authors suggested that repeated exposure to the synthetic cannabinoid CP 
55,940 induced upregulation of 5-HT2A at a protein level, but not at mRNA level in 
the rat hypothalamic paraventricular nucleus (Franklin et al., 2013a). It also 
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increased 5‐HT2A receptor protein levels and 5‐HT2A receptor mRNA levels in rat 
prefrontal cortex and the upregulation of 5‐HT2A is mediated through CB2 receptor 
activation (Franklin and Carrasco, 2012). However, other studies showed that 
chronic treatment with HU210 or ∆9-THC did not affect 5-HT2A ligand binding and 
mRNA expression in mouse brain (Dowie et al., 2010). Furthermore, Ibarra-Lecue 
et al. (2018) reported that chronic ∆9-THC exposure did not induce changes in 
expression and density of 5-HT2A receptors in mouse brain, but lead to activation 
of the Akt/mTOR pathway and induced alterations in 5-HT2A receptor functionality 
(Ibarra-Lecue et al., 2018).   
The monoamine oxidase enzymes (MAO) terminate the actions of 
neurotransmitter, for example 5-HT, dopamine and norepinephrine through 
metabolism. MAO A has a higher affinity for 5-HT, dopamine and norepinephrine, 
whereas MAO B has higher affinity for phenylethylamine or benzyl amine (Shih et 
al., 1999). However, there are few studies of the effects of cannabinoids on MAO 
activity, Fisar et al. (2010) reported that ∆9-THC, anandamide and WIN 55,212-2 
had weak MAO inhibitory activity (Fišar, 2010 522). Therefore, verification of MAO 
protein expression was performed as their modulation might be involved in 
neurological dysfunction of many types. The results showed that there was no 
significant difference in MAO B protein expression in all exposed group, but there 
was a general increase in protein expression among the treatment groups between 
9.5% up to 27% in particular after mixed exposures. This increased expression 
might result from increases in ROS production as higher concentrations of 
hydrogen peroxide enhance MAO-B activity (Konradi et al., 1986). DARPP-32, 
which plays a vital role in controlling the efficacy of dopaminergic 
neurotransmission in the forebrain, showed no significant changes in protein 
expression. This is in contrast to mice models using CP55, 940 (Andersson et al., 
2005) and ∆9-THC (Borgkvist et al., 2008) both showing an increase in DARPP32 
phosphorylation. 
4.5.5 Preliminary metabolism experiments 
The RNA sequencing analysis showed changes in phase I and phase II 
metabolising enzymes. In addition, the western blotting analysis of the phase II 
metabolising enzyme GSTP1 showed that ∆9-THC inhibited its expression. This 
brought to attention the potential effects of SCRA as inducers or inhibitors of drug 
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metabolising enzymes. The use of SCRA particularly with other drug of abuse or 
therapeutic agents adds further risks related to metabolic drug interactions, either 
by potentiating toxicity or attenuating therapeutic effects.  
Studies published in the literature related to the effect of SCRA on metabolising 
enzyme are very limited. Therefore, the metabolism experiment was conducted to 
study the effect of cannabinoids on paracetamol metabolism. Paracetamol was 
chosen as its metabolic pathways, phase I (cytochrome P450) or phase II 
(conjugation), have been well studied and paracetamol is a readily used painkiller 
and is available without prescription. The preliminary data suggested that the 
tested SCRA, (MDMB-CHMICA and 5F-ADB), and ∆9-THC decrease paracetamol 
concentration in the cell culture media. The results tend to suggest that MDMB-
CHMICA, 5F-ADB and ∆9-THC might induce paracetamol metabolism. Previous 
studies of the effects of cannabis on cytochrome P450 showed that ∆9-THC 
inhibited CYP2C9 and CYP3A4 function, while CBD inhibited CYP2C19 and 
CYP3A4 function (Rong et al., 2018). Synthetic cannabinoids MAM-2201 weakly 
inhibited the activity of CYP1A, in addition MAM-2201 inhibited CYP2C9, UGT1A3 
and UGT2B7 (Kong et al., 2018, Alsherbiny and Li, 2019). 
Unfortunately, the paracetamol metabolites sulphate, glucuronide and glutathione 
conjugates in both culture media and in cell lysate were not measured due to 
technical problem.  
Therefore, further investigation is required to elucidate the effects of SCRA on 
metabolising enzymes activity. Although the results of the metabolism experiments 
are incomplete and a final conclusion cannot be drawn, it sheds light on the 
potential indirect toxic effect of SCRA abuse through their interactions with other 
drugs and chemicals; this may be of particular importance for poly-drug use and 
clinical treatment of users.  
Collectively, the evidence provided in this chapter suggests that the cytotoxicity of 
NPS varies widely and different SCRA produce different effects on cell viability. It 
shows that subtle changes in chemical structure might enhance cytotoxicity as 
illustrated by differences in effects between MDMB-CHMICA and MMB-CHMICA.  
In addition the study elucidated the effect of repeated exposure of cannabinoids on 
both protein and gene expression, with induced changes expression of genes 
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involved in various neural pathways. The results suggest that the SCRAs have 
more of a profound effect than the natural cannabinoids ∆9-THC. As MDMB-
CHMICA significantly changed 154 gene in comparison to 55 in ∆9-THC. Most of 
these changes are related to oxidative state, protein synthesis and perturbing 
mitochondrial function; these could potentially lead to subtle but potentially lasting 
changes in the brain. These changes were reflected in the expression of some of 
functional proteins such as Cox Va and GSTP1, in addition to the possible drug- 
drug interactions that might lead to serious consequences. Further studies are 
required to elucidate more information about the effects of SCRA, taking into 
consideration the complexity of the pathways involved.  
All of these results demonstrate evidence of direct toxicity of NPS on human 
neuronal cells, especially immature cells, with differences in potency between 
















 General discussion 
 
Over the last decade, many different NPS, otherwise referred to as “designer 
drugs” or legal highs”, have appeared in the drug market as alternatives to 
traditional drugs of abuse. These new substances are usually synthesised with 
slight modifications in chemical structures to evade legislation but maintain the 
pharmacological action of the related traditional drug of abuse. More than 730 NPS 
were reported to the EMCDDA between 2005 and 2018 (EMCDDA, 2019). 
The use of NPS is a cause of concern, Firstly, little known about their 
pharmacology, toxicology and especially their longer-term effects. Secondly, they 
are perceived as “legal” and thus perhaps “safe” (Corazza et al., 2014) by many 
users. There is also uncertainty about the type and amounts of NPS sold to users. 
These substances can cause significant toxic effects that requiring hospitalization 
and some cases of exposure are fatal. Finally, there is no accurate estimation 
about the number of users in the population.  
The aims of this research were to assess the patterns and incidence with time of 
NPS toxicity in the UK by analysis of data collected by NPIS, to investigate the 
pharmacological effects of SCRA on 5-HT transporters and to determine the 
cytotoxicity and the potential transcriptomic and proteomic changes induced by 
chronic SCRAs exposure.  
NPS are a relatively new phenomena and there is no complete picture of their use. 
There are challenges in studying NPS prevalence as there is no specific system 
for collecting data about their use in the UK. There are also large numbers of 
substances involved and these continue to change in term of chemical types 
involved and their legal status. NPIS data were selected for studying the 
prevalence of NPS toxicity because these data are available and collected 
continuously using consistent methodology, enabling the monitoring of emerging 
new drugs causing toxicity in UK users (Wood et al., 2014). The findings from 
analysing the NPIS data between 2009 and 2018 revealed that the most common 
types of NPS reported were SCRAs (including products) and stimulants. These 
finding are in line with those from the US (Palamar and Acosta). Most people 
involved were young and there was a preponderance of males but there was no 
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obvious geographic localisation of NPS use or evolution within the UK. The types 
of NPS reported in the UK for the last 10 years varied widely; the first spikes in 
NPS use were in 2010 with the appearance of mephedrone as a popular stimulant, 
in particular used by school and university students (Dargan et al., 2010). The 
number of toxicities and fatalities associated with its use resulted in its legal control 
in April 2010 (Wood et al., 2010, Maskell et al., 2011). This restriction of 
mephedrone use lead to replacement with other stimulants such as ‘benzo fury’ 
and ‘Ivory Wave’ and the substances involved in theses preparations were soon 
also controlled to reduce their harms. The time trend then showed a gradual 
increase in enquiries related to branded products and SCRA, associated with their 
easy availability over the internet, appealing marketing and (in some cases) 
legality. These enquiries started to reduce at the end of 2015.   
The increasing and decreasing trends with time can be correlated with the 
introduction of specific legislation for individual psychoactive substances, 
culminating with the introduction of the PSA in May 2016. The PSA enactment was 
considered necessary to break the cycle of replacing controlled drugs with 
chemically similar uncontrolled alternatives. Since enactment of the PSA, the 
number of enquires and TOXBASE® access relating to NPS have been 
significantly reduced. This reduction also mirrors reductions in the numbers of 
shops and websites selling NPS. As a consequence NPS availability was reduced, 
prices have increased and street dealers and dark net websites have become the 
most important sources of NPS (Van Buskirk et al., 2017, Home Office, 2018). 
Reduction in NPS use are also evidenced by reductions in the total number of 
admissions for mental and behavioural disorders due to psychoactive substances 
in England, Wales and in Northern Ireland in 2016-2017 (Home Office, 2018).  
Studying the prevalence of NPS use can be challenging, despite there are different 
data sources, but each source has its limitations (Table 2.1). For this research, the 
analysis of NPIS data was selected to help to provides an overview of NPS toxicity 
across the UK and to provide demographic and geographical information about 
users. It also has important limitations, the most important of which is that there is 
no analytical confirmation of the substance(s) involved in episodes of toxicity and 
the rate of reported cases may decline when the substance involved become more 
familiar. Therefore, toward a comprehensive understanding of NPS use in the UK, 
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it would be important to combine data related to NPS use from different data 
sources, giving that each data source has its own limitations. This process is called 
data triangulation and helps gain multiple perspectives and data validation and 
decrease the impact of the various limitations of each individual data set (Carter 
N et al., 2014). For example, in the UK the Identification of New Psychoactive 
Substances (IONA) study aimed to identify the chemical substances involved in 
severe toxicity of suspected NPS patients presented to UK hospitals and correlate 
it with clinical features presented (Thomas et al., 2018). IONA provided information 
about the changes in NPS use and that SCRA was the most common type being 
used, in addition to identifications to the changes in NPS types over time which can 
be linked with the NPIS to confirm the NPS type for users with severe toxicity. 
Similarly, the STRIDA project in Sweden runs as collaboration between the 
Swedish Poison information centre (PIC) with Karolinska University Laboratory and 
provides toxicological analysis for the acute poisoning episodes reported to PIC 
and emergency departments. The project was able to provide an overview of the 
drug situation in Sweden and served as warning system to identify new emerging 
NPS in that country (Helander et al., 2020).  
Having defined the incidence of NPS poisoning, there remains limited information 
about their pharmacological and toxicological effects. In light of that, the next 2 
parts of the research focused on understanding some of the basic pharmacological 
actions and toxicological properties of SCRA, as these were the most commonly 
used group of NPS identified by the NPIS data. Such understanding is expected to 
provide an insight into the underling mechanisms of action and potential adverse 
effects and to inform the development of treatments with the aim of decreasing the 
adverse effects from use of these potentially hazardous substances. 
The adverse effects reported with some SCRA use such as tachycardia, 
hallucination, vomiting, chest pain, seizures etc. could be consistent with increases 
in 5-HT activity (Yip and Dart, 2014, Papanti et al., 2014). The direct interaction of 
SCRA with the serotonergic system is not well studied. The structural similarity 
between indole core SCRA and 5-HT led to speculation that SCRAs with this core, 
such as JWH-018, might have a direct inhibitory effect of on 5-HT uptake. The 
development and optimisation of an ex-vivo rat brain slice 5-HT uptake assay was 
successfully achieved and validated using the selective serotonin reuptake 
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inhibitor fluoxetine. Contrary to the original hypothesis, this study did not find a 
significant effect of either JWH-018 or the non-indole SCRA CP 55,940 on 5-HT 
uptake. Published studies have tested cannabinoid effects on 5-HT uptake and 
showed that at high concentration ∆9-THC, anandamide and WIN 55,212-2 
inhibited SERT activity leading to increased 5-HT availability (Velenovská and 
Fišar, 2007, Molina-Holgado et al., 1993, Banerjee et al., 1975). The differences in 
methodologies, type and concentrations of the tested SCRA with this study might 
explain the differences. However, the discrepancies between different SCRA in 
term of chemical structure and potency does not exclude the possibility that other 
SCRA might have a direct effect on 5-HT uptake. The occurrence of serotonergic 
effects might also be due direct activation of 5-HT receptors or inhibition of MAO 
activity (Fišar, 2010) or occur indirectly through upregulation of 5-HT2A receptors 
(Franklin and Carrasco, 2012, Franklin et al., 2013a). Therefore, 5-HT2A and MAO 
protein expression were further investigated on mature human neuronal cells using 
indole core synthetic cannabinoids (MDMB-CHMICA, MMB-CHMICA) and an 
indazole core SCRA (5F-ADB). There were no significant effects on protein 
expression but there was a 10 to 14% reduction in 5-HT2A expression and 10 to 
17% increase in MAO B protein expression. Collectively, the tested cannabinoids 
seem not to have indirect effects on the serotonergic system.  
The toxicological investigations focused on the neurotoxicity of SCRA in 
comparison to ∆9-THC and selected stimulants. The choice of SCRA used in this 
research was based on their frequency of use at the time of research and the 
dearth of information about their cytotoxicity, particularly in the brain. To model the 
potential neurotoxicity of NPS, in particular SCRAs, a human neuronal stem cell 
model was used. This is believed to be the first time a human relevant model has 
been used and this is important because a species specific model provides a better 
prediction of human toxicity (Scott et al., 2013). Nevertheless, the use of hNPSC 
model comes with some limitations. Firstly, the model has not expressed all the 
cells phenotypes in equivalence to human neuronal cells. Secondly, the 2D in vitro 
model does not mimic all the complexities of tissue or organ toxicity in vivo; in term 
of physiologically relevant conditions such as blood perfusion, drug metabolism, 
protein binding and passing blood brain barrier.  In addition, the cells were exposed 
continuously to the tested chemical for 14 days which is not a truly representative 
208 
 
of the human exposure although the daily use cannot be excluded. Moreover, the 
effect of chronic use cannot be withdrawn from 14 days exposure only. Therefore, 
it would be interesting to investigate the changes after 24 hours,7 days or 
intermittent SCRA exposure and compare the different time points 
The profile of the cytotoxicity of SCRAs was investigated together with other 2 
commonly used NPS, mephedrone and 25I-NBOMe. This research revealed 
diverse effects of these substances on cell viability. The synthetic cannabinoids 
MDMB-CHMICA, MMB-CHMICA and 5F-ADB; (5-10 µM) and the hallucinogenic 
stimulant 25I-NBOMe (10 µM) were toxic to immature neuronal cells rather than 
mature cells with different potencies. 25I-NBOMe showed early and substantial 
toxicity, whereas MDMB-CHMICA and 5F-ADB showed toxicity after 7-14 days of 
exposure. In contrast, mephedrone and MDMA were toxic to mature cells with 
mephedrone showing more marked acute toxicity. The differences in cytotoxicity 
may be due the differences in mechanisms of action and potencies of the different 
NPS, as different SCRA may activate or inhibit different pathways.  
It is interesting to note that the slight alteration in chemical structure between 
MDMB-CHMICA and MMB-CHMICA produced a different toxicity profile which 
could be reflected in important differences in their impact on human health. In 
addition, comparing toxicities of NPS with the traditionally misused drugs MDMA 
and ∆9-THC demonstrated that SCRA and other NPS (except mephedrone), were 
more toxic in immature neuronal cells. Also, they showed earlier toxicity, in 
particular 25I-NBOMe, and this may put users at greater risk of clinically important 
neurotoxicity.  
To understand the changes induced in hNPSC cell line upon continuous exposure 
to SCRA, RNA sequencing was used to study potential transcriptomic changes due 
to SCRA exposure. Understanding the transcriptome is crucial to associate 
changes in the genome with effects on functional protein expression and on 
complex biological networks (Ozsolak and Milos, 2011).  
The number of genes differentially changed due to cannabinoid exposure varied 
widely. MDMB-CHMICA induced almost 3 times as many genes changes 
compared to ∆9-THC (154 genes versus 55 genes). The number of genes 
differentially changed in 5F-ADB treated cells was only 20, this is believed to be 
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due to variance in the response from the quadruplicate samples analysed as 
shown in the PCA. 
The MT-tRNA genes were differentially changed among MDMB-CHMICA, 5F-ADB 
and ∆9-THC treated groups. Taken into consideration that there are only 22 MT 
tRNA genes expressed in human cells, there were 9 changed in MDMB-CHMICA 
treated cells, 2 in 5F-ADB treated cells and 6 in ∆9-THC treated cells. Two of the 
MT-tRNA genes were commonly changed among all 3 exposure groups. The MT-
tRNAs play an important role in protein synthesis in the mitochondria. The increase 
in expression of different MT-tRNA after cannabinoid exposure suggests that the 
cells are under stress as MT-tRNA can serve as a stress biomarker and are key in 
initiating a stress response such as increases in the level of ROS, DNA damage, 
metabolic changes and mitochondrial dysfunction (Huber et al., 2019). These 
findings could have important implications for cannabinoid users, because the 
concentrations used in this study were very low in comparison with concentrations 
used in other studies. 10 nM for each SCRA and ∆9-THC was used to simulate 
non-toxic, biologically relevant concentration and was intended to trigger their 
mechanisms of action. This concentration did not significantly change cell viability 
but was able to disturb their function. This is demonstrated by the results, as the 
potential increase in ROS, protein synthesis and the perturbation in mitochondrial 
function triggers protective mechanisms within the cell to relieve the stress and 
keep the cells viable. The changes disturbances of mitochondrial protein synthesis 
might suggest the harmful effect of cannabinoids on its function. As mitochondria 
is the main source of cellular energy and are vital for maintaining the cellular 
homeostasis through the regulation of many biological processes. LGI1 was 
commonly down regulated in the 3 groups and a reduction in LGI1 gene expression 
can lead to structural damage of the hippocampus and short duration seizures 
(Plantone et al., 2013, Finke et al., 2017). These features are consistent with the 
reports of poor memory performance in chronic SCRA and cannabis users (Sticht 
et al., 2015, Cohen et al., 2017).  
The functional analysis of the altered genes revealed the involvement of many 
pathways, most associated with increased cellular stress. The MDMB-CHMICA 
treated cells showed activation of EIF2 and mTOR, both indicative of increased 
protein synthesis; this might lead to slight elevation of ROS levels and 
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consequently inhibit both the SUMOylation and Sirtuin pathways. The activation of 
the TGF-β, BMP and NOTCH pathways might indicate a mechanism for protection 
of the cells against apoptosis. In contrast, 5F-ADB stimulated apoptosis through 
activation of p53 and the actin cytoskeleton pathways. The study suggested that 
different SCRA activate the apoptotic pathway by different mechanisms, as 
demonstrated by activation or inhibition of different signalling pathways. The role 
of apoptosis in induction of cell death by SCRA was suggested previously in other 
studies (Tomiyama and Funada, 2011, Oztas et al., 2019, Almada et al., 2017). 
Oztas et al. (2019) suggested that the activation of different death pathways from 
synthetic cannabinoid exposure is concentration dependant. 
The functional changes induced by ∆9-THC were different from those of the SCRA. 
∆9-THC did not activate the apoptotic pathway but might affect phase I and phase 
II metabolism. The IPA analysis showed that ∆9-THC inhibited the aryl 
hydrocarbon receptor signalling that is involved in xenobiotic metabolism (Nebert, 
2017).  In addition, ∆9-THC significantly upregulated some cytochrome P450 as 
shown by the differential gene expression analysis and significantly inhibited the 
protein expression of the GSTP1 metabolising enzyme. This effect on the 
metabolic pathways might not only influence the detoxification capacity for other 
chemicals and xenobiotic but also provoke drug-drug interaction as many cannabis 
users are also poly-drug users (Hall and Lynskey, 2005, Perkonigg et al., 1999) 
and this could lead to adverse health effects. 
 In line with the various effects of ∆9-THC on metabolising enzymes, a preliminary 
metabolic experiment was conducted to examine the effect of SCRA and ∆9-THC 
on paracetamol metabolism. The results suggested that ∆9-THC exposure 
significantly induced paracetamol metabolism. Although the results are incomplete 
and inconclusive due to technical problems, it indicates the importance of 
considering drug-drug interaction during clinical assessment. 
In addition, the analysis of ∆9-THC induced changes suggested possible adverse 
effects on learning and memory through the inhibition of Ephrin-B2 and Wnt/β-
catenin signalling in the hippocampus. This is consistent with reports that chronic 
cannabis use is associated with cognitive and learning deficits (Pope Jr et al., 2002, 
Messinis et al., 2006, Solowij et al., 2002).  
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To complement the mRNA sequencing analysis of MDMB-CHMICA, 5F-ADB and 
∆9-THC, some proteins of interest were investigated by western blotting. An 
interesting finding from this study was that ∆9-THC induced GFAP expression, 
while there was no such effect in SCRA exposed cells. Further investigation is 
required to determine which type of astrocytes involved in relation to ∆9-THC 
exposure; As A1 reactive astrocytes are more toxic than the A2 reactive astrocytes 
which proliferate and support neuronal regeneration in models of acute trauma 
(Liddelow and Barres, 2017). 
In addition, MDMB-CHMICA was able to significantly induce mitochondrial 
complex IV subunit Va which could potentially lead to increased ROS production. 
In contrast, ∆9-THC slightly inhibited the complex I NDUFA9 subunit which might 
also lead increased ROS production. The fluctuations in ROS levels play a role in 
cellular signalling pathways that target proteins, polysaccharides, lipids and DNA 
(Stadtman and Levine, 2000, Rubbo et al., 1994, Kaur and Halliwell, 1994, Richter 
et al., 1988). An effect of cannabinoids on mitochondrial respiration is supported 
by studies that suggested that CB1 receptors are expressed in neuronal 
mitochondria (mtCB1) and directly control energy production through reduction in 
cyclic AMP, protein kinase A activity and complex I enzymatic activity (Bénard et 
al., 2012). In addition to a recently published studies which reported synthetic 
cannabinoids THJ-2201 and 5F-PB22 promoted the hyperpolarization of 
mitochondrial membrane and that THJ-2201 disrupted mitochondrial function and 
triggered apoptotic cell death (Alexandre et al., 2020). 
In conclusion, this research started by estimating the incidence of episodes of 
toxicity associated with different NPS in the UK and established that the 
substances most commonly implicated in recent years have been SCRA. The NPIS 
data together with other data sources can be used to monitor the harm caused by 
recreational drug use and identification of new emerging drugs. This in turn will 
help policy makers to take steps to reduce the impact on public health, including 
legal control measures when these are appropriate.  
The research then explored the potential pharmacological effects of SCRA on 5-
HT uptake as several toxic effects of SCRA might suggest increased serotonergic 
activity. The research, however, did not demonstrate an effect of indole SCRA on 
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5-HT reuptake. Toxicological investigations using the hNPSC cell line suggested 
that synthetic cannabinoids are more potent neurotoxins than ∆9-THC and they 
are more toxic to immature than mature cells, highlighting their potential dangers 
to younger users. In addition, this research indicated that SCRA induce different 
pathways within the cell that might lead to different clinical outcomes. The 
toxicological investigations indicated that cannabinoids might influence 
mitochondria, an important finding because efficient mitochondrial function is vital 
in the CNS These changes in SCRA users could adversely affect human health 
and might have a long-term effect on brain structure and functions such as memory 
and cognition. The RNA sequences analysis open the door for further research to 
fully understand the underlying mechanisms involved in the SCRA effects on 
human brain and it is not possible to draw any conclusion on their effects and how 
to link it with the clinical manifestations.   
Understanding the prevalence of use and toxicity, pharmacological effects and 
clinical and cellular toxicology of NPS is important, considering their recent 















The understanding of the condition surrounding NPS use will help in controlling its 
use. This needs accurate and adequate data collection system to monitor the NPS 
problem and then to analyse the impact of regulations. This study would suggests     
developing the NPIS collection data system by including more information about 
the reported cases such as education and ethnicity. In addition, the NPIS in UK 
receive enquires from the health professionals only, it would be beneficial if there 
is specific phone line for taking public enquires. This will enable to include more 
poisoning cases in particular some drugs users do not prefer seeking medical help. 
Furthermore, there would be value in co-ordinating other data collecting systems 
including amalgamating data collected in England, Wales, Scotland and Northern 
Ireland to get a picture of the whole UK. In addition, collating data about NPS from 
additional sources, such as data from confirmed analytical samples from hospital 
admissions as well as post mortem data, together with information reported by the 
users about side effects from websites and blogs, such as Drugs Forums and 
surveys will help to develop an overall picture of NPS use in term of pattern of 
toxicity, demographic use and new emerging substances. This data triangulation 
will decrease the impact of the limitations of each individual source and will help 
health professionals and policy makers in managing the problems posed by NPS. 
The functional gene analysis showed changes in MT-tRNA, therefore further 
validation of these results will be needed, for example using Quantitative PCR 
(qPCR). 
Further characterization of the proteins/pathways that are changed by SCRA in 
neuronal cells is of major interest and will clarify the mechanisms that link SCRA 
to clinical presentations and permanent changes from repeated use. This could be 
done using the following methods: 
1. Investigation of the morphological changes to neuronal cells using 
Immunocytochemistry (ICC) techniques. 
2.  Measuring the oxidative stress that might be triggered by cannabinoid 
exposure by measuring ROS levels in cells by using the MitoSOX-based 
assay. 
3. Use of mitochondrial function assays such as Mitochondrial Membrane 
Potential (MMP) Assay and seahorse assay. 
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4. It would be beneficial to measure not only the increased or decreased in 
protein expressions, but also the phosphorylated forms. Protein 
phosphorylation changes the protein function to become activated or 
deactivated and this plays an important role in modifying protein function 
such as measuring the phosphorylated form of EIF2 and Erk1/2 proteins. 
This done by western blotting technique using phosphorylated 
antibodies.   
The brain is just one of many organs that might be affected by SCRA as the 
adverse effects reported from SCRA was not limited to neurological one only.  
Further investigations would be needed studying other organ systems such as the 
heart, respiratory system, kidneys and especially the liver as this is the major site 
of drug metabolism 
Other research that would be of value includes: 
1. Further study of the pharmacology and toxicology of prevalent and 
emerging SCRA 
2.  Research into the optimum management of acute SCRA intoxication, 
including evaluation of potential therapies.  
3.  Development of accurate field tests for SCRA that can adapt to changes 
in the drug market.  
4.  Determination of the longer-term health effects of SCRA use, including 
effects on memory and cognition and on reproductive and foetal health. 
Finally, as the existing data about NPS showed that use is largely by younger 
populations, it would be beneficial to identify the motives for and circumstances of 
use. This would assist with in planning the most appropriate interventions to reduce 








1. List of the differentially expressed genes 
1.1 The genes with the most statistically significant changes after MDMB-
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ENSG00000205746 PKD1P4  
Polycystin 1, transient 
receptor potential 
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ENSG00000213073 CHP1P2  
calcium binding 
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1.2 The genes with the most statistically significant changes after 5F-ADB 
exposure of mature cells. 
 
 
Ensembl_gene_id hgnc_symbol Description 
log2Fold 





tRNA isoleucine  1.17 4.8E-26 7.8E-22 MT 
ENSG00000210107 MT-TQ 
Mitochondrially encoded 
tRNA glutamine  1.06 4.4E-10 1.8E-06 MT 
ENSG00000269378 ITGB1P1  
integrin subunit beta 1 
pseudogene 1  1.50 4.6E-06 2.5E-03 19 
ENSG00000196167 COLCA1 
Colorectal cancer associated 
1  -1.92 7.8E-06 3.2E-03 11 
ENSG00000144045 DQX1 
DEAQ-box RNA dependent 
ATPase 1  -4.12 3.2E-05 7.4E-03 2 
ENSG00000184343 SRPK3 SRSF protein kinase 3  1.33 7.6E-05 1.4E-02 X 
ENSG00000196218 RYR1 ryanodine receptor 1 1.31 1.0E-04 1.6E-02 19 
222 
 
ENSG00000183018 SPNS2 sphingolipid transporter 2  1.05 1.2E-04 1.7E-02 17 
ENSG00000171700 RGS19 
regulator of G protein 
signalling 19  2.05 1.3E-04 1.8E-02 20 
ENSG00000081479 LRP2 LDL receptor related protein 2 1.13 1.4E-04 1.8E-02 2 
ENSG00000108231 LGI1 
leucine rich glioma inactivated 
1  -1.24 1.3E-04 1.8E-02 10 
ENSG00000150667 FSIP1 
fibrous sheath interacting 
protein 1  2.66 2.2E-04 2.4E-02 15 
ENSG00000109255 NMU Neuromedin U -1.68 3.3E-04 3.3E-02 4 
ENSG00000255326 
 
Nnovel transcript -1.00 4.0E-04 3.7E-02 11 
ENSG00000099725 PRKY 
Protein kinase, Y-linked, 
pseudogene  -4.32 4.7E-04 4.0E-02 Y 
ENSG00000118972 FGF23 Fibroblast growth factor 23  -1.09 4.8E-04 4.0E-02 12 
ENSG00000163694 RBM47 RNA binding motif protein 47  -2.97 4.9E-04 4.0E-02 4 
ENSG00000181790 ADGRB1 
Adhesion G protein-coupled 




subunit  -1.20 5.9E-04 4.5E-02 1 
ENSG00000121101 TEX14 
Testis expressed 14, 
intercellular bridge forming 
factor  1.88 6.5E-04 4.7E-02 17 
 
 
1.3 The genes with the most statistically significant changes after ∆9- THC 
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ENSG00000236439   
ribosomal protein 








ENSG00000280852   
Adaptor-related 



















2. The List of the differentially expressed genes overlapped between 
MDMB-CHMICA, 5F-ADB and ∆9- THC. 
 
2.1 The most common genes changed between MDMB-CHMICA and 5F-
ADB treated cells.  
 

















motif protein 47 
















1.988 2.01E-72 1.169 7.82E-22 
ENSG00000118972 
FGF23 Fibroblast growth factor 23 -1.642 
2.59E-












pseudogene 1  
1.0426 0.0213 1.1954 1.08E-02 





2.2 The most common genes changed between MDMB-CHMICA and ∆9-
THC treated cells. 
 


































beta -1.2801 2.92E-03 -1.3267 3.53E-03 
ENSG00000214402 LCNL1 
lipocalin like 1 




inactivated 1 -1.3475 1.25E-03 -1.6128 1.23E-04 
ENSG00000153902 LGI4 
leucine rich 
repeat LGI family 











































specific RNA 15 -1.5247 1.04E-24 -1.0697 9.03E-13 
ENSG00000260589 STAM-AS1 
STAM antisense 
RNA 1 -1.3850 1.89E-03 -1.4299 2.35E-03 
ENSG00000272540    Novel transcript 1.877449 6.67E-17 1.09759 4.32E-05 
ENSG00000227081   
 ribosomal 
protein S27 
pseudogene -1.62308 1.78E-02 -1.6836 2.23E-02 
ENSG00000263826    Isoform 2 EIF4A2 1.277838 1.45E-07 1.12303 2.34E-05 
ENSG00000269399    Novel transcript -1.23716 3.00E-07 -1.0274 4.51E-05 
ENSG00000269378  ITGB1P1 
 Integrin subunit 
beta 1 















2.3 The most common genes changed between 5F-ADB and ∆9-THC 
treated cells. 
 
ensembl_gene_id  hgnc_ symbol 
  
Description 
































receptor B1 1.11 4.44E-02 1.09 1.98E-02 
ENSG00000196167 
COLCA1 colorectal cancer associated 1 -1.92 3.17E-03 -1.73 3.44E-03 
ENSG00000196218 
RYR1 ryanodine receptor 1 1.31 1.60E-02 1.20 1.27E-02 
ENSG00000081479 
LRP2 LDL receptor related protein 2 1.13 1.81E-02 1.17 4.83E-03 
ENSG00000269378 
 ITGB1P1 
 Integrin subunit 
beta 1 










3. The significant canonical pathway analysed by the ingenuity pathway 
analysis software. 
 
3.1 The canonical pathways that were significantly changed in 






Ratio z-score Molecules 


















BER pathway 2.21 0.333 #NUM! OGG1,POLE,APEX1,PCNA 
Sirtuin Signalling 
Pathway 

















1.95 0.145 1.414 CREB1,MAP2K2,ZNF423,PRKAR1B,MA
GED1,TAB1,MAPK11,SMURF1,BMP7,G
REM1,SMAD9 





Biosynthesis V (from 
Ins(1,3,4)P3) 





















Telomere Extension by 
Telomerase 
1.84 0.267 #NUM! XRCC6,XRCC5,TNKS2,HNRNPA2B1 
Adipogenesis pathway 1.79 0.119 #NUM! HDAC2,FGF1,TXNIP,SREBF1,HDAC10,
ATG7,GTF2H4,KLF3,SMAD9,FZD5,HDA
C6,CTBP2,ZNF423,DDIT3,KAT6B,BMP7 
Role of BRCA1 in DNA 
Damage Response 
1.79 0.138 0 POU2F1,FANCL,MSH6,ARID2,CDKN1A,
BRCC3,SMARCA4,BARD1,E2F3,FANCF
,SMARCB1 





Mechanisms of Viral 
Exit from Host Cells 














Heme Biosynthesis II 1.74 0.333 #NUM! CPOX,UROD,HMBS 
Chondroitin Sulfate 
Degradation (Metazoa) 
1.74 0.25 -1 HYAL1,HEXB,GALNS,CEMIP 
Wnt/β-catenin 
Signaling 







1.62 0.5 #NUM! CPOX,UROD 
Proline Biosynthesis I 1.62 0.5 #NUM! PYCR1,PYCR3 
Role of Wnt/GSK-3β 
Signaling in the 
Pathogenesis of 
Influenza 














1.47 0.211 0 IPPK,IPMK,INPPL1,INPP5A 




Serine Biosynthesis 1.42 0.4 #NUM! PSAT1,PHGDH 
2-oxobutanoate 
Degradation I 
1.42 0.4 #NUM! DLD,PCCB 
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Protein Kinase A 
Signaling 








tRNA Charging 1.38 0.154 0 CARS2,MARS2,PARS2,VARS,WARS,E
ARS2 
Mouse Embryonic 
Stem Cell Pluripotency 














3.2  The canonical pathways that were significantly changed in 5F-ADB 





value) Ratio z-score Molecules 
Molecular Mechanisms of 




p53 Signalling 2.46 0.045 1.342 ADGRB1,BBC3,PIK3R2,BAX,TNFR
SF10B 







1.91 0.0408 #NUM! PIK3R2,PRKAR1B,SH2B2,RPS6KC
1 
Actin Cytoskeleton 




Signaling In Dorsal Horn 
Neurons 
1.68 0.0348 1 CAMK2B,PIK3R2,KCNN3,PRKAR1
B 
NGF Signaling 1.61 0.0331 1 PIK3R2,BAX,RPS6KC1,RHOA 
Superpathway of 
Cholesterol Biosynthesis 1.58 0.0714 #NUM! PMVK,LBR 
Methylglyoxal Degradation 




1.57 0.333 #NUM! PPAT 
Hypusine Biosynthesis 1.57 0.333 #NUM! EIF5A 
Cellular Effects of 




pathway 1.49 0.0258 0.447 
GUCY1A2,PIK3R2,KCNN3,PRKAR
1B,BAX 
Gap Junction Signaling 1.48 0.0256 #NUM! CSNK1A1,GUCY1A2,SGSM3,PIK3
R2,PRKAR1B 






1.45 0.25 #NUM! DLD 
Role of BRCA1 in DNA 
Damage Response 1.44 0.0375 #NUM! POU2F1,MSH6,SMARCB1 
Breast Cancer Regulation 
by Stathmin1 1.41 0.0244 #NUM! 
CAMK2B,PIK3R2,PRKAR1B,ARHG
EF4,RHOA 
Hereditary Breast Cancer 
Signaling 1.37 0.0278 #NUM! HDAC2,PIK3R2,MSH6,SMARCB1 
2-ketoglutarate 
Dehydrogenase Complex 1.35 0.2 #NUM! DLD 
Serine Biosynthesis 1.35 0.2 #NUM! PHGDH 
Myo-inositol Biosynthesis 1.35 0.2 #NUM! ISYNA1 
2-oxobutanoate 
Degradation I 1.35 0.2 #NUM! DLD 
Notch Signaling 1.33 0.0526 #NUM! MAML3,DLL3 
Role of NFAT in Cardiac 









3.3 The canonical pathways that were significantly changed in ∆9-






Ratio z-score Molecules 
Glutamate Degradation III 
(via 4-aminobutyrate) 
3.5 0.6 #NUM! GAD2,ABAT,SUCLG2 
BER pathway 3.36 0.333 #NUM! OGG1,LIG1,APEX1,PCNA 
Notch Signalling 2.9 0.158 #NUM! 
DLL1,PSEN2,MAML1,MAML3,HEY
1,DLL3 






2.52 0.667 #NUM! ABAT,SUCLG2 






1.84 0.333 #NUM! PGAM2,TIGAR 
Role of BRCA1 in DNA 
Damage Response 












1.56 0.0943 #NUM! 
RGR,GNB3,GUCY1A2,GUCY1A1,O
PN3 









Cell Cycle Control of 
Chromosomal Replication 
1.47 0.0893 #NUM! CDK11B,MCM2,LIG1,CDK12,PCNA 
Aryl Hydrocarbon 
Receptor Signalling 


















Superpathway of Inositol 
Phosphate Compounds 
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